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GENERAL INTRODUCTION 

1 
General introduction 
Atherosclerosis and dementia are major problems in elderly people. Atherosclerosis, 
dle principal cause of tnyocarclial infarction, stroke and peripheral arterial disease, is 
the nlost important cause of mortality in western countries,l Dementia is the major 
threat to the wellbeing of older people. It is an extremely devastating condition, as a 
state of cotnplete dependency often follows an extended period of loss of personality 
and cognition.2 Since the frequency of both atherosclerosis and dementia increases 
with advancing age, the two conditions ate enormous problctns in our ageing socie-
ties.3,4 
High levels of total and low density lipoprotein (LDL) cholesterol and low levels 
of high density lipoprotein (HDL) cholesterol predispose to d,e development of 
atherosclerosis.s The apolipoprotein E polymOlphism (APOE) is an important de-
terminant of the level of d,ese lipids in serum. The APOE gene has three common 
alleles, APOE*2, APOE*3 and APOE*4, which determine d,e protein isoforms 
apoE2, apoE3 and apoE4, respectively.' Compared to homozygotes for APOE*3, 
the most common genotype, APOE*2 is associated with lower levels of total and 
LDL cholesterol and with higher levels of HDL cholesterol, wlUle APOE*4 has op-
posite effects.6 However, studies on the association between APOE and atheroscle-
rosis have been inconsistent. 7,8 fvloreover, it is yet unclear to what extent APOE is 
related to mortality and cardiovascular diseases in the general population. 
Besides its role in lipid metabolism, d,e APOE*4 allele is more prevalent in pa-
tients with Alzheimer's disease d,an in cognitively normal controls. AldlOugh tillS 
association is well established, reported risks vruy tremendously across sturues.9- 11 
The large majority of these investigations arc cross-sectional studies based 011 clinical 
patient-seties. Selection bias Inay have played a tole in these studies, as well as possi-
ble APOE related selective sUl'Vival. It is yet unclear whether the APOE*2 allele mal' 
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exert a protective effect, and whether serwn apoE level contributes to the aetiology 
of Alzheimer's disease. In addition, it remains to be determined whether the APOE 
genotype is also involved in other dementing diseases, and, related to the lattcr topic, 
whether APOE testing could be used in the differential diagnosis of dementia. Fur-
thennore, the combined effects of the APOE*4 allele and atherosclerosis deserve 
further attention, as these arc both common risk factors for demclltia. 12 
TIle ain1 of this thesis was to further investigate the role of apolipoprotein E in 
atherosclerosis and dementia. These studies reflect an epidemiological approach to 
genetic susceptibility. 
References 
1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 19905. Nature 1993;362: 
801-9. 
2. CummingsJL Dementia: the failing brain. Lancet 1995;345:1481-9. 
3. Van Duijn CM. Epidemiology of the dementias: recent developments and new approaches. J 
Neurol NCllroSurg Psychiatry 1996;60:478-488. 
4. Hart- en vaatziekten in Nederland. Cijfers over ziekte en sterfte. Nederlandse Hartstichting. 
Den Haag, 1997. 
5. Pooling Project Research Group. Relationsh.ip of blood pressure, serum cholesterol, smok-
ing habit, relative weight and ECG abnormalities to incidence of major coronary events: fi-
nal report of the pooling project. J Chron Dis 1978;31:201-306. 
6. Davignon j, Gregg RE, Sing F. Apolipoprotein E polymorphism and atherosclerosis. Arte-
riosclerosis 1988;8:1-21. 
7. De Andrade l'vI, Thandi I, Brown S, et al. Relationship of the apoljpoprotein E polymor-
ph.ism with carotid artery atherosclerosis. Am j Hum Genet 1995;56:1379-90. 
8. I Jixson jE and the Pathobiological Determinants of Atherosclerosis in Youth (PD1\ \') Re-
search Group. Apolipoprotein E polymorphism affect atherosclerosis in young males. Arte-
rioscler Thromb 1991;11: 1237-44. 
9. Corder EH, Saunders AM, Strittmatter \"'\'J. ct al. Gene dose of apolipoprotein E type 4 allele 
and the risk of Alzheimer's disease in late onset f.1.milies. Science 1993;261:921-3. 
10. Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele E4, dementia, and cogni-
tive decline in a population sample. Lancet 1995;346:1387-90. 
11. lvlycrs lu-I, Schaefer Ej, \X'ilson P\X'F, et al. Apolipoprotein E E4 association with dementia 
in a population-based study: the Framingham stud),. Neurology 1996;46:673-7. 
12. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and the preva-
lence of dementia and j\lzheimer's disease in the Rotterdam study. Lancet 1997;349:151-4. 
4 
2 
GENETIC EPIDEMIOLOGY 
OF ALZHEIMER'S DISEASE 
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Review on 
genetic epidemiology of Alzheimer's disease 
Introduction 
Dementia is a major health problem in the elderly. Following an extended period of 
loss of personality and cognition, the disease often results in a state of complete 
dependency. By far the most conunOl1 cause of dementia is Alzheuner's disease 
(AD), which is clinically characterized by a gradual, progressive decline in intellectual 
functions.! Besides, psychosis, depression, agitation and anxiety are conunOll 
manifestations.2 The most frequently used diagnostic criteria for AD are described by 
the National Institute of Neurological and Communicative Disorders and Stroke and 
tl,e Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).' 
The diagnosis of AD is considered to be probable when alternative causes of 
dementia are excluded.'·' According to the NINCDS-ADRDA criteria, a deftnite 
diagnosis is ll1acle when a probable diagnosis of AD is confirmed at autopsy.3 The 
neuropathologic characteristics of AD arc senile plaques, neurofibrillary tangles, 
amyloid angiopathy and neuronal loss, resulting in a decreased activity of the enzyme 
choline acetyl transferase. S Senile plaques are extracellular deposits of predotuinantly 
f3-amyloid. Neurofibrillary tangles arc intraneuronal inclusions, which are in part 
composed of abnormally phosphorylated tau proteins. 
The prevalence of AD increases with advancing age. It affects less than 1 percent 
of 60-64 year olds, and up to 40 percent of those over age 85.' Also the incidence 
increases witll aging, and is estimated to be 1 per 1000 person yea" in 60-64 year 
olds, and 25 per 1000 person years in individuals older tl,an 85 years.' In AD 
research, patients with early onset are often distinguished from those with late onset. 
There is however no uniforlll definition, and frequently used cut-off points are the 
age of 60, 65 and 70 years. Besides age, previous head injury or depression as well as 
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low educational leveL atherosclerosis and exposure to alwniniwll were found to be 
risk factors for AD. 7~9 The use of anti-inflanunatory dlUgS or estrogens seems to 
decrease the risk of ADJ,IO Smokers were also found to have a decreased risk in 
cross-sectional shldies,lI but at an increased risk in a follow-up study.12 
Besides, genetic factors playa role in the etiology of AD. Familial clustering has 
long been recognized,13 and a positive fanuly hist01Y of dementia is one of the 
most consistent risk factors. 14 A distinction is often made between patients with 
familial and sporadic AD. Again, there is no uniform definition of these Eortl1s of 
disease. The frequently used criterion of a positive family history of dementia, 
however, docs not necessarily indicate genetic susceptibility. !vIan), people, and not 
just those individuals who arc genetically predisposed, develop AD in old age. On 
the other hand, there is significant likelihood that genetically susceptible relatives 
decease before the onset of AD. Given these litnitations, it may not be surprising 
that clitucal manifestations of the two AD types appeared to be sitnilar. 15,16 
However, patients with familial AD filay have a more rapid disease progression,17 
and an earlier onset than cases with sporadic AD.16 
11,e fust step towards the localization of the genes implicated ill AD (or their 
alternative forms, alleles) was ac1ueved through litlkage analysis, wluch requires no a 
priori knowledge of the pathogenesis. With dus teclltuque, one can study ill large 
families the extend to wluch a localized marker allele is inherited together with a 
putative disease allele. Several mutations have now been identified that are by 
thetnselves sufficient to cause AD (ie. autosotllal dominant tnutations). In addition, 
a nlllnber of genes have been studied because tIley code for proteins wluch are part 
of the AD pathology. Through tIus candidate gene approach, COllUnon variations in 
genes (i.e. pol),tnolplustns) were identified wluch increase the risk of AD, but are by 
themselves not sufficient to cause the disease. These genes are refett:ed to as 
susceptibility genes. 
In tius review, the genes involved in AD will be discusscd in light of tilCir relativc 
contribution to tIle developtnent of disease and tilCir putative role in thc 
pathogenesis. First, we will consider the autosomal dominant tnutations and the 
susceptibility genes. Next we will review tI1C interaction between different genes and 
enviroll1nental risk factors for AD. Finally, wc will discuss the cmucal and public 
health implications. 
Autosomal dominant mutations 
Amyloid precursor protein 
The localization of the first gene involved in AD was hinted to by dIe observation 
that AD is very conunon in middle-aged patients with trisomy 21 (Down's 
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syndrome).18.19 As tnost Down's syndrome patients carry three copies of 
chromos01ne 21 instead of two, this finding indicated that overexpression of one or 
more genes on chrotnosotne 21 may lead to the development of AD. In 1987, the 
gene encoding for the amyloid precursor protein (APP) was isolated and localized on 
chromosome 21 (region 21ql1.2-21q21.2).20 API' is the precursor for 13-amyloid, a 
protein that accmnulates in setille plaques and cerebral blood vessels in AD brains. 
Therefore, the APP gene was considered to be a candidate for AD despite the fact 
that the causal relation between senile plaque formation and the development of AD 
was an issue of debate. Arguing strongly against a causal relation is the absence of a 
relation between severity of dementia in AD patients and f3-amyloid burden.21 
:tvIoreovcr, sctille plaques can also be observed in brains from nondementecl elderly.22 
In 1991, a mutation in the APP gene was identified which leads to Jill." Since 
then, several othcr APP mutations have been found that cause autosotnal dotninant 
fonns of AD with an early onset.24 Each of dlese variations change the coding for 
one amino acid. At position 717, three different substitutions of valine have been 
found: to isoleucine (VaI717 .... Hle),23)s.29 to phenylalanine (VaI717--7Phe),30 and to 
glycine (VaI717--7Gly).31 Other mutations include a substitution of asparagine instead 
of lysine at position 670 (Lys670--7Asn),32 methionine for leucine at position 671 
(Met671--7Leu), and alanine instead of glycine at 692 (Ala692--7Gly).33 
It has become clear that mutations in d,e APP gene may explain only a limited 
munber of patients widl AD."·" The Va1717--7Ile mutation was found in only nine 
farnilies23,2S-29; these include families froln European as well as Japanese origin, which 
suggests that several independent mut1tions may have occurred. The other APP gene 
tnutations have been observed in one family each. Although the clinical and public 
health implications of dlCse rare mutations are dlUS litnited, the fmding d,at APP 
mutations lead to AD implies that fi-atnyloid is most likely involved in dIe disease 
etiology. Several studies have examined the consequences of the APP mutations to 
d,e fl-amyloid protein (i.e., the product of d,e API' gene). 'TI,e consequence of d,e 
VaI717--7Ile mutation may be that longer fl-amyloid fragments are generated, which 
aggregate more rapidly.40 For the Lys670--7Asn and the Ala692--7Gly mutations, the 
secretion of fi-amyloid appears to be illcreased:u-43 Although several functions have 
been proposed for fl-amyloid and APP, d,eit function is not yet known ..... APP 
resembles, on the basis of its amino acids sequence a cell-surface receptor:tS 
APP mutations are not solely related to AD but may also lead to other disorders. 
A mutation in codon 693 of the APP gene, replacing glutamic acid by glutamine 
(Glu693--7Ghl), causes Hereditary Cerebral Hemorrhage widl Amyloidosis of d,e 
Dutch type, an autosomal donlinant form of hemorrhage due to amyloidosis.46•47 The 
Ala692--7Gly mutation results i11 Jill and in cerebral hemorrhages due to congo-
phylic amyloid angiopadly.33 
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Presenilins 
Since APP could only explain the deYeiopment of AD in a small number of families, 
several groups have searched for other implicating genes. In 1992, the second AD 
gene was localized on chrol11osome 14.48 However, this gene could not be isolated 
until 1995." It was designated presenilin 1 (PS-l) because of the presenile onset of 
disease in the families shldied. It has been suggested that mutations in tillS PS-l gene 
may cause up to 70 percent of all autosomal dominant AD with onset before 55 
years.49~51 However, screening of a population-based sample of early onset AD 
patients, revealed PS-ltllutations in not morc than 7 percent.52 At present, over 40 
different rnutations in PS-l have been describcd.49.60 The diverse ethnic origin of 
patients with the Saine PS-l variation suggests a high frequency of new l11utattons. 
Therefore, it cannot be excluded that mutations in the PS-l gene can also be found 
in AD patients with the sporadic form (i.e., cases with no family histOlY of dementia). 
Mutations in the PS-l gene mal' also lead to AD with a late onset. Carriers of two 
type 1 alleles at intron 8, a polymorphistn that is not expressed, were found to have 
an increased risk for the late onset fOlm of AD. 61 However, this finding could not be 
confirmed by others." TI,e exact proportion of AD patients that can be ascribed to 
PS-ltllutations has yet to be detetmined. 
\X1ithin months after the identification of PS-l, a similar gene on chromosome 1 
was localized, which was termed presenilin 2 (PS-2).58 At present, two PS-2 muta-
tions that cause AD have been found. But, PS-2 llmtatiolls appear to be a rare cause 
of early onset AD. One of the PS-2 llmtatiolls was identified in seven families of 
Volga-German origin.63 rnle second PS-2 llmtation was found in an Italian AD 
family. 58 
The role of the presenilins in the pathogenesis of AD is unknown. '11,e gene 
product ofPS-l is a membrane protein.51 PS-l has been found in senile plaques from 
AD patients, and not only in those with a mutation in the PS-l gene.6-t It has been 
suggested that a mutation in PS-l leads to greater secretion of long B-amyloid which 
aggregates tnore rapidl}r.60,65 
Susceptibility genes 
Apolipoprotein E 
Before the discove1)' that apolipoprotein E (apoE=protcin, APOE=gcne) is 
inyolved in the etiology of AD, apoE had been studied because of its piyotal role in 
lipid metabolism."TI,e APOE gene is localized on chromosome 19 (region 19q13.2) 
and has three common alleles (APOE*2, APOE*3 and APOE*4) that code for three 
different isoforms (apoE2, apoE3 and apoE4, respectively)." The apoE isoforms are 
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sttucturally very similar, but differ in one or two amino acids: apoE3 has cysteine on 
position 112 and arginine 011 position 158, apoE4 has arginine on these positions, 
and apoE2 cysteine.67 In populations of European ancestry, the APOE*3 allele has a 
frequency of 0.77. APOE*2 and APOE*4 are less common (allele frequencies 
respectively 0.08 and 0.15 in populations of European origin).68 APOE*4 is more 
rare in Chinese and Japanese populations (0.06-0.12),68 and more frequent in 
Africans (0.21) and in Finns (0.23).68.69 
Strength of association In 1991, linkage to chrOlllosome 19 was reported in 
families with late onset AD"O One of the genes located in this region is APOE. As 
the apoE protein was also found in senile plaques, APOE was tested as a candidate 
gene for AD." In 1993, Strittmatter and colleagues reported d,at the APOE*4 allele 
frequency was significandy increased in familial AD patients derived from a brain 
bank.?l Since then, nwnerous research groups confirmed the increased frequency of 
d,e APOE*4 allele among AD patients.72-97 In a meta-analysis of the findings up to 
early 1995," bod, early and late onset AD as well as sporadic and familial types, were 
associated with APOE*4 (table). However, an increased APOE*4 frequency in fa-
milial early onset AD has not been reported consistendy.93.99-lol Part of d,e discrep-
ancy between studies on familial early onset AD can be explained by the lack of uni-
form criteria for familial disease. 
Several studies showed that subjects with two copies of d,e APOE*4 allele 
01Omozygotes) have a higher risk compared widl dlOse with one copy 0letero-
zygotes) (odds ratios vary from 4.9-34.3 and /.6-5.1 respectively),,2-7S.'O-".".87>9I>97 
Table - APOE*4 allele frequencies in various AD types' 
Type AD Number of Number of APOE*4 95% confidence 
studies patients frequency interval 
Early onset familial AD' 2 143 0.42 0.36 to 0.48 
Early onset sporadic AD 4 168 0.28 0.23 to 0.33 
Late onset familial AD 8 601 0.48 0.45 to 0.51 
late onset sporadic AD 24 1562 0.37 0.35 to 0.39 
Nondemented controls 2000 0.14 0.12toO.16 
* Based on a meta·analysis.98 
t Cases were not examined for all currently known autosomal dominant mutations, later studies did 
not find an association.93.99.101 
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There is some evidence that the APOE genotype effects the age at AD onset. 
APOE*4 homozygotes were found to have a 3-16 years earlier onset as compared 
with notl-APOE*4 catriers.73,81,87,102~106 The age of onset effect was however not 
observed consistendy.82.96.97,107.109 Also the role of the APOE*2 allele in AD is a 
tnatter of controversy. Several studies reported a decreased APOE*2 frequency in 
AD patients (0.01-0.05), independent of the effect of APOE*4, which suggests a 
protective effect.75,92,1lQ..-1I3 In contrast, others found an increased frequency of 
APOE*2 (0.13-0.14).114,115 
Heterogeneity of studies Despite the large number of investigations compatible 
with an increased .risk of AD for carriers of APOE*4, the strength of tItis association 
varies considerably. TIle differences across studies are probably the result of the 
differences in ascertaitunent ,of cases (clinic- versus popuL1tion-based, prevalent 
versus incident), the heterogeneity in case-series studied (familial or sporadic, latc 
onset versus early onset) and d,e diagnostic criteria used (possible, probable or 
definite AD). The large majority of studies used clinic-based patient-series, and all 
studies except two1l6,t17 are based on prevalent cases. Thus, selection may also have 
occurred because of referral bias and sUlvival bias associated ,vith d,e APOE 
genotype. 
Possible bias An important aspect regarding referral bL1s is that APOE may, in 
part, detennine dIe symptoms of AD,118-120 which may effect clinical referral. Also, 
the fact d,at APOE*4 carriers more often have a positive family history of de-
mentia,80,91 could lead to referral bias.121 C01l1pared with AD cases from a conl-
munity-based study, patients from a memory clinic indeed had a higher APOE*4 
allele frequency, an earlier disease onset, and a lnore advanced state at assessment. l22 
\V'idl regard to putative prevalence-incidence bias, investigations of the role of 
APOE in progression and sU1'\~val of AD are relevant. However, studies on APOE 
and the rate of progression of AD have yielded inconclusive results. 102,tol,to7,12J-127 No 
relation between APOE and mortality has been found by some groups,I09,"" while 
others desctibed an increased survival in AD patietlts with APOE*4,102,tol,114,12J and a 
decreased sUlvival for early onset AD patients ,vith APOE*2.114 A problem in d,e 
interpretation of these studies is that each of dlese investigations is based otl 
prevalent patients who may have entered the study at different stages of disease. Also 
dIe characteristics of the AD patients and the definition of disease duration varied 
considerably. However, if dIe finding dlat APOE*4 carriers sUlvive longer is correct, 
the risk of AD associated ,,~d, APOE*4 may be inflated in studies of prevalent 
patients conducted to date. 129 
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Incidence studies Indeed, in two population-based studies on incident patients, in 
which participants were included before onset of dementia, a relatively low APOE*4 
frequency had been obsetved. 1t6,1l7 However, one of these studies focussed on 
dementia and not AD specifically,1I6 which may explain in part the low APOE*4 
frequencies observed (0.17 in patients using DSM-III-R criteria,130 and 0.26 in cases 
diagnosed with ICD-10 criteria).13! However, also the other stndy on incident AD 
patients reported a low APOE*4 frequency (0.13),117 and used the NINCDS-
ADRDA criteda.3 As this latter stndy was performed among Italian-Amedcans in 
whom APOE*4 is relatively rare, the frequency of this allele in AD cases was still 
significantly increased compared with tlle unaffected controls (0.08).117 Age- and sex-
specific risk estimates associated with the va.rious APOE genotypes await large scale 
incidence studies. 
Causal inference: smdies of different populations An important issue to resolve 
is whetller APOE is causally related to AD or whetller anotller, neighbodng gene 
exerts the patllOgenic effect. 11,e latter sitnation is known as linkage disequilibrium. 
Indeed, polymorphisms flanking the APOE gene have been found to be associated 
with AD in some stndies.92,93,132 Investigations of different populations may shed 
light on the possibility of linkage disequilibriwn. If APOE*4 is causally related to 
AD, one expects to find an association in each population studied, assuming that 
there are no strOtlg effect modifiers which differ across populations. The association 
between APOE*4 and AD has been confirmed in various populations, including 
those of African, Chinese and Japanese origin.133~137 However, findings in persons of 
African origin have been inconsistent. In a small study on Nigerians, no association 
between APOE*4 and AD was observed." Whereas one study in African-Americans 
reported that APOE*4 was a strong risk factor for AD,133 others found a lower 
APOE*4 associated risk of AD for African-Americans compared Witll Caucasians.13' 
Causal inference: experiInentai studies In spite of the weak associations in the 
studies on incident cases,116,1I7 and on patients of African descent,69,133,134 dlere is 
support from experimental stndies that APOE is causally related to AD. It has been 
shown tl,at tl,e Il-amyloid burden is related to tl,e APOE genotype.84,85,9G,103,!38,139 The 
apoE isoforms may have a specific effect on the forlnation, aggregability,I40-143 or 
clearance,""!+! of Il-amyloid. Also isoforms specific differences in tl,e binding to Il-
runyloid have been reported, though not consistently,145.147 TIle apoE4 isoform may 
bind less strongly tllan apoE3 to tau and lvlAP2c proteins, which may result in tl,e 
development of neurofibrillary tangles,!4.,!49 another neuropathologic featnre of AD. 
Altel11atively, the transport of lipids could be compromised in APOE*4 carriers, 
leading to a poor reinnervation after neuronal cell loss,150 The cholinergic neuro-
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transmitter system relies heavily on lipid homeostasis,I50 and tIle choline acetyl-
transferase activity in the AD brain may be inversely reb ted to the nwnber of 
APOE*4 alieles.ISI,I" In vitro studies suggest that apoE3 facilitates and apoE4 
inhibits neurite outgrowth,153,15..f- Recently, apoE4 has been shown to have decreased 
antioxidant activity, and apoE2 increased activity, as compared with apoE3. 155 Apart 
fro1u structural differences between the apoE isofonlls, it was found that the apoE 
content decreases with increasing APOE*4 allele copies in the AD brain,I56 
Other susceptibility genes 
A t1tunber of genes have been studied because of the possible role of the gene 
product in the AD pathology. Like apoE, ul-antichymOl:1ypsin (ACI) binds to 13-
atnyloid, and serves as a stimulatol), factor in the polymerization of B-amyloid.142 In 
the AD brain, ACr is expressed particularly Ul areas that develop l3-amyloid 
deposits. 1s7 Therefore, the ACf gene was considered to be a candidate gene involved 
for AD. AJdlOugh in one study, homozygotes for the Acr* A allele were found to 
have an 1.5-fold UlCreased risk of AD as compared with od,er subjects,l58 tltis could 
not be confirmed elsewhere. 1s9 
The association between APOE*4 and AD led to shldies of genes whose 
products bUld to apoE. The Very Low Density Lipoprotein receptor (VLDL-r) is 
one of dle receptors for lipoproteins containing apoE.l60 Subjects hOlnozygous for 
the A2 allele of d,e VLDL-r gene had a two- to dlfeefold increased risk of AD in a 
Japanese study.t61 However, these fmdings could not be verified in Cauc(lsians. 162,163 
There is sotne evidence that the gene encoding dle precursor protein of non-
amyloid-13 component (NACP) may be involved in d,e pathogenesis of AD. Among 
carriers of APOE*4, the NACP allele 2 was found to be more frequent Ul 
non-demented elderly d1atl Ul AD patients. l64 11,e observation dlat the NACP allele 
2 may exert a protective effect remains to be conHrmed. 
The CYP2D6B allele may increase the risk of Parkinson's disease and the Lewy 
Body variant of AD,I65,I" aldlOugh not consistendyl67 111e protein product of 
CYP2D6 is involved in detoxifying envirotunental toxins. l6S As there are sunilacities 
between AD and Parkinson's disease and familial aggregation of these disorders has 
been observed,7 CYP2D6B was studied in AD. 11,e CYP2D6B allele was found to 
be associated widl milder synaptic padlOlogy in AD brainsl " A recent study suggests 
that dle frequency of tIus allele was comparable in AD patients and in controls. 
Therefore, the role of d,e CYP2D6B allele Ul d,e development of AD may also be 
limited. 
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Interaction of genes and environmental factors 
As large nwnbers of patients and controls arc needed to study rare gene-gene and 
gene-envit0111nent interactions, studies up till now focused on the most frecJuent 
genetic risk factor for AD, the APOE*4 allele. Several studies found the strongest 
effects of APOE*4 on AD to occur in those with a positive family history of 
de1nentia.80,91,%,98,170 However, for most d01ninant mutations, no interaction with 
APOE*4 was obselved61.93.99-101 The exception may be the Va1717---Hle 1\1'1' 
tnutation, for which APOE appears to effect the age of AD onset. i7I ,l72 Patients with 
APOE*2 had a Jater onset age,l7I,l72 while disease onset was earlier in cases with 
APOE*4.172 It is controversial whether there is interaction between APOE and the 
putative susceptibility genes ACT, VLDL-r and NACP.158.159,16I-164,173 
There is S01ne evidence that the association between APOE*4 and AD 1nay be 
tnodified by gender,7.~,t74-176 In a study of familial AD, women who cany one 
APOE*4 allele had a similar risk of AD as women canying two APOE*4 alleles. 177 
In tnen, to the conU'ary, no sigtuficant differences \vere obsenred between APOE*4 
heterozygotes and non~APOE*4 car.tiers. I03,I77 However, a gender specific APOE*4 
associated risk of AD was not found by others,178 The interpretation of these 
findings is hampered by the fact that these are based on prevalent patients, and may 
be the result of gender specific differences in cardiovascular mortality related to 
APOE*4. 179 
'rhe odds ratio for AD associated \vidl APOE*4 may decrease widl age. 7S,II3,ISO In 
very elderly subjects the APOE*4 frequency was sintilar in AD patients and 
cognitively nor111al individuals. lSI There arc several explanations possible including 
age-dependent expression of the APOE gene and interaction of APOE*4 with an 
age dependent factor. However, in one of the population-based studies of incident 
AD patieills, the APOE*4 related risk of AD did not vary with age.'l7 Further 
studies of age-specific risk are clearly needed. 
Senun cholesterol levels arc partly detel'1nined by genetic factors, including dle 
APOE gene." It has been suggested that total cholesterol level may modulate the 
APOE*4 associated risk of AD.175 Also the presence of generalized adlerosclerosis 
seems to potentiate the effects of APOE*4 on the risk of AD.' 
A previous head injury inay be another ellvirotunental factor involved in the 
etiology of AD.9 A synergistic interaction was observed between the effects of 
tralUnatic head injury and APOE*4. 182 APOE*4 carriers without a previous head 
injury had a twofold increased risk of AD, while APOE*4 carriers with a head injury 
were on a tenfold increased cisk.lS2 This observation was supported by a postmortem 
study which suggested that deposition of fl-amyloid after head injury may depend on 
the number of APOE*4 alleles. I" 
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A recent study suggests that reactivation of hctpes simplex vlius type 1 in the 
brain, .is only associated with the develop1l1cnt of AD when the APOE*4 allele is 
present. IM If confinned, this finding indicates another genc-enviromnent interaction. 
In several case-control studies, an inverse relation between smoking and AD has 
been rcported.l I The putative protective effect of stnoking inay be limited to 
APOE*4 carriers with a family histOl), of dementia. I85 11us relation should be further 
investigated, since previous studies have been subject to selection bias, survival bias 
and recall bias. Indeed, in a recent follow-up study, smokers were found to have an 
increased risk of dementia, especially in the absence of APOE*4. 12 
Estrogen use during menopause tnay lower the risk of AD.1O Among WOlnen 
with APOE*4, the protective effect of estrogen was stronger compared with Wotnen 
without APOE*4, although these differences were not statistically significant. lO In a 
study of AD patients with early onset, the protective effect of estrogen use was 
found to be limited to women who carried APOE*4. 186 
Limited information is available on the interaction of APOE with the use of 
nonsteroid anti-inflammatol), dlugs. Although the strongest evidence for an asso-
ciation was found in persons without APOE*4, there is no significant evidence for 
effect tnodification. 187 
Clinical and public health implications 
There are three potential applications of testing for the presence of AD nlutations: 1. 
for predictive testing in unaffected individuals in order to identify persons at high 
risk of AD, 2. as a diagnostic test, and 3. to select demented patients for therapy. 
Despite the high .risk of AD associated with the known dominant lllutations in the 
APP, PS-l, and PS-2 genes, testing will be not be valuable because these lllutations 
are very rare. Only in patients frotn families with an autosomal dOlninant fottn of 
AD, screening for these mutations may be useful. 111is section will therefore focus 
on APOE*4, by far the most frequent genetic risk factor for AD. 
Predictive testing Many authors have argued against the use of APOE genotyping 
in the prediction of whether or not S01neone will develop AD.188-193 An important 
arglUllent is that reliable APOE specific estimates of the lifetime risk of AD are 
lacking. Estimates, based on data from various case-series, indicate that APOE*4 
caniers have a substantial chance of 110/ developing AD during a lifetitne. l92 Although 
there is some evidence that APOE typing can identify asymptomatic people at lugh 
risk of AD,194,195 in the absence of preventive strategies, pre symptomatic testing 
see1ns to be of litde usc and to be unethical. 
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Diagnosis It has been suggested that APOE testing be used in the diagnosis of 
AD. IS') Although APOE genotyping may further increase diagnostic certainty in a 
population of pwbable AD patients,I')6 its value in the differential diagnosis of dellleJIlia 
is limited as APOE*4 may also be associated with other dementing illnesses than 
AD.I')7 Increased APOE*4 frequencies have been reported in patients with vascular 
dementia,'J-l-,I')s,t')') Lewy Body diseasc,200-20J Parkinson's disease delnentia,2()..\ frontal 
lobe dementia,205)% and Creutzfeldt-Jakob disease.207 Findings on APOE and the 
non-AD demcntias are s01newhat controversial howcver,20S-214 with the exception of 
Lewy Body disease. The probable association between APOE*4 and the most 
itnportant alternative diagnosis for AD, vascular de1nentia,94,I,)S,199 nlay litnit the utility 
of APOE testing in tbe differential diagnosis of dementia. There is an ongoing 
debate on tlus issue. The Ame.rican Collcge of lvledical Genetics/ A.merican Society 
of HlUnan Genetics and others did not recommend APOE genotyping in the 
diagnosis of AD."o The National Institute on Aging! Alzheimer's Association 
Working Group concluded that physicians may choose to use APOE genotyping as 
an adjunct to other tests currently employed for AD diagnosis. 1')1 
Tberapy It has further been suggested that APOE genotyping may be valuable in 
the evaluation of therapy. Tacrine, an acetylcholinesterase inhibitor,21S was found to 
be less effective in demented APOE*4 carriers, as compared with patients who do 
not carty an APOE*4 allele. lSI However, in tIus small study, patients were selected 
fr01n a group who cOlnpleted the trial, and \vho showed maximal change. 151 
Diagnostic c.riteria were not described, and it is not clear whedler dlere were baseline 
differences in the stage of disease between patients with and without APOE*4l51 
Besides, several outcomes were used WitIl no adjustment for multiple testing. lSI Tills 
finding is tberefore preliminary and needs to be confirmed by others. 
Discussion 
In recent years, remarkable progress has been made in the unraveling of the genetic 
basis of AD. 'TIle possible itlteraction of various AD genes and environmental 
factors is schematically represented itl thejigll/lJ. Yet, research on the genetics of AD 
is far from completed. Various mutations in three genes (API', PS-1 and PS-2) have 
been identified which can lead to AD, but these are all extremely rare. The APOE*4 
allele is a cOttunon risk facto!, but despite the overwhelming evidence for an 
increased frequency of dus allele in AD patients, there are currently no reliable age 
and gender specific risk estimates available. The risk of AD associated with the 
. APOE*2 allele also remains to be resolved. Up till now, findings on otber 
susceptibility genes have been difficult to reproduce. 
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It is to be expected that other, yet unknown genes arc involved in the etiology of 
AD. Familial aggregation in the general population or in genetically isobted 
populations could not be explained by already known AD genes only.S2,80.91~I6~17 The 
yet unknown AD genes arc rllost likely implicated in the etiology thtough lllore 
cotllplex tnechanisms than the ones identified to date. 
Classical linkage analysis does not seetn to be a pr01nislng technique to detect 
these new genes, as families with AD patients in multiple generations arc rarc, and 
linkage analyses did not yield clues." An alternative approach is to exantine affected 
sib-pairs, hut this requires a large number of siblingS.218 In recent years, lunch 
attention has been paid to the possibility of localizing disease genes using case-series 
instead of families.2I' 'lbe statistical power of these studies in the general population 
is limited, but the situation is lllore favorable in isolated populations were there is 
usually less genetic variability.219 However, extrapolatioll of dlese findings to the 
general population may be limited. As experimental research will identify more and 
more details of the protein chemistl}' of AD, and the I-hunan Genome Project 
advances further in identifying genes, the opportunities for candidate-gene studies 
\vill increase. However, all of the above techniques for the identification of new 
genes are subject to false positive findings. As there is usually no a priori hypothesis 
as to which allele is associated with the disease, and a large number of alleles can be 
tested, problems related to multiple testing are encountered. 
An important aim in genctic-epidetniologic research will be to determine dle 
contribution of newly identified genes to dle occurrence of disease. For dlis ptupose, 
Vascular factors 
ACT Head trauma 
VLDL·r HSV-l infection 
NACP Smoking 
Estrogens 
APP 
PS-l AD NSAIDs PS-2 Education 
Genes Environment 
Figure - Schematic representation of various genetic and environmental factors involved 
in the etiology of Alzheimer's disease (AD), 
TIle thickness of the arrows indicates the evidence of a causal association. APr indicates the 
amyloid precursor protein gene, rS-l the presenilin 1 gene, rS-2 the gene for presenilin 2, 
ACT denotes the O:l-antichymotrypsin gene, VLDL-r the gene for the very low density 
lipoprotein receptor, NAcr the gene for non-amyloid-B component of amyloid precursor 
protein, and APOE denotes the apolipoprotein E gene. HSV-l indicates herpes simplex virus 
type 1, and NSAIDs denotes non-steroidal anti-inflammatory drugs. 
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populatiotl-based studies are needed in order to overC01ne referral bias. The problein 
of survival bias can only be overCOine in a follow-up setting. However, in these 
sul'veys it has been difficult to implement neuropathologic confirmation of the 
diagnosis. An estimated 10 percent of clinically diagnosed AD patients appear to 
have another detnenting illness at autopsy.no Tlus inay l'esult in diagnostic nllS-
classification which reduces statistical power. Nevertheless the problem of 
nllsc1assification in population-based studies is outweighed by the opportunity to 
study gene-envirotunent interactions, using prospectively collected data on exposure. 
Further research will thus be important to unravel the pathogenesis of AD, and 
eventually to develop effective therapy. Transgenic atilinals carrying AD ulutations 
can be useful for tIus purpose. Given tile devcloprnents in pharmacology and 
genetics, it is likely that genetic testing will be used to identify subgroups that will 
benefit froin new tIlerapeutic interventions. For susceptibility genes, unraveling 
interactions WitIl preventable risk factol's may ultimately lead to a new area in genetic-
epidemiology, prevention of disease in genetically susceptible groups. 
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3 
ApOLIPOPROTEIN E GENOTYPING 
AND DIFFERENTIAL DIAGNOSIS 
OF DEMENTIA 

3.1 
APOE testing in the 
differential diagnosis of dementia 
Introduction 
Considerations based on 
existing literature 
In Alzheimer's disease, there is a gradual decline in cogntt:1ve functions, often 
accompanied by alterations in personality and behaviour.') Despite these charac-
teristics it can be difficult to differentiate Alzheimer's disease form other types of de-
tllcntia, especially in its early stages. Although there is not yet effective treatment 
available, it is important to make d,e right diagnosis. Firsdy, reversible dementing 
illilesses should be diagnosed and treated. Secondly, given d,e devastating course, it is 
crucial to correcdy inform d,e demented patient and his family which future lies 
ahead. 
A diagnosis of Alzheimer's disease is usually made in two steps. Firstly, it is in-
vestigated whether a dementia syndrome is present, usually using d,e DSM-III-R 
criteria.} TIus is a clinical diagnosis, in which ncw:opsychological testing can play an 
important role. Secondly, it is investigated whether the clinical picture fits that of 
Alzheimer's disease, while other causes of dementia arc excluded. For the latter 
purpose, various diagnostic tools can be USCd,4 The association between the 
1\POE*4 allele of d,e apolipoprotein E gene (APOE),5,6 brought some investigators 
to recommended 1\POE testing as a differential diagnostic tool.' 
If APO£ testing can truly distinguish Alzheimer patients from od,er demented 
individuals, it implies d,at 1\1'OE*4 is differentially associated widl Alzheimer's 
disease d,an widl other dementias. As d,C value of 1\pOE typing in d,C differential 
diagnosis of dementia has not yet been investigated in patients who are referred 
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because of a possible dementia syndrolnc, dus article aims to explore tIus issue on 
the basis of the existing literature. Firsdy, d,e association between d,e APOE*4 allele 
and the nOl1-Alzheimer's disease dementias will be reviewed. Secondly, SOlnc tneth-
odological issues will be discussed. 
Apolipoprotein E and the 
non-Alzheimer's disease dementias 
Vascular dClnentia, dementia due to cerebrovascular disorders, is after Alzheimer's 
disease the 1UOSt conunon cause of dementia.8 Classically, it is characterised by a 
sudden onset and focal neurological deficits. Different diagnostic criteria can be used, 
but the overlap is poor.9 As atherosclerosis seems also to be related to Alzheimer's 
disease,1O the distinction £r01n vascular detnentia is often difficult, and may be 
artificial. Atnong patients with vascular dementia, an increased frequency of the 
APOE*4 allele has been obselved: 0.21-0.46 versus 0.15 in d,e general popula. 
tion,lI-B However, others did not find an association between APOE*4 and vascular 
dementia (allele frequency 0.06·0.14).14." It should be noted however, that studies 
supporting the association between APOE*4 and vascular delnentia are tnethod-
ologically superior. 'I1lerefore it seems to be likely dtat APOE*4 is related to vascular 
dementia. 
Diffuse Lewy body disease was found to be associated in neuropadlological 
studies widl an increased APOE*4 allele frequency (0.22-0.42).17." Diffuse Lewy 
body disease is a type of dementia characterised by confusion, anxiety, hallucinations 
and parkinsonism. Lewy body disease is however a controversial entity, and may be a 
variant of Alzheimer's disease. 
DClnentia after the onset of Parkinson's disease is often characterised by mental 
slowing, decreased flexibility, and a deficit in recalling, while recognition may be un-
altered. Still, the distinction widl Alzheimer's disease may be difficult, as also 
Alzheimer patients may develop parkinsonism.20 It is still unclear whedler Parkin-
son's disease delnentia is related to APOE*4: an increased allele frequency has been 
described (0.32),21,22 but dus was not confirmed by od,ers.23~4 Of d,ese studies, two 
wcre population-based,22,24 and contradicting. 
It rcmains to be clarified whether frontal lobe dementia is association with 
APOE*4. Two publications report an increased APOE*4 frequency (0.25-0.38),2\~6 a 
third one does not (0.09).27 The clitucal picture of frontal lobe dementia is, in its early 
stages, dominated by alterations in personality and behaviour; memory disorders 
usually occur later on. 
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Cognitive impairment is frequently found in depressive patients. TIle loss of 1no-
tivation and attention, may result in a decreased performance with cognitive testing. 
Disorders of mood are also frequent in the early stages of detnentia. Therefore, the 
rustinction between early dementia and depression in tbe elderly can be rufficult. The 
APOE*4 allele frequency was found to be increased in a small study among depres-
sive elderly people." Tlus finillng remains to be confirmed by others. 
Discussion 
In order to be useful in diagnosis, it is essential that a test result changes diagnostic 
certainty. Therefore, we can compare the pre-test probability (or a plioli probability) 
with the post-test probability (or (/ pos/,lioli probability). The (/ pliOli probability of 
Alzheimer's rusease, P(AD), in a demented patient is 50-70%, the proportion Alz-
heimer patients among all demented subjects.!,· Using Bayes' paradigm the a pos/eliOli 
probability P(AD I APOE*4) can be calculated, wluch is d,e probability of Alz-
heimer's rusease given carrierslup of APOE*4: 
P(AD)·P(APOE*41 AD) 
P(ADIAPOE*4) = 
P(AD)·P(APOE*4IAD) + P(no AD)·P(APOE*41 no AD) 
'TI,e gain (the rufference between the a priori and tbe a posteriori probability) in-
creases with a decreasing denominator of the above ratio. 'TIus denominator de-
creases when P(no APOE*41 no AD) increases, because P(APOE*41 no AD) + 
P(no APOE*41 no AD) = 1. P(no APOE*41 no AD) is known as tbe specificity. 
Therefore, d,e larger the specificity tbe larger the ruagnostic gain. 
As oudined above, APOE*4 seems to be associated widl the most important 
alternative ruagnosis for Alzheimer's rusease, vascular dementia, and possibly also 
with od,er dementing diseases. It is dlCrefore not to be expected tbat the specificity 
of APOE testing among dementia patients will be lugh. The gain of ruagnostic 
certainty will tbus not he substantial. 
l1leoretically, it is not be expected dlat d,e presence or absence of a risk factor 
can easily be used for ruagnostic purposes,2' A test should be positive in the ruseased 
Q.e. high sensitivity), and negative in tbose witbout tbe rusease (high specificity). The 
sensitivity can be written as 
P(APOE* 41 AD) = P(APOE * 4)· P(ADJAPOE * 4) 
P(APOE * 4)· P(A~APOE* 4)+ P(noAPOE * 4)· P(ADJnoAPOE * 4) 
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RR . P(APOE * 4) + 1-P(noAPOE * 4) 
1+ 1-P(APOE*4) 
RR·P(APOE*4) 
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As tlus relates to differential diagnosis, RR denotes the relative risk of Alzheimer's 
disease associated Witll APOE*4, ill a population of demented patients. Also 
P(APOE*4) refers to the proportion of APOE*4 camers among demented 
individuals. 
If at least 50% of Ille Alzheimer's patients are test positive (sensitivity more than 
50%), it follows that: l-P(APOE*4) < RR·P(APOE*4). 
'TIus is true when APOE*4 is conunon and/or tl,e relative risk is lugh. It has not 
yet been reported what the proportion is of persons carrying one or two APOE*4 
alleles, among subjects who are refereed because of a possible dClnentia syndrolne, 
Given tl,e putative relationslup between APOE*4 and tl,e non-Alzheimer's disease 
dementias) it is to be expected that the relative risk of Alzheimer's disease associated 
with one or two APOE*4 alleles among dementia patients, will be close to one. 
Therefore, tl,e sensitivity of APOE testing in tl,e differential diagnosis of dementia is 
expected to be low, and as discussed above, probably tl,e same ,vill hold true for the 
specificity. 
APOE genotyping has been recommended as a relatively cheap test, tllat could 
replace otl,er diagnostic tools.' However, demented APOE*4 carriers can still suffer 
a treatable disease, altllOugh chances arc linuted. The devastating course and the 
linllted therapeutic possibilities for Alzheimer's patients, justify a stately ainled to 
exclude (rare) types of dementia wluch can be cured. These diagnostic tests should 
therefore never he omitted. 
It has further been suggested tl,at APOE genotyping could identify a subgroup of 
Alzheinler patients who could benefit best from treatment. Tacrine, an acetyl-
cholinesterase inlubitor,30 was found to be less effective in demented APOE*4 
carriers, as compared to patients who do not carry an APOE*4 allele.31 As this v,ras a 
small study, with several methodological wcakllcsses,32 tlus fmding needs to be 
confirtned by others. 
As the advantages of APOE testing seem to be small, Ille disadvantages may be 
large. The disclosure of the APOE genotype may cause unnecessary concern in the 
offspring of Alzheinler patients, especially in tllOse homozygous for APOE*4." 
Currently, APOE geno!)'Ping is not a useful test in tl,e diagnosis of Alzheimer's 
disease. Of course tllls will change when there is more evidence that the effects of 
new tllerapeutics will depend upon tllt APOE geno!)'Pe. 
36 
APOE testillg: fOllsideralioJls based 011 existing literatllre 
References 
1. CummingsJL. Dementia: the failing brain. Lancet 1995;345:1481-4. 
2. McKhann G, Drachman D, Folstein tvl, et al. Clinical diagnosis of Alzheimer's disease: re-
port of the NINCDS-ADRDA \Vork Group under the auspices of Department of Health 
and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:39-44. 
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 
third edition, revised. \'X'ashington DC, American Psychiatric Association, 1987. 
4. Corey-Bloom J, Thai L], Gabsko D, et at. Diagnosis and evaluation of dementia. Neurology 
1995;45:211-8. 
5. Stritunatter \X'J, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding 
to B-amyloid and increased frequency of type 4 allcle in late-onset familial Alzheimer disease. 
Pwc NaclAcad Sci USA 1993;90:1977-81. 
6. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association 
between apolipoprotein E genotype and Alzheimer disease. JArviA 1997;278:1349-56. 
7. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of 
Alzheimer's disease. Ann NeuroI1995;38:6-14. 
8. Ott A, Breteler MMB, Van Harskamp F, et a1. Prevalence of Alzheimer's disease and vascu-
lar dementia: association with education. The Rotterdam Study. BM] 1995;310:970-3. 
9. Gold G, Giannakopoulos P, Montes-Paixao C, et al. Sensitivity and specificity of newly pro-
posed clinical criteria for possible vascular dementia. Neurology 1997;49:690-4. 
10. Hofman A, Ott A, Breteler M:rvrB, et al. Atherosclerosis, apolipoprotein E and the preva-
lence of dementia and Alzheimer's disease in a population-based study: the Rotterdam ShId}'. 
Lancet 1997;349:151-4. 
11. Slooter AJC, Tang M-X, Van Duijn CM, et a1. Apolipoprotein E 84 and the risk of dementia 
w.ith stroke. A popuhtion-based investigation. JArvIA 1997;277:818-21. 
12. Noguchi S, Murakami K, Yamada N. Apolipoprotein E genotype and Alzheimer's disease. 
Lancet 1993;342:737. 
13. Frisoni GB, Calabresi L, Geroldi C, et a1. Apolipoprotcin E 84 allele in Alzheimer's disease 
and vascular dementia. Dementia 1994;5:240-2. 
14. Sakoda S, Kuriyama M, Osame M, et al. Apolipoptotein E 84. Neurology 1994;44:2420. 
15. Kawamata J, Tanaka S, Shimohama S, et al. Apolipoprotein E polymorphism in Japanese 
patients with Alzheimer's disease or vascular dementia. J Neurol Neurosurg Psychiatry 1994; 
57:1414-6. 
16. Higuchi S, Arai H, Nakagawa T, et al. The apolipoprotein E gene in Binswanger's disease 
and vascular dementia. Clio Genet 1996;50:459-61. 
17. Lippa CF, Smith '1\'7, Saunders At\'l, et al. Apolipoprotein E genotype and lew)' body dis-
casc. Neurology 1995;45:97-lO3. 
18. Benjamin R, Leake A, Edwardson JA, et al. Apolipoprotein E genes in lewy body and Park-
inson's disease. Lancet 1994;343:1565. 
19. Pickecing~Brown SM, t:fann DlvfA, Bourke JP, et at. Apolipoprotein E4 and Alzheimer's 
disease pathology in lewy body disease and in other B-amyloid-forming diseases. Lancet 
1994;343:1l55. 
20. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein 84 allele is associated 
with a more aggressive form of Alzheimer's disease. Ann NeuroI1997;41:615-20. 
37 
Chapter 3.1 
21. Ami H, Mummatsu T, Higuchi S, et at Apolipoprotein E gene in Parkinson's disease with or 
without dementia. Lancet 1994;344:889. 
22. De Rijk .Me, Bretelec MMB, Ott A, et al. Apolipoprotein E genotype, Parkinson's disease, 
and dementia in Parkinson's disease: the Rotterdam study. Submitted. 
23. Koller \\TC, Glatt SL, Hubble JP, et al. Apolipoprotein E genotypes in Parkinson's disease 
with and without dementia. Ann Neurol199S;37:242-S. 
24. Marder K, Maestre G, Cote L, et al. The apolipoproteio e4 allele in Parkinson's disease with 
and without dementia, Neurology 1994;44: 1330-1. 
25. Stevens 1\'1, Van Duiin eM, De Kni;ff P, et a1. Apolipoprotein E gene and sporadic frontal 
lobe dementia. Neurology 1996. In press. 
26. Schneider ]A, Gearing M, Robbins RS, et al. Apolipoprotein E genotype in diverse neurode-
generative disorders. Ann Neurol 1995;38: 131-5. 
27. Pickering-Brown SM, Siddons M, Mann DrvlA, et al. Apolipoprotein E allelic frequencies in 
patients with lobar atrophy. Neurosci Lett 1995;188:205-7. 
28. Krishnan KRR, Ritchie JC, Tupler LA, et al. Apolipoprotein E e4. Neurology 1994;44:2420-
1. 
29. Baron JA. The clinical utility of risk factor data. J Clill Epidemial 1989;42:1013-20. 
30. Davis KL, Powchik P. Tacrine. Lancet 1995;345:625-30. 
31. Poirier J, Delisle M-C, Quir.ion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic 
deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92: 
12260-4. 
32. Slooter AJC, Van Duijn CI\t Genetic Epidemiology of Alzheimer disease. Epidemiol Rev 
1997;19:107-19. 
33. Bird TD, Bennett RL. Wh}' do DNA testing? Practical and ethical implications of ne\v 
neurogenetic tests. Ann NeuroI1995;38:141-6. 
38 
Abstract 
3.2 
APOE testing in the 
differential diagnosis of dementia 
The Rotterdam Study 
II is a llIaller of debale }vh,lh,r apolipopJVIein E genolyping is meflll illlh, d[Dilmlial diagnosis 
oj Alf{/;eilller's disease. 117, invesligaled Ibis isme alllong 249 llIi1dly 10 1lI0deraiely delllenied 
palienls detived jiVIlI a poplllalion-based silldy. Apolipoptvlein E genolyping IVas nol associaled 
,vdh a slalislically signijitanl dlange Ii} diagnoslic m1milly. Il7e condllde Ihal apolipoptvletil E 
gellotyping seelllS 10 be oj lillIe val", in Ihe difjimllial diagnosis of Alf{/;eilller's disease. 
Introduction 
The E4 allele of the apolipoprotein E gene (APOE*4) is a major susceptibility factor 
for the development of Alzheimer's disease (AD).I~ It is a matter of debate whether 
apolipoprotein E (APOE) genotyping is valuable in the differentiation of AD from 
other causes of dementia.3-S However, up till now, these statements are based on data 
£r01n various case series, which tnay be subject to bias. In particular, test charac-
teristics that are derived from selected series of patients may not be applicable to the 
disease spectrum in d,e general population. We present data on d,e performance of 
APOE genotyping as a differential diagnostic test of AD among patients widl dif-
ferent subtypes of dementia in a population-based survey. 
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Methods 
TIus study" is based on tI,e Rotterdam Study, a population-based cohort study of 
subjects aged 55 years and over, including institutionalised persons. Dementia was 
diagnosed as described previously,6 Briefly, of tI,e 10275 eligible subjects, cogtutive 
function was assessed in 7528 (73%), Screen positive subjects were furtI,er evaluated 
using an intenriew with a close relative, neuropsychological tests, neurological 
examination and neuro-imagil1g. A panel assessed, based on all available infonnation, 
whether a detnentia syndrome was present according to DS:tvI-III-R criteria.? A 
diagtlOsis of AD was made according to the criteria of tI,e NINCDS-ADRDA8 A 
diagtlOsis of AD WitIl cerebrovascular disease (CVD) was based on a history of 
stroke or neuro-itnaging findings, that were considered not ditecdy etiologically 
related to tIle dementia, Vascular dementia (VD) was diagtlOsed in accordance with 
tIle criteria of tIle NINDS-AIREN.' Parkinson's disease dementia (PDD) was 
diagnosed if tIle dementia started after the onset of idiopatIuc parkinsonism, Overall, 
474 patients witIl dementia were detected, For tIus study we limited ourselves to 
subjects WitIl mild or moderate impairment (i,e, crnucal dementia rating scale (CDR) 
2 or less and milllmental state examination score (I'vll'vlSE) 16 or more), since tI,ese 
are the people who are most likely referred to a clinic with suspicion of dementia. 
Of tI,e 347 subjects witIl mild or moderate dementia, a random sample of 249 
patients (mean age 83,5 years; SD 7,3) was included in the present analysis, The 
relative frequency of different subtypes of dementia in our study population was as 
follows, Probable or possible AD was diagnosed in 74% (n=185), AD with CVD in 
7% (n=18), VD in 16% (n=40), PDD in 6% (n=16) and otIler dementias in 3% 
(n=8), APOE genotyping was performed as described earlierlO,ll without knowledge 
of the diagnosis, 
Test charactel1stics for a diagnosis of AD (probable or possible AD, or AD witIl 
CVD) were calculated, using cases with any other type of delnentia as the reference 
group, 'l1,e diagnostic work-up as described above was used as the golden standard, 
We calculated the sensitivity and specificity of a diagnosis of AD based on tI,e 
presence of at least one APOE*4 allele. The same was done for the presence of two 
APOE*4 alleles, In tI,e latter analysis, tIle presence of one APOE*4 allele was 
considered to be a non-positive/ non-negative test result, i.e. heterozygotes were ex-
cluded,12 Moreover, we calculated tIle predictive value and tI,e likeWlOod ratio of 
zero, one and two APOE*4 alleles, The likeWlOod ratio refers to tI,e proportion of 
AD patients witIl a given APOE genotype divided by the proportion of tIlOse with 
anotI,er type of dementia witIl tI,e same APOE genotype, \'\Ihen a likeWlOod ratio 
exceeds 1, the probability of disease increases; when the likelihood ratio is less than 1, 
tI,e probability of disease decreases; when the likeW,ood ratio approaches 1, tI,e test 
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Table 1 - The presence of APOE*4 in Alzheimer's disease and other dementia types* 
Alzheimer's disease Other dementias 
All AD Probable AD' Possible AD AD+CVD All VD 
(n=185) (n=141) (n=44) (n=18) (n=64) (n=40) 
APOE4-E4- 0.68 0.67 0.68 0.56 0.61 0.58 
(0.61 to 0.74) (0.60 to 0.75) (0.54 to 0.82) (0.33 to 0.79) (0.49 to 0.73) (0.42 to 0.73) 
(n=125) (n=95) (n=30) (n=10) (n=39) (n=23) 
APOE4+E4- 0.26 0.26 0.27 0.44 0.34 0.38 
(0.20 to 0.32) (0.18 to 0.33) (0.14 to 0.40) (0.21 to 0.67) (0.23 to 0.46) (0.22 to 0.53) 
(n=48) (n=36) (n=12) (n=8) (n=22) (n=15) 
APOE4+E4+ 0.06 0.07 0.05 0.00 0.05 0.05 
(0.03 to 0.10) (0.03 to 0.11) (0.00 to 0.11) (0.00 to 0.00) (0.00 to 0.10) (0.00 to 0.12) 
(n=12) (n=10) (n=2) (n=O) (n=3) (n=2) 
* Values are proportions (95% CI) and numbers. AD=Alzheimer's disease; CVD=cerebrovascular disease; VD=vascular dementia; 
PDD=Parkinson's disease dementia. 
, Including subjects with AD + CVD. 
PDD 
(n=16) 
0.56 
(0.32 to 0.81) 
(n=9) 
0.38 
(0.14 to 0.61) 
(n=6) 
0.06 
(0.00 to 0.18) 
(n=l) 
CiJapter 3.2 
is unlllfonnative. 12 All analyses were performed for the whole study population) and 
in strata of age, gender and family history of dementia. 
Results 
Table 1 shows that the APOE*4 alleles was equally distributed in AD patients and in 
those with another type of dementia (X2=8.9; P=0.35). In all patient groups, the 
APOE genotype distribution was in Hardy-Weinberg equilibrium. III table 2 test 
characteristics are shown for a diagnosis of AD based on th~ APOE genotype. We 
found a poor sensitivity, and a reasonable specificity. 11,e presence of one APOE*4 
allele was not informative to diagnose AD (table 3), since the corresponding pre-
dictive value tended to be less than the a P';O/; probability (0.74, 95% CI: 0.69 to 0.80, 
Table 2 - Sensitivity and specificity of a diagnosis of Alzheimer's disease based on the 
APOE genotype* 
Sensitivity Specificity 
APOE*4+ 0.32 0.61 
(0.26 to 0.39) (0.49 to 0.73) 
APOE4E4' 0.09 0.93 
(0.04 to 0.13) (0.85 to 1.0) 
* Values are means (95% CI), 
t Heterozygous APOE*4 carriers were excluded. 
Table 3 - Test characteristics of APOE genotyping in the differential diagnosis of 
Alzheimer's disease* 
APOE4-E4-
APOE4+E4-
APOE4+E4+ 
* Values are means (95% 0), 
42 
Predictive value 
0.76 
(0.70 to 0.83) 
0.69 
(0.58 to 0.79) 
0.80 
(0.60 to 1.00) 
Likelihood ratio 
1.11 
(0.89 to 1.38) 
0.75 
(0.50 to 1.15) 
1.38 
(0.40 to 4.75) 
APOE testiNg: the Rotterdam St/If!Y 
lable 1). The probability of AD in case of two APOE*4 alleles slightly increased to 
0.80 (95% CI: 0.60 to 1.00). However, ti,e corresponding likelihood ratio of 1.38 was 
not significantly different from 1. Also, only 0.06 (95% CI: 0.03 to 0.10) of ti,e AD 
patients carried tlus genotype. 
Our ftndings were sunilar for men and women, and for subjects with and without 
a family lustory of dementia. When ti,e study population was stratified in age tel' tiles, 
the sensitivity decreased and the speciftcity ulcreased with ageulg. Speciftcally, in the 
youngest age tertile (aged 82 years or less), ti,e sensitivity associated Witll one 
APOE*4 allele 01' more was 0.41 (95% CI: 0.29 to 0.54) and the specificity 0.56 (95% 
CI: 0.37 to 0.75). In tills subgroup APOE genotyping did not increase diagnostic 
certaulty either. Our results did not change when AD patients with CVD were 
excluded. Moreover, furtller restriction to only mildly demented subjects (those with 
a M~v[SE score of at least 18 and a CDR less tI,an 2, and ,vitllin 3 years after the 
onset of symptoms) resulted in similar findings. 
Discussion 
Our study suggests tI,at APOE gena typing is of little value in distinguishing AD 
patients from otller demented subjects. The advantage of tlus study is ti,e single-
centre, population-based design. A weakness however, is dle lack of neuro-
pathological confirmation of the clinical diagnoses. We found a relatively low 
APOE*4 allele frequency in AD patients, as did otl,er population-based studies. B •l4 
Our study population is relatively old, consequently APOE*4 is less prevalent. 15 
However, in our study APOE gena typing is not informative in younger patients 
eidler. 
A1t1lOugh at tills moment tI,ere is no causal treatruent available for AD patients, 
ti,e disease should be diagnosed Witll care. Treatable causes of dementia should be 
detected, and correct information should be provided about ti,e prognosis. Our 
population-based study suggests that APOE genotyping is not useful in ti,e 
differential diagnosis of AD. 
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ApOLIPOPROTEIN E 
AND RISK AND PROGNOSIS 
OF DEMENTIA 

4.1 
Apolipoprotein E4 increases the risk 
of dementia with stroke 
Abstract 
Objective To iJJvestigate the flsso(jfltiOJJ betweeJJ the flpolipopmteiJJ E (APOE) gCllo[ypes aJJd 
delllCl/tia iJJ patieJJts with stmke, defiJJed flS either [JfIsOilar dellleJItifi (VD) or AlzjJeilller's disease 
Ivith cmblvvflscJJlflrdiseflSe (AD+CVD). 
Design and Setting PopJJlatioJJ-bflsed, mse-coJJtml st/{{!y jiVIII Rotterdalll flJJd New Yod, City. 
Participants 187 dellle11ted patie11ts with stlVke Ivm mllpm,d with 507 c011f1vls silllilm' i11 age 
fl11d ethJJic gml/p. 
Main Outcome Measures The APOE allele jipql/eJlries ';1 PfltieJIts fl11d c011tmls, the otitis 
mtio (OR) of dellleJJtia with stmke, T/D fl11d AD+CT/D, (/fljllsted for age, gClldC/; mide",yalld 
edllmtioll fl11d the pe","t flttdbl/table lisk Irlated to the APOE*4. 
Results Ovemll, delJJe11ted PfltieJIts Ivith stmke had fI higher APOE*4 allele jiPql/e",y tha11 
c011tmls. COl/pam/ to APOE*3 hOl/JorYgote iJJdividllals, APOE*4 hOlllorYgotes hfld a seve11fold 
iJJt1VtlSet! Jisk of deme11tia with stmke, while pmoJJs Ivith the APOE3E4 genotype had {/ 11early 
twofold ,;mmse i11lisk. Risks flSsoriated with APOE*4 did 110t vary by the sl/bDpe o/dellle11tifl 
Ivith stmke or by flge or ge11dC/: The pem11t attdbl/fflble dsk "Iflted to the APOE*4 amo11g 
demCl/ted patie11ts with stmke IVflS 41% oveml/. 
Conclusion APOE*4 is fI gemtic dsk ffldorfor dellle11tifl with stmke, i11dl/di11g T/D mid 
AD+CT/D. This may illp/y shmd genetic sllsceptibility to demeJ/tifi flssoriflted widl stmke mid 
AD. Altematioe/y, dellle11tifl ill patie11ts with stlvke, flS OI"Wlt/y dejilled, may illdllde pati",ts with 
AD. 
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Introduction 
The elevated risk of Alzheimer's disease (AD) among individuals with the APOE*4 
allele of the apolipoproteill E gene (APOE=gene, apoE=protein) has been con-
fumed worldwide.'-s Among patients widl dementia and stroke, d,e role of APOE 
remains uncertain/rl2, Many studies have been litnited by small lllUnbers of patients 
and other tnethodological issues. The aim of tltis population-based, case-control 
study was to examine the relationship between the APOE genotypes and denlcl1tia 
with stroke, or its subtypes vascular dementia (VaD) and AD with cerebrovascular 
disease (AD+CVD), while considering d,e effects of age, gender and edullc ongin. 
Methods 
Data were pooled from individuals participating in two population-based studies, in 
Rotterdam, 11,e Nedlerlands and in New York City (Washington Heights). From all 
participants, info1med consent was obtained and d,e study was approved by d,e local 
medical ethics Cotlunittees, and the Institutional Review Board. 
11,e Rotterdam study is a population-based cohort study of d,e total population 
in a suburb, aged 55 years and older, including institutionalised persons. The objec-
tive was to investigate determinants of chronic disabling diseases.13 The cohort in-
cludes 7983 subjects (response rate 78%) who were examined from 1990 to 1993. In 
1993 and 1994, 88% of the participants who were alive (n=6315) were re-examined. 
Cogtlltive performance was assessed by d,e lvIitll Mental State Examination and by 
d,e Geriatric Mental State schedule. Dementia was diagnosed using a three-phase 
design, as described elscwhere,l4 Diagnosis included an interview with a relative, neu-
ropsychological testing) an examination by a behavioural neurologist and an IvIRl 
scan. 
T1,e \ll?ashington Heights study consists of a random sample of Medicare recipi-
ents in northern New York City provided by d,e Healdl Cate Financing Admullstra-
tion. The objective of this investigation was to estimate the frequency of various agc-
related disease~ of the nelVOUS system and identify detcumnants of disease. The rc-
sponse rate was 72%, and did not differ by edullc origin. 'l1,e 2250 participants un-
derwent an annual asscssment. A physician elicited thc medical history and con-
ducted a standardised ncurological examination. 1\ standardised neuropsychologi~al 
battery15.16 and assessment of activities of daily livil1g werc used to ascertain cognitive 
and functional criteri~ for dctnentia. 
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Diagnosis 
All infonnation was reviewed at consensus conferences in either Rotterdam or New 
York. A panel of clinicians arrived at consensus for diagnosis of delnentia according 
to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) defuu· 
tion. n The diagnosis of stroke was implemented similarly in Rotterdam and New 
York using the World Health Organization (WHO) crite11a." At both sites, direct 
questioning of the next-of-kin or care-giver established the diagnosis of stroke, sup-
plemented by neurological examination and brain imaging. The diagnosis of AD was 
based on the National Institute of Neurological and Con1ffiun1cative Disorders and 
Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-
ADRDA) critet1a,l9 A diagnosis of dementia with stroke was considered for all de-
Inented patients with a hist01J' or clinical evidence of stroke, and further subdivided 
into: VaD, AD+CVD or delnentia with stroke (\mclassified". VaD was based on the 
criteria of the National Institute of Neurological Disorders and Stroke and d,e Asso-
ciation Internationale pour Ia Recherche et l'Enseignement en Neurosciences 
(NINDS-AIREN).'o A diagnosis of AD+CVD was based on a history or clinical 
evidence of stroke (including brain imaging), judged not to be d,e cause of dementia, 
in patients who would have othenvise met criteria for AD. VaD was distinguished 
fron1 AD when the onset of dementia occurred within 3 tnonths after the stroke or 
when there was an ablupt change or a stepwise decline in cognitive function. A diag~ 
nosis of dementia with stroke "uncL1ssified" (UNC) was made when limited infor-
tnation was available, such as the absence of brain imaging, or in the absence of a 
temporal relationship between detnentia and stroke. All diagnoses were made with-
out knowledge of the APOE genotype. 
Study population 
Included were patients widl dementia and stroke. The participants from d,e Wash-
ington Heights study included two patients with autopsy confirmed VaD. Excluded 
were patients with AD alone or dementia due to other causes. The comparison 
group consisted of a rand01n satnple of individuals without dementia in the Rotter~ 
dam and Washil1gton Heights studies for whom DNA was available. For evelY case, 
approximately duee cOl1trols were matched on both age (10-year intelval) and edimc 
group. Atnong I-lispanics, there were too few controls above age 85 years, thus all 
available controls were included with adjustments made in the analysis. This resulted 
in a study population of 187 patients wid, dementia and stroke and 507 c·ontrols. 
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Ethnic group 
There \Ver~ no African-Atnericans or Hispanics in the Rotterdam study. In Wash-
ington Heights, inclividuals were classified as African-American, Caucasian (both 
non~Hispanic) or Hispanic groups by standardised, direct interview with the individ~ 
ual or a family member.>! 
Laboratory analysis 
Genotypes were perfonned using a polymerase chain reaction, using methods lll0di-
lied from those previously described.4.',22,23 
Statistical analysis 
APOE allele frequencies were determined by counting alleles and calculating sample 
proportions. No:rmally distributed, continuous data were studied using an analysis of 
variance (AN OVA) model, and the chi square test was used for categorical data. The 
relative risk of dClnentia with stroke, VaD or AD+CVD was estimated as an odds 
ratio (OR) in a multiple logistic regression analysis, and presented with a 95% con£i~ 
dence intelval (CI) using APOE3E3 as d,e reference. To adjust for confounding, we 
added age alld residency (Rotterdam or New York), gender and education to the 
model. Logistic regression analyses were also performed stratified by age, gender, 
eduuc group and residency. TIle proportion of dementia with stroke among 
APOE*4 catriers dIat is attributable to APOE*4 was estimated as the attributable~ 
risk percent (AR%). 
Results 
Characteristics of d,e patients and controls are outlined itl {able 1. 11,e distribution of 
d,e APOE alleles in the colltrols from Rotterdam did not differ from dlOse it, New 
York (Rotterdam~ APOE*2 0.092, APOE*3 0.769 and APOE*4 0.138 vs. NY~ 
APOE*2 0.081, APOE*3 0.784 and APOE*4 0.135; X2=0.4, df=2, ]>=0.8), nor did 
the distribution of d,e APOE alleles differ among patients widl dementia and stroke 
(Rotterdam~APOE*2 0.071, APOE*3 0.709 and APOE*4 0.220 vs. NY~ APOE*2 
0.078, APOE*3 0.729 and APOE*4 0.193; X2=0.4, df=2, P=0.8). The distribution of 
subdiagnoses of dementia and stroke did not differ by location (Rotterdam~ 
AD+CVD 33%, VaD 51%, UNC 16% vs. NY~AD+CVD 41%, VaD 46%, UNC 
13%; X2=1. 7, df=2, ]>=0.4). Moreover, d,e APOE allele frequencies did not differ by 
subtype of dementia (AD+CVD~ APOE*2 0.071, APOE*3 0.729 and APOE*4 0.2 
vs. VaD~ APOE*2 0.072, APOE*3 0.722 and APOE*4 0.206; X2=0.5, df=4, P=0.9). 
Therefore, we pooled the data from d,e two sites. 
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'11,e distribution of APOE genotypes were similar in patients with prevalent and 
incident disease (X2=2.1, df=4, 1'=0.7), thus these groups were also combined. This 
resu1ted in a study population of 187 patients with dementia and stroke, subclassified 
as follows: 2 patients (1%) with definite VaD, 16 individuals (9%) with probable 
VaD, 72 subjects (39%) with possible VaD, 70 persons (37%) with 1\D+CVD, and 
27 patients (13%) who could not be classified as either VaD or AD+CVD. The 
control group consisted of 507 non-demented individuals frequency matched by 10-
year age intenral and ethnic group (table 1). However) demented patients were still 
older and less well educated than controls. There were also more women alllong the 
patients than controls. 
The distribution of the A1'OE genotype in patients and controls was in Hardy-
\Veinberg equilibrium suggesting no selective inbreeding or slttvival. The frequency 
of the APOE*4 allele was significandy higher in demented patients widl stroke as 
compared to d,e controls (control A1'OE*2=0.086, APOE*3=0.778, APOE*4= 
0.136 vs. dementia widl stroke APOE*2=0.075, 1\POE*3=0.719, APOE*4=0.206; 
X2=1O.2, df=2, 1'=0.006). Table 2 shows that, compared widl APOE3E3, d,e OR for 
dementia widl stroke associated widl the APOE3E4 genotype was increased nearly 
seven-fold (OR=6.9; 95% CI 1.6 to 29.4) wlule the OR associated widl APOE*4 
Table 1 - Description of study population 
Dementia 
VaD AD+CVD Controls Variables with Stroke 
(n=187)' (n=90) (n=70) (n=507) 
Age' 80.1 (7.6) 79.1(8.1) 80.2 (7.1) 76.8 (7.1) 
Sex 
men 51 (27%) 29 (32%) 16 (23%) 200 (39.8%) 
women 136 (73%) 61 (68%) 54 (77%) 305 (60.2%) 
Residency 
New York 96 (51%) 44 (49%) 40 (57%) 301 (59%) 
Rotterdam 91 (49%) 46 (51%) 30 (43%) 206 (41%) 
Ethnicity 
Caucasian 97 (51.5%) 48 (53.0%) 34 (48.6%) 292 (57.6%) 
African-American 35 (19.0%) 15 (17.0%) 19 (27.0%) 77 (15.2%) 
Hispanic 54 (29.0%) 27 (30.0%) 16 (23.0%) 138 (27.2%) 
Asian 1 (0.5%) 0(0%) 1 (1.4%) 0(0%) 
Educationt 7.2 (3.6) 7.0 (4.0) 7.8 (3.4) 9.2 (3.9) 
* Includes patients with "unclassified" dementia with stroke (11=27). VaO:= vascular dementia. 
AD+CVO := Alzheimer's disease with cerebrovascular disease. 
t mean (SO) in years. 
51 
Chapter 4. 1 
heterozygosity was increased nearly two-fold (OR 1.8; 1.2-2.7). Adjustment for age, 
eth.uc group or study site did not change d,e ORs. 
The AR% or proportion of dementia with stroke among individuals wid, an 
APOE*4 that is attributable to APOE*4 was 41% (95% CI 37 to 44%), in VaD d,e 
AR% was 33% (95% CI 29% to 38%) and in AD+CVD d,e AR% was 44% (95% 
CI 39 to 48%). 
APOE*4 allele frequency and relative risk associated with at least ol1e APOE*4 
allele did not change wid, increasing age. TI,e APOE*4 frequency among demented 
patients wid, stroke was similar in women (0.210) and men (0.196). No effects of d,e 
APOE*2 allele were observed as compared to d,e APOE3E3 genotype. 
TI,e relationslup between APOE*4 and dementia in patients with stroke did not 
vat')' by study site or subtype of dementia (VaD or AD+CVD). However, among 
African-Americans and Hispanics d,e OR for dementia wid, stroke associated with 
APOE*4 homozygosity was lugh (10.7; 95% CI 1.1 to 80.4), while d,e OR associated 
wid, APOE*4 heterozygosity was only slighdy increased (OR=1.3; 95% CI 0.7 to 
2.4). Among Caucasians, the OR for dementia wid, stroke associated with APOE*4 
homozygosity and heterozygosity were both increased (OR=3.2 and 2.2, respective-
ly), but ol1]y APOE*4 heterozygosity was statistically significant (OR=2.2; 95% CI 
1.8 to 3.9) due to the small number of Caucasian homozygotes (OR=3.9; 95% CI 0.6 
to 28.7). 
Table 2 - The odds ratio for dementia with slroke associaled with APOE genotype: 
APOE Dementia with Stroket Vascular Dementia AD+CVD Controls 
E3E3 n=92 OR=l n=48 OR=l n=33 OR=l n=302 
(reference) (reference) (reference) 
E2E2 n=O OR=- 11=0 OR=- 11'=0 OR=- n=2 
E2E3 n=24 OR=1.1 n=10 OR=0.9 n=lO OR=1.3 n=68 
(0.7 to 1.9) (0.4 to 1.9) (0.6 to 3.3) 
E2E4 n=4 OR=0.9 n=3 OR=1.2 n=O OR=- n=15 
(0.3 to 2.9) (0.3 to 4.5) 
E3E4 n=61 OR=1.8 n=24 OR=1.3 n=26 OR=2.2 n=117 
(1.2 to 2.7) (0.8 to 2.2) (1.2 to 3.8) 
E4E4 n=6 OR=6.9 n=5 OR=1O.5 1l"'1 OR=3.3 n=3 
(1.6 to 9.4) (2.4- to 6.6) (004 to 34.3) 
* Relative risks estimated as odds ratio with adjustment for age, gender, residency and education. 
t Includes 27 patients who could not be classified as either vascular dementia (VaO) or 
Alzheimer's disease with cerebrovascular disease (AO+CVD) as well as patients with VaD and 
AD+CVD. 
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Discussion 
An increased risk of detllcncia with stroke) which included patients with either VaD 
or AD+CVD, was found to be associated with the APOE*4 allele. The association 
between APOE*4 and dementia with stroke was similar in women and men and did 
not valY with increasing age. The APOE*4 allele was associated with a higher relative 
risk of dementia with stroke in both the homozygous and heterozygous configura-
tion) but among African-Atllcricans and Hispanics the strongest effect was observed 
in individuals homozygous for APOE*4. No effects of the APOE*2 allele were ap-
parent. 
We pooled data from two population-based studies because prior studies had 
included too few patients and controls to investigate the relationship between APOE 
and dementia with stroke. 'n,e distribution of the APOE alleles and the subtypes of 
dementia with stroke were similar in two studies, lessening the possibility that the 
results reflect admixhlre of genetically distinct populations. Nevertheless) all analyses 
were adjusted for residency and ethnic group. Although autopsy confirmation was 
limited to two patients, the diagnostic work-up in both populations was relatively 
complete. lvIore extensive neuropathological examination will be essential to increase 
the diagnostic certainty and to further clarify the association between APOE*4 and 
delnentia with stroke. 
Previous investigators9- 12 used other criteria than the NINDS-AlREN.20 The in-
consistency of the association in earlier studies may also have been related to the use 
of hospitalized patients and controls that did not reflect the patient population."" 
Alternatively) some of these differences might reflect the presence of other genetic or 
environmental risk factors, that modify d,e APOE*4 effects. APOE*2 was previ-
ously found to be associated with VaD,1O but several studies have found no effect of 
tIlls allele.7-9.12 
Studies of stroke and APOE have also been inconsistent. Patients wid, ischaemic 
stroke have been reported to have both a higher APOE*2 frequency," and APOE*4 
ftequency)25 than controls) but others have found 110 association between tIle APOE 
genotype and stroke." Although d,e occurrence of a stroke seems unrelated to d,e 
APOE genotype) tIle outconlC after intracerebral haemorrhage may be worse for 
individuals with an APOE*4 allele.27 
Our results imply that individuals who develop dementia wid, stroke and dlOse 
who develop AD may share genetic susceptibility. The apoE protein may be acti-
vated in the response to cerebral ischaemia and it may function in compensatory syn-
aptogenesis.28,2' Alternatively, the apoE protein may be involved in the padlOgenesis 
of VaD or AD+CVD through its effects on lipids. Compared to apoE3, apoE4 in-
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creases total cholesterol and LDL-cholesterollevels which could increase the risk of 
atherosclerotic vascular disease; ApoE2 has the opposite effect.30 
Cerebrovascular disease and AD. are conunon disorders and it is not smprising 
dlat they tuay overlap in sotne inclividuals.31 Thus, dementi.'l in patients with stroke, 
as currently defined, mal' include a substantial number of individuals with AD. As 
many as 15% to 30% of individuals with stroke and clinically diagnosed dementia 
prove to have mixed diagnoses at postmortem exanlluation which include AD and 
cerebrovascular disease.32 
TI,e APOE*4 related risk of dementia and stroke was slightly different in Cauca-
sians than in other etlmic groups paralleling our work in AD.' We previously 
proposed that in African-Americans and Hispanics a modifying gene or environ-
mental factor might alter tl,e effects of one APOE*4 allele, but fails to protect 
against tl,e consequences of two APOE*4 alleles.' 
We conclude that APOE*4 is a genetic risk factor for dementia in patients \Vitll 
stroke, also classified as having eitl,er VaD and AD+CVD. TI,e degree of association 
may vat}' by ethnic group. To furtller elucidate the patilOgenesis of tl,ese types of 
dementia, the role of vascular risk factors and disease should be studied in relation to 
ti,e APOE genotype. Furthermore, additional genetic susceptibility or modifier loci, 
as well as environtnental factors should be investigated. 
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Serum apolipoprotein E 
and Alzheimer's disease 
Tbe ~U)OE*4 allele of Ibe apolipopmlelil E gene (A1'OE) is all iIJJp0l1alll I7sk faclorfor AIZ-
beillJer's disease (AD). II bas beell sllggesl,d Ibal levels of apolipopmleill E (apoE) ill plasllJa mv 
illelrased iii AD. III liJis popilialioll-bas,d Sllldy, we jiJ/llid Ibat senllll apoE leuels w,," lower ill 
pmbable AD palieills tVIIJplllfd 10 lol-delll,"led lwlflvis (0.75 /plloi/ I (SD 0.35), /lmliS 0.83 
JUllol/ I (SD 0.40), 1'<0.05). Tbis jilldillg is ill acmrdm/(, wilb lower senllll apoE le/lels as ob-
SClwd ill ranieIJ oflbe ~U)OE*4 allele, who {/If o/lClw!msellled ill AD. After adjl/SllIJelil for age, 
sex, lolal pmfelil, albllmill Ie",!, body mass illdex alld Ibe ~)OE genotype, Ibe diUem/(, ill senllll 
apoE 1e",ls Imgefy disappeaml. Om'popllfalioll-based sllldy sllggesls Ibal Ibe I,,!el of apoE ill senllll 
seellJs 1I0t 10 lVllflibllle 10 Ib, palbogenesis of AD, illdependelll of Ibe APOE gellolype. 
Introduction 
Alzheimer's disease (AD) is a progressive, neurodegenerative disorder characterized 
by neurofibrillary tangles and senile plaque deposition in the brain parenchyma. The 
1\POE*4 allele of the apolipoprotein E gene (APOE) is a well established risk factor 
for AD, I but d,e mechanism of action is still incompletely understood. Up till now, 
d,e large majority of studies focused on the APOE gene, and not on the corre-
sponding protein (apoE). 'D,e level of apoE in plasma is only partly determined by 
the APOE genotype.' Increased plasma apoE levels have been observed in AD.' 
Plasma apoE levels can not directly be compared to intracerebral levels, as these rep-
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resent two distinct pools, separated by the blood-brain-bamer.4 However, in AD, the 
blood-brain-bamer was found to be unpaired, which may allow some pl1s1na protein 
to penetrate the brain parenchyma.S If con fumed, the finding that apoE level is in-
creased in plastna of AD patients is of interest, as plasma apoE level is related to vas-
cular discascs,l',7 and there is growing evidence that vascular factors pby a role in the 
etiology of AD.8 11,e aim of this population-based investigation is to further study 
the role of selUm apoE level in AD. 
Methods 
Study population 
This investigation is based on the Rotterdam Study, a population-based cohort study 
of subjects aged 55 years and over, including institutionalized persons.9 Dctnentia 
was diagnosed as described previously.'O Briefly, of the 10275 eligible subjects, 7983 
participated in the study, and cognitive function was assessed in 7528 (73%). Screen 
positive persons wcre further evaluated using an interview with a close relative, neu-
ropsychological tests, neurological examination and neuro-imaging. A panel of physi-
cians, a neurologist and a l1curopsychologist, diagnosed dementia in 474 persons 
based on the DSlvl-III-R definition." AD was diagnosed according to the NINCDS-
ADRDA criteria 12 in 72% of the dementia cases. The present study was restricted to 
probable AD patients with onset less than 3 years before examination for this study, 
in order to limit any selective survival. 8,13 TIle control gtuup consisted of a randotn 
sample of participants without dementia. Blood samples were drawn by venipuncture 
from non-fasting subjects. In 129 probable AD patients and 890 controls the APOE 
genotype and selUm apoE levels were determined on coded samples without know-
ledge of the diagnosis, using standard medlOds.2,14 For the analysis of seiunl total 
protein and albwninlevel, a calorimetric medlOd was used (Hitaclu 747 Bohringer). 
Statistical analysis 
Differences in senUll apoE level were studied using a. tllultiple linear regression 
IllOdel, with adjustments for age and sex. To examine whether known determinants 
of senun apoE such as total protein, albwnin level and body mass index, could ex-
plain an association between seium apoE level and probable AD, we included these 
variables in the regression tllodel. To study the association between serum apoE and 
probable AD, independent of d,e APOE genotype, we further added the APOE 
genotypes to the lllodei. '111e chi-square test was used to compare categorical data, 
and the two sample t test to study notmally distributed, continuous variables. 
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Results 
Descriptive statistics of the study popubtion arc presented in lable 1. Probable AD 
patients were significantly older and included a higher proportion of females tl,an the 
controls. In addition, probable AD cases had lower senun albwnin levels, and a 
lower body mass index than the controls. Senun apoE levels were statistically signifi-
cantly lower in patients with probable AD tl,an in ti,e non-demented controls. 
Table 2 shows the relationship between selUm apoE levels and tl,e APOE geno-
type for probable AD patients and cognitively normal incfu~duals. The distribution of 
the APOE genotype in both groups was in Hardy-Weinberg equilibrium. In both 
cases and controls, tl,e APOE*2 allele was associated witll higher, and the APOE'4 
allele with lower serum apoE levels. For each genotype, senun apoE level was lower 
in probable AD cases tl,an in the controls, although tllis was not statistically sigtlifi-
cant. The exception is tl,e APOE2E2 stratum, but tllis contained only one patient. 
As shown in table 3, senun apoE levels were statistically significantly lower in 
probable AD patients after adjustments were made for age and sex. As body mass 
index, protein and albwnin level was related to both probable AD as well as senun 
apoE level Qatter data not shown), we exatnined whether these variables could ex-
plain the association between senun apoE level and probable AD. When we adjusted 
for these variables, the difference in senlm apoE level between cases and controls 
slightly decreased, and was borderline statistically sigtlificant (P=O.06). As discussed 
above, se1um apoE levels are lower in APOE*4 carriers, who are over-represented in 
AD.! To test whetllCr an association between senun apoE level and probable AD 
may be explained by ti,e different distribution of the genotype, tl,e APOE genotypes 
were entered into ti,e model. Tllis resulted in a furtller decrease of ti,e difference in 
senun apoE levels between cases and controls. 
Table 1 - Characteristics of the study population. * 
Age (years) 
Females 
Serum protein (gil) 
Serum albumin (gil) 
Body mass index (kglm') 
Serum apoE (~moljl) 
Alzheimer's disease 
n=129 
84.1 (6.5) 
73% (94) 
70.4 (5.6) 
40.8 (2.8) 
25.3 (3.8) 
0.75 (0.35) 
Controls 
n=890 
68.2 (7.2) 
59% (526) 
70.5 (5.8) 
44.0 (2.7) 
26.6 (3.8) 
0.83 (0.40) 
* Values are unadjusted means (SD) or percentages (numbers) based on all available data. 
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Discussion 
Up until now, plasma apoE in AD has been examined in one stud)' oniy, by Taddei 
ct a1., who reported increased levels.3 However, it should be noted that tills study was 
small, and may have been subject to selection bias. As the cases were referred to a 
geriatrician, and the controls were spouses or volunteers, it is more likely that the 
cases suffered additional disorders than the controls. For example, stroke and Inyo-
cardial infarction are frequent conditions in a geriatric clinic, which are related to se-
Table 2 - Serum apoE level in demented and controls, according to APOE genotypes.* 
APOE Genotype Alzheimer's disease Controls 
n=129 n=890 
E2E2 2.27{-) 1.76 (0.67) 
n=l n=7 
E2E3 1.08 (0.41) 1.17 (0.48) 
n=16 n=130 
E2E4 0.98 (0.31) 1.11 (0.44) 
n=3 n=18 
E3E3 0.72 (0.29) 0.81 (0.34) 
n=69 n=498 
E3E4 0.60 (0.18) 0.64 (0.26) 
n=33 n=221 
E4E4 0.39 (0.23) 0.43 (0.13) 
n=7 n=16 
* Values are mean serum apoE levels (SD) (~moIJl), adjusted for age, sex, body mass index, 
total protein and albumin level, with numbers. 
Table 3 - Difference in serum apoE level between Alzheimer's patients and controls.* 
Covariates 
Age, sex 
Age, sex, protein, albumin, bmi t 
Age, sex, protein, albumin, bmi, APOEt t 
Alzheimer's disease 
n=129 
·0.11 (·0.21 to ·0.G2) 
·0.09 (·0.19 to 0.00) 
·0.05 (·0.14 to 0.04) 
Controls 
n=890 
o (reference) 
o (reference) 
o (reference) 
* Values are mean differences (95% confidence interval) in serum apoE level (~lmoIJl). 
t bmi indicates body mass index. 
t APOE denotes the apolipoprotein E genotype. 
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1um apoE levels.6,7 Further, in the study by Taddei et al. no adjustments were made 
for factors that could confound the proposed association, including body mass in-
dex, total protein and albrumn level.' As these factors may be related to both serum 
apoE level and AD, they might obscure an association of apoE level with AD. 
We found a close relationship between APOE genotype and serum level, con-
£inning previous reports.2 Therefore, it seems unlikely that the small difference in 
selum apoE level between cases and controls, is the result of tneasurement error in 
the laboratory tests. Unfortunately, we did not have autopsy confirmation of the di-
agnoses. Therefore, we can not rule out that we misclassified the dementia subtype in 
sotne instances. However, with clinical examination alone, approximately 900/0 of AD 
caSes can be diagtlosed correctly. IS The restriction to patients with recent onset, lim-
ited the possibility of selective mortality. n A strength of our study is that it is popu-
lation-based with a high response rate, which minimized the possibility of selective 
inclusion. 
We found that probable AD patients had non-significantly lower selum apoE 
levels than the controls, when we adjusted for age, sex, body mass index, total pro-
tein and albrumn level. Although apoE levels in senun and in the brain can not di-
rectly be compared, as these represent two separated pools,4 it is interesting tllat 
apoE levels were found to be reduced in tl,e hippocampus and cerebrospinal fluid of 
AD patients. 16,17 By contrast, APOE*4 allele expression was found to be increased in 
the AD brain. I8 It is however unclear whetller tlus is cause or consequence. 1'vIore 
research is required to determine tl,e role of intracerebral apoE levels in the etiology 
of AD. 'nus study suggests that in serum tl,e difference in apoE level between prob-
able AD cases and non-demented controls results largely from differences in tl,e 
distribution of the APOE genotype. Therefore, tl,e level of apoE in senun seems not 
to contribute to tl,e pathogenesis of AD, independent of the APOE genotype. 
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Apolipoprotein E genotype 
and progression of Alzheimer's disease 
Abstract 
The APOE*4 allele of Ihe apolipopmteill E gelle ill<1?flses Ihe I;sk of AI'lPeimer~ disease (AD), 
bllt il is (olJllvw/Jial w/;ether if also aj}etlS the disease COl/rse. HOJJJcve/j all sll/dies 011 Ihis issm IfP 
IIlIlilllOW flI? based 011 paliellis who may have beell illc/llded at difJimlt slages of disease. III lhis 
popllialioll·based Silldy, 97 palimls IP,," illc/lldcd al a similar slage, i.e. befim Ihe ollsel of {)'II/p-
101l/S, alld followed for liP 10 5 ),efllJ. Il7e fllllld Ihallhe APOE*4 allel, was 1101 a slmllg dele/mi-
lIalll of sll/vival ill AD. As cha/lge ill cogllilive jil//e/ioll alld seue/;!)' of de/llmlia w"" sill/ilarfor 
AD palimls IV/~h alld wilholll APOE*4, 0111' silldy sllggesls thai the pmgmsioll of AD is 1101 
Idated 10 the APOE*4 allele. 
Introduction 
Carriers of the APOE*4 allele of the apolipoprotein E gene (l\POE) have an in-
creased risk of Alzheimer's disease (AD).'" The risk of AD is elevated, and the mean 
age of symptom onset reduced, as the l1lunber of APOE*4 alleles increases.'" These 
observatiol1s may suggest that APOE*4 accelerates the l1curodegenerative process 
underlying AD. However, findings on APOE and progression or mortality in AD 
have been very inconsistent.4-12 Several g1:oups reported that APOE*4 carrying AD 
patients have even a slower rate of deterioratiollJ4,1t and an increased survival com-
pared to patients without APOE*4.7,11 In addition, a decreased sutvival was sug-
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gested for early onset AD patients who cauy the APOE*2 aliele. 12 Od,ers found d,at 
APOE does not affect course,.·!O or mortality in AD.5 A problem in the intell'reta-
cion of these findings is that patient characteristics varied considerably across studies. 
As all investigations up until now are based on prevalent patients, enrolment may 
have been at different stages of disease. TIle aim of this investigation was to ShIdy 
whether APOE*4 affects the rate of decline or sUlvival in AD. All patients entered 
this population-based study at d,e same stage, i.e. before d,e onset of symptoms. 
Methods 
Study population 
TIllS investigation fOims part of d,e Rotterdam Study, a population-based cohort 
study aillong persons aged 55 years or over, described in detail elsewhere,l4 The 
Rotterdam Study was approved by the Medical Edllcs Comnlittee of Erasmus Vlll-
versity. Participants were recmited from 10275 eligible residents of a suburb of Rot-
terdam, including institutionalised persons. A total of 7983 participants (response 
rate 78%) were examined at baseline. Of dlese, 7528 persons (94%) were cog1lltively 
tested, of whotn 474 were diagnosed as dctncl1tcd and excluded from the present 
study. At follow-up, after an average of 2.1 years (SD 0.9 years), 6315 persons (79%) 
were fe-examined. 
The analyses presented here arc restticted to AD patients who were non-de-
mented at baseline, of whom blood was available for APOE typing. Of d,ese 97 in-
cident AD patients, 9 had died before the follow-up examination. Futthennore, 2 
refused to participate and 1 was inaccessible. 'Ibus, 85 AD patients were examined at 
least twice. Follo,v-up on tnottality was complete for all 97 patients. 
Diagnosis 
For the assessment of demel1tia, we used dle satne protocol at baseline al1d at follow-
Up.lS,16 Briefly, all subjects were screened on cognitive functioning. Screen positives 
underwent further neuropsychological testing, and an informant was interviewed on 
daily functioning of the participant. Persons ,vho were suspected of detnentia were 
examined by a neurologist, undenvent neuropsychological testing, and, if possible, 
had a 1Ylagnetic Resonance Imaging brain scan tnade. 15,t6 Of subjects v.rho could not 
be re-examined in person, infonnation was obtained from general practitioners and 
the regional institute for outpatient tnent'll healdl care (RIAGG), which covers the 
entire study population. Examinations by d,e RlAGG include (informant) inter-
views, neurological and neuropsychological testing, blood biochemistry and sypllllis 
serology. The diag1lOsis of AD was made by a panel of study physicians, a neurolo-
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gist and a l1europsychologist, which reviewed all existing information and used crite-
ria of the National Institute of Ncurological and Corrunurucative Disorders and 
Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-
ADRDA).l7 The age at symptom onset was taken to be d,e midpoint between base-
line age and the age at diagnosis. 
Follow-up procedures 
Cognitive function was cvaluated with the Dutch version of the :NIini !vIental State 
Examination (I'vllVISE; maximum best score: 30 points).18 The stage of AD was as-
sessed with the clinical delllcntia rating scale (CDR).19 At the first and second wave 
of the Rotterdalll study, the ~llvISE was administered by specially trained research 
assistants. As part of the diagnostic evaluation, a CDR score was denoted by a neu-
rologist or a study physician. All participants who were diagnosed as having AD after 
baseline were invited for additional follow-up examinations, at intervals of approxi-
mately 15 months. 111ese includcd a neurological examination, cognitive testing, and 
an intclview with the caregivcr. The two additional follow-up examinations wcre per-
formed by a neurologist or a resident in neurology, using a standardised protocol. All 
measurements were carried out widlOut knowledge of the APOE genotype. 
Data on mortality for d,e present study were available until April 1996 (mean 
duration 4.3 years (SD 1.1». Information on the vital status of all participants was 
obtained at regular intervals from d,e municipal healdl authorities. 
Apolipoprotein E genotyping 
The APOE genotype was determined on coded DNA samples, as described in detail 
elsewhere.3 Those who performed d,e genotyping were blinded to d,e participants' 
test scores. Briefly, a polymerase chain reaction was conducted, and the amplification 
products were digested widl HhflI. The resulting restriction fragments were separated 
using precast ExcelGel gels (phal1nacia Biotech, Uppsala, Sweden) and visualised by 
silver staining. The results were read by dltee persons itldependendy. In case of dis-
crepancies, APOE genotyping was repeated. 
Statistical analysis 
Patients were assigned to one of two groups, those with and without an APOE*4 
allele. Persons widl d,e APOE2E3 and dlOse with APOE3E3 were combitled, as 
well as homozygotes and heterozygotes for APOE*4 because of limited statistical 
power for separate analyses. Simple comparisons were done with,t tests and){2 tests 
as appropriate. 
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ivlortality in AD patients with and without at least one APOE*4 allele, was com-
pared by Kaplul1-ivleier survival curves using the log tank statistic. To overC01ne pos-
sible confounding, we used Cox proportional hazard anal),ses. Baseline age, sex, and 
education level were further predictors, and the tltunber of months from symptotll 
onset was the time variable. 
To evaluate the change in ivllvISE and CDR scores, a generallincar ln1.xcd model 
was usecl,20 with random intercept and ranclO1u rCg1:cssion coefficient for the dura-
tion of follow-up. For practical reasons, the CDR staging was coded as: 0 (no de-
menth), 1 (questionable), 2 (mild), 3 (moderate), 4 (severe), 5 (profound) and 6 
(terminal), and reported as the modified CDR (mCDR). By introduci.ng d,e interac-
tion tenn between duration of follow-up and carriership of APOE*4, it was assessed 
whedler d,e average change in mCDR or lVll'vISE score differed between camers and 
non-carriers of APOE*4. In case of mCDR, robust standard errors were employed 
as this score is not nonnally distributed. 'I11e ~fJ'vISE score however appeared to be 
normally distributed in dus population of AD patients. In all analyses, adjustments 
were made for age, sex, and education level. 
Results 
The distribution of me APOE genotype in our study population was: APOE2E3: 
6% (n=6), APOE2E4: 2% (n=2), APOE3E3: 57% (n=55), APOE3E4: 32% (n=31) 
and APOE4E4: 3% (n=3). The APOE genotype distribution was in Hardy-
\Veinberg equilibrium (XZ=O.6; df=3: P>O.2), wluch i.ndicates that d,ere was no 
selective sUivival associated with APOE. S01ne characteristics of the study popu-
lation are shown in table 1. Carriers of APOE*4 were younger, included a lower pro-
Table 1 - Baseline characteristics of the study population' 
Baseline age 
Age at onset 
Women 
Men 
Primary education only 
Secondary education or more 
APOE'4-
11"'61 
82.S (7.0) 
83.8 (7.0) 
82% (SO) 
18% (11) 
63% (3S) 
38% (21) 
APOE'4+ 
n~36 
80.0 (6.9) 
81.3 (6.9) 
7S% (27) 
2S% (9) 
34% (11) 
67%(21) 
* Values are means (SO) or proportions (numbers); data on education level were missing in 9 
patients. 
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portion of WOlnen, and had less often primal), education only, but none of these dif-
ferences were statistically significant. 
Among APOE*4 carriers, 17 patients (47%) had died, among non-APOE*4 car-
riers 28 subjects (46%). The jiglll" shows that overall survival was the same in 
APOE*4 carriers and patients without tlus allele. Specifically, ti,e median survival in 
APOE*4 carriers was 3.3 years (95% confidence interval (CI) 2.9 to 3.8) after symp-
tom onset. Patients without ti,e APOE*4 allele had a median survival of 3.4 years 
(95% CI 2.9 to 3.9) after onset of symptoms (log rank=O.OI; df=l; P=0.93). As 
APOE*4 carriers were on average younger) and the survival after onset was similar, 
the mortality rate in carriers of the APOE*4 allele was lugher when we adjusted for 
age, sex and education level (relative risk 1.5; 95% CI 0.8 to 2.8). 
As shown in lable 2, lVlMSE as well as mCDR scores were similar for carriers and 
non-carriers of APOE*4. 11,e annual rate of decline in lVlMSE score was also equal 
for patients with and without APOE*4 (difference=-O.I; SE=0.6; P=0.88). Furtller-
more, ti,e annual increase in mCDR score was similar in botll groups (dif-
ference=O.O; SE=O.4; P=0.98). 
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Figure - Survival curves for Alzheimer patients with (-) and without (- _.) APOE*4 from 
onset of symptoms. 
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Discussion 
III summaty, our study suggests that the rate of decline in AD is not related to the 
presence or absence of the APOE*4 allele. Furthermore, APOE*4 seeins not to be a 
strong deterrninant of survival once AD has started. 
This is the first study on APOE and the course alld sutyival m AD, in which pa-
tients were emolled before sylnptoll1 onset. Of coneen1 is the level of education, 
which is an important determinant of the rate of AD progression.21 Persons with 
higher premorbid intelligence may be at a biologically 1110re advanced stage of the 
neurodegenerative process at sytnptom onset, and their disease may therefore prog-
ress lnore rapidly,13,21 The Rotterdam study population is however rather h0111ogcnc-
ous with respect to education level,ls therefore, all patients werc presumably at a 
biologically smillar stage at enrohnent. Besides, adjustmellts were made for differ-
ences in education level. An advantage of dus study is the population-based setting, 
which litnited selection bias. In these settings) the implementation of autopsy con-
firmation of d,e AD diagnosis may be difficult, and tlus is obviously a limitation of 
the present study. However, clinical examinations were extensive, and the diagnosis 
may be expected to be correct m approximately 90% of AD cases widl clinical ex-
aminations alone.22 \V.le used ,veIl recognised measures to estimate the rate of disease 
progression: d,e MMSE score for cogtutive function, d,e CDR scale for d,e stage of 
delnentia) and vital status. WidI up to 5 follow-up years) dus is one of dIe studies 
with longest duration, reported so far. 
Table 2 - MMSE and mCDR scores for Alzheimer patients with and without APOE*4' 
Fo]low-upf APOE*4- APOE*4+ 
number MMSE mCDR number MMSE mCDR 
0 n=61 26.0 0.0 11""36 26.0 0.0 
(22.0·28.0) (0.0·0.0) (22.0·28.1 ) (0.0·0.0) 
2 31 n=57 20.0 2.0 n=28 20.0 2.0 
(14.0·24.2) (1.0·2.2) (15.8·25.1 ) (1.0·3.0) 
3 46 n=47 14.0 2.0 11""25 16.0 2.0 
(4.0·21.0) (1.0A.0) (4.0·23.0) (1.0A.0) 
4 63 n=33 12.0 3.0 n=15 10.0 3.0 
(1.4·20.0) (2.0·5.0) (2.2-20.8) (1.6-5.0) 
* MMSE means mini-mental state examination; mCDR denotes modified Clinical Dementia 
Rating scale, coded as: a (no dementia), 1 (questionable), 2 (mild), 3 (moderate), 4 (severe), 5 
(profound) and 6 (terminal); values are medians with lDth and 90th percentile. 
f Visit and mean number of follow·up months. 
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Inconsistent findings have emerged from studies on APOE and the course of 
AD.4-12 However, all these investigations included patients in various stages of dis-
ease,4-12 hamperitlg comparisons of the rate of decline. 13 Furthennore, several studies 
included patients who were referred to specialised centres,4,7-9,1l and may have been 
subject to referral bias. Important aspects regarding referral are firstly that APOE*4 
was found to be related to the symptotnatology of AD,23-25 and secondly that 
APOE*4 carriers more often have a positive family hist01Y of dementia. Therefore, 
APOE*4 carriers may, on average, be referred to a memory clinic at an earlier stage 
of disease. Tlus could explain why in some studies APOE*4 carrying AD patients 
had a less aggressive disease course,4.7.11 as decline in AD may be slower in the earlier 
stages as compared to later stages. 13 
Earlier, we reported an increased mortality among APOE*2 canying AD patients 
\Vitll an early onset.12 In the present study, we found tl,at APOE*2 carriers and pa-
tients with APOE3E3 had sinillar sUlvival, and we did not observe differences across 
age strata. As none of tl,e participants of tlus study had an onset before 65 years, we 
could not study whetller APOE*2 has differel1tial effects in early- versus late onset 
AD. 
Overall, the presence of APOE*4 was not related to survival once AD had 
started. However, when adjustments were made for age, sex and education level, 
tnortality was non-significantly increased in APOE*4 carriers relative to patients 
without tlus allele. TIus finding may be explained by the relationslup of APOE*4 
with cardiac co-morbidity," as death in AD patients not necessarily reflects an end-
stage of dementia. 
The observation that APOE*4 increases tl,e risk of AD, while it seems unrelated 
to its progression, suggests tltat the processes tltat irutiate AD differ from tl,ose tl,at 
detelmine its progression. APOE*4 might trigger a cascade of neurodegenerative 
processes, tl,at subsequently continue independently of the APOE genotype. If tl,is 
were tme, it may imply that agel1ts tltat could block tl,e harmful effects of tl,e apo-
lipoprotein E4 isoform, or resemble tl,e bel1eficial effects of apolipoproteul E2 or 
E3, may not retard furtl,er decline once AD has started. 
In conclusion, our population-based study suggests tltat APOE*4 is not related 
to progressiol1 of AD. APOE*4 appears to ulcrease the risk of AD, and to reduce 
the age at symptotn onset,l-7 However, once the disease has started, the rate of de-
cline seems not to be ulfluenced by APOE*4. 
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Apolipoprotein E and atherosclerosis 
Introduction 
Lipoproteins and apolipoproteins 
Extraction of plasma lipids yields triacylglycerols (triglycerides), phospholipids, cho-
lesterol and cholesteryl esters as well as a small fraction of free fatty acids. The trans-
port of these hydrophobic lipids in aqueous plasma is made possible by associating 
the more insoluble lipids (triglycerides and cholesteryl esters) with more polar ones 
(phospholipids and cholesterol), and d,en combining them with protein to fonn a 
hydrophilic lipoprotein. Several groups of lipoproteins have been identified. These 
are chylomicrons, very low density lipoproteins (VLDL), low density lipoproteins 
(LDL), and high density lipoproteins (HDL). Besides, d,ere are two od,er lipoprotein 
classes: chylomicron rcrrmants and VLDL-remnants or intermediate density lipo-
proteins (lDL). The density of lipoproteins increases as d,e protein content rises and 
d,e lipid content falls. Triglycerides are the predominant lipids in chylomicrons and 
VLDL, whereas cholesterol and phospholipid are d,e predominant lipids in LDL and 
BDL, respectively. 'D,e protein part of lipoproteins is known as apolipoproteins or 
apoproteins, constituting nearly 60% of some HDL and as litde as 1% of chylotni-
crons. Fourteen distinct apolipoproteins have been identified, each associated with a 
specific class of lipoproteins. Apolipoprotein E (apoE) is found in chylomicrons and 
its remnants, in VLDL and in HDL.' 
Apolipoprotein E 
ApoE is a single polypeptide with a molecular weight of 34200 D. After post-trans-
lational cleavage, it has 299 amino acids. There are three conunon isoforms: apoE2, 
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apoE3 and apoE4, which cliffer in one or two runino adds. TIle most COllUllon form, 
apoE3, contains a cysteine residue at position 112 and an arginine residue at posicion 
158. ApoE2 has cysteine at both positions, and apoE4 has there arginine. 'Il,e bio-
synthesis of apoE is under control of a single genetic locus on region qI2-q13.2 of 
chromosome 19. TI,e apoE2, apoE3 and apoE4 isoforms are coded by three 
codominant alleles: APOE*2, APOE*3 and APOE*4, respectively. 'Il,e allele fre-
quencies in Caucasians are 0.08, 0.77 and 0.15 respectively. In Japanese and Chinese 
the APOE*4 frequency is lower, in Africans and J-tinns higher.2,3 Besides, more than 
20 other apoE isoforms have been identified, with allele frequencies below 0.001. 
The liver is the major site of apoE production, but apoE is also synthesised in the 
brain. TI,ese pools are stricdy separated as circulating apoE can not pass the blood-
brrun-barricr.4,s ApoE plays a role in tissue regeneration, immunoreguL1tiOll, cell dif-
ferentiation and g1:0Wdl.6 Interestingly, in persons who can not synthesise apoE, neu-
rologic, endocrine, and inullune functions are normal; the only apparent abnonnality 
is d,e metabolism of lipoproteins. 7 
Metabolism of lipoproteins 
Dietary triglycerides and cholesterol are packed in the intestinal mucosal cells to-
gether with several apolipoptoteills into chylomlcrons. After entry in the circulation, 
the apolipoprotein composition of d,ese particles changes, partly because of acquisi-
tion of apoE. During subsequent lipolysis the chylomicrons become stnaller, and the 
remnants are cleared from d,e circulation by d,e LDL receptor related protein (LRP). 
ApoE serves as a high affinity ligand for this receptor. 
VLDL carries triglycerides from d,e liver to the extrahepatic tissues. Newly se-
creted VLDL contains several apolipoproteins, but litde apoE. TI,e apoE content in 
VLDL increases after release in d,e circulation. VLDL is cleared from d,e blood-
stream by LRP or the LDL-receptor, using apoE as a high avIDity ligand. TI,e rem-
nant particles (IDL) are furdler hydrolysed and converted into LDL, dlCreby loosing 
apolipoproteins. TI,e resulting LDL particles contain 60-70% of total plasma cho-
lesterol, which are cleared from d,e circulation by d,e liver and by cells from the re-
ticulo-endodlelial system, such as macrophages in ti,e subendothelial space. 
HDL, anod,er lipoprotein that contains apoE, is the major lipoprotein involved 
in the transport of cholesterol from the peripheral tissues to d,e liver. Esterified 
cholesterol can be transferred from HDL to chylomicrons, VLDL, and LDL. Od,er 
HDL particles are removed frotn the circulation, using apoE as a ligand for receptor 
binding. 
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Atherosclerosis 
TIle transport of lipoproteins into the artery wall is the first stage of an atheroscle-
rotic lesion. TIlls transport is a concentration-dependent process that does not re-
quire receptor-tnediated endocytosis.8,9 Lipoproteins that have been trapped in the 
subendothelial space are oxidised. Mildly oxidised LDL induces monocyte adher-
ence, tnigration and conversion into nlacrophages. It further stimulates apoE secre-
tion by tnacrophages. Oxidised lipoproteins accwnulate with cholesterol in these 
macrophages to fonn foam cells, the hallmark of the £'ltty streak IO HDL on the 
other hand, protects against oxidation of LDL. Foam cells secrete products that also 
promote the further prog.:ession of the atherosclerotic plaque. 1O \'Vhen LDL be-
conles lllghly oxidised, it gets toxic to macrophages,11 which may cont1-ibute to the 
fonnation of the necrotic core found in the second stage of an atherosclerotic lesion, 
the fibrous plaque. 'Dus is a central acellular area of lipid from necrotic foam cells, 
covered by a fibrous cap contain.itlg snl00th Inuscle cells and collagen. The ~owing 
lesion then encroaches the arterial lumen, by the tnigration of new mononuclear 
cells, dIe proliferation of macrophages and slnoodl muscle cells, dIe production of 
an extracellular matrix and the accwnuL'ltion of lipid in the necrotic core. to The final 
stage is a cotnplex lesion, widl dttotnbus fOffilation by deposition of fibrin and 
platelets. l'vlildly oxidised LDL further contributes to arterial occlusion by stimulating 
dle release of coagulant agents, and by inhibiting reactive vasodilatation. The plaque 
is dlought to weaken as a result of cell death and the secretion of proteases from 
foam cells. 12 Besides, dIe atherosclerotic lesion is subject to calcification. A weakened 
plaque over an area of calcification predisposes to plaque rupture, because of differ-
ent physical properties wluch arc subjected to the pulses of arterial blood pressure. 
Apolipoprotein E, lipids and atherosclerosis 
Lipid levels 
The APOE polym01plusm pardy determines the level of plasma cholesterol, and dus 
effect further depends on diet and gender. 13 There seems not to be a consistent rela-
tionslup between the APOE genotype and triglycerides or HDL cholesterollevels2 
APOE*2 carriers have lower levels of total cholesterol, LDL-cholesterol and apo-
lipoprotein B, and higher levels of apoE.I,"" APOE*4 carriers show d,e opposite in 
most populations studied. 14.1S The "cholesterol-lowering" effect of APOE*2 is two 
or drree times d,e 'cholesterol-raising' effect of d,e APOE*4 allele, depending on the 
popUlation studied.2 The APOE*2 allele can however not be regarded as entirely 
betllg1l, as it is also associated with type III hyperlipoproteinenila. 
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Lipid metabolism 
APOE*4 carriers have a more efficient catabolism of chylomicron remnants and 
IDL, compared to persons with other APOE genotypes.' 'l1lerefore, the rate of con-
version of VLDL remnants to LDL is higher, resulting in a dowuregulatioll of he-
patic LDL receptors. These APOE*4-mediated alterations lead to lower concentra-
tions of cholesterol-containing remnant particles, and higher levels of cholesterol-
rich LDL particles. 'TIle net alteration is an increase in total cholesterol concentration. 
The apoE isoforms also differ in their preference to various lipoprotein cbsses, 
which may lead to different clearance rates.' 
ApoE is also produced by macrophages in atherosclerotic lesions. n Loading of 
tnacrophages with cholesterol stimulates apoE synthesis and secretion, which regu-
lates the storage and efflux of cholesterol.17 ApoE secretion by macrophages may 
further inhibit il,e aggregability of pbtelets and modubte lymphocyte function. In 
addition, apoE interacts with the extracellular matrix, thereby influencing the reten-
tion of lipoproteins." 
Atherosclerosis and vascular disease 
Among healthy young adults who died of external causes, APOE*4 camers had 
more atherosclerotic lesions at autopsy than those widlOUt dus allele. 19 In patients 
with diabetes mellitus, APOE*2 tended to protect from macro- and tnicroangiopa-
illy, while APOE*4 had a predisposing effect.'" 
Con flicting results have emerged on the association between APOE and coronary 
heart disease (CHD).21." In a meta-analysis on illC risk of G·ID, it was found that 
APOE*4 carriers had a 1.3 fold increased risk, and APOE*2 carriers have a similar 
risk, as compared to h01nozygotes for APOE*3.25 However, most of these studies 
were cross-sectional and may be subject to bias. In prospective studies, an increased 
l1sk of fatal CHD,26~7 as well as a sinillar risk of all CI-ID28 have been reported for 
carriers of APOE*4. 
It is not yet clear whether il,ere is an associatiol1 between ille APOE gel10types 
and cerebrovascular disease. In cross-sectional studies, no rel1tionship was found 
between APOE and stroke,29-31 as well as an increased risk for APOE*2 carriers,32 
and an elevated dsk for carriers of APOE*4." In follow-up studies on APOE and 
stroke no association was observed in two studies, 28,34 but others reported a de-
creased risk for APOE*2 carriers younger illan 80 years." 
Atherosclerosis of the carotid arteries, as estimated by ultrasonography, was 
found to be weakly associated wiill il,e APOE*2 allele." However, ilus study may 
have been subject to bias, as any participant with clinical evidence of atherosclerosis 
had been excluded." Another investigation reported il,e opposite association be-
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tween the APOE genotype and carotid artery adlerosclerosis. 37 In dus study, 
APOE*2 carriers had less carotid artery intima~meelia thickness than APOE*3 ho~ 
mozygotes. APOE*4 carriers had the thickest carotid artety intima~meelia.37 
Transgenic mice 
ApoE deficient mice have delayed clearance of lipoproteins, exhibit vety severe hy~ 
percholesterolemia and develop adlerosclerotic lesions that resemble those in hu-
mans, especially when fed a high-fat diet,38.39 In apoE deficient mice dlere was a 
not111alisation of plasma lipid levels, and regression of atherosclerotic lesions after 
introducing apoE expression.40,41 Local production of apoE by macrophages was 
found to diminish adlerosclerosis, independent of its cholesterol lowering effect,42 
ApoB levels in human atherosclerosis 
Pindings on apoE levels in 111.unans with atherosclerotic disease arc not straightfor-
ward. l\poE concentrations were found to be lughcr,43.4s or no diffcrent46 in CHD 
patients as c01npared to control subjects. In persons with a previous stroke, apoE 
levels were found to he lower compared to a control group free of cerebrovascular 
elisease." A problem with the latter study is that the APOE genotype elistribution in 
controls was very unusual. 
Conclusion 
ApoE plays an important role in lipid metabolism. TI,e assocIation between the 
APOE genotype and atherosclerotic elisease is not yet clear, and the mechanism of 
action of tlus putative relationship is incompletely understood. Furdler studies are 
needed to cbrify the role of selum apoE levels in d,e association between the APOE 
genotype and tile development of atherosclerotic lesions. 
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Apolipoprotein E and 
atherosclerosis 
The Rotterdam Study 
The apolipopmteill E (APOE) PObWiOlphislli }illIY deJines th, apoE isojimm, alld pfl/1IY dele/' 
111ims the leI,,1 of "poE ill semlll. Flildillgs ollth, APOE g",of)pe, S'I1I111 apoE Iml alld athem-
sde/vsis haw beell illmllsistmt. A popillatioll-based emss-sediollal Stlldy was poiol7lied 011 934 
sllbjeds to illvestigate the assotiatioll betweellthe APOE gellotyp', Senl/ii apoE levels alld athemsde-
IVsis. A/helVsdemsis was lIoll-iIlVtlsiw(y assessed l!J the preseJlce of p/aq/les i/l the CO/l/lIlO/l catvlid 
tIItnies (CCAs), calcificatiolls of the abdomil/al aOlla, the CCA illlima-111edia wall Ihkklless, alld 
Ihe allkle 10 al7li blood pmslll" illdex. Assodaliolls w"" arljllSled for age alld sex. Can;m of Ihe 
APOE*2 allele had a lowerp""al",,, ofCCA plaqlles. a 1I01l-sigllificallllY deamsed p"""I"'l< of 
fl0l1a ca/tificatiolls, a thillner CC4 i}Jtillla-media aNd a Jloll-sigJlificaNtlY bight,. fll/kle-arlJl lildex, 
"laliPe 10 Ihe APOE3E3 gmllp. Ollerall, Ihe APOE*4 allele IVaS 1101 assodaled wilh Ihe alhem-
sdnv,-is lildimlol>, allhollgh Ihe APOE4E4 gellof)p' was weaklY Idaled 10 alhemsc/,msis ill Ihe 
abdomillal aOlla alld pedpheml mle/its. ArljllSlillgfor SemlJi apoE, lolal or high dmsity lipopmleill 
(HDL) cholesleml levels did 1101 essellliallY aller Ihese filldillgs. 5el1l111 apoE le/lels Ivm lIotldaled 
to alheroJdeJvsis ill the (01111110/1 mrolid at1eties, bllt i1wwlSIil,g Sfnl/" apoE levels lVf/t! related /0 
flO/ta takijhwliol/s aJld 100ver allkle-film i/Jdexes. These associatiolls diminished lvhen at!JlI,sllJJeJlls 
wm made for lolal OIId HDL ,ho/eslemi. 0111' millIs sllggesllhal Ihe APOE*4 allele is 1101 a 
SflVlIg lisk .(ador for a/helVse/erosis. The cOl/sistent trelld for all iI/verse assodatiol/ betweell 
~APOE*2 alld alhemsc/emsis was illtlep",d",1 of sel7ll1l apoE. lolal alld HDL ,holeslemll",,1, 
alld IIi'!)' IbereJillr mllll }iVIll difjem",s ill apoE isqfomlS. 
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Introduction 
Atherosclerosis is the Inost important cause of morbidity and tuortality in western 
countries. High levels of total and low density lipoprotein (LDL) cholesterol and low 
levels of high density lipoprotein (HDL) cholesterol predispose to the development 
of atherosclerosis.' Senun levels of these lipids are partly detennined by the apolipo-
protein E genotype (APOE). TI,e APOE gene has three common alleles, APOE*2, 
APOE*3 and APOE*4, which fully deter1nine the protein isofonns apoE2, apoE3 
and apoE4, respectively.2-l Compared to homozygotes for APOE*3, the most C01n-
mon genotype, APOE*2 is associated with lower levels of total and LDL cholesterol 
and witll higher levels of HDL cholesterol, wlUle APOE*4 has opposite effects.2.' 
ApoE plays a pivotal role in the transport of lipoproteins," and is involved innumer-
ous processes in the arterial wallS 
Studies on the APOE polymorphism and clittical vascular disease have been in-
consistent.6 In a lncta-analysis on APOE and coronary heart disease (CHD), 
APOE*4 appeared to be a weak risk factor (summary odds ratio 1.3), wlUle no asso-
ciation with APOE*2 was ObSCiycd,G However, almost all of these investigations arc 
based on hospital-based patient-series in which selection bias could have played a 
role. In one prospective population-based survey, APOE*4 was found to be a risk 
factor for fatal CHD.7 In a similar Shldy however, no association of APOE*4 was 
found with eitller CHD or stroke.s No effects of APOE*2 were observed in tI,ese 
two stuclies.1,8 
There is a limited nwnber of investigations on ti,e APOE genotype and atllero-
sclerosis. An autopsy study suggested a predisposing role for APOE*4, and a 
protective effect of APOE*2, in ti,e development of atherosclerosis.' In studies on 
atherosclerosis of the cMotid arteries, inconsistent associations with i\POE have 
been reportcd. 10- 13 
The APOE genotype partly detertnines serum apoE levels.2~ Also, ti,e role of 
senun apoE level in atherosclcrosis is unclear. In patients with atherosclerotic dis-
ease, apoE conccntrations wcre found to be highcr,I4 and lowcrl5 than in controls. 
As serum apoE levels are partly detennined by ti,e APOE gcnot)'pe,2~ and ti,e 
APOE alleles fully dcfine the apoE isoforms,4 it is unclear whether a putative relation 
between APOE and atherosclerosis is the result of either different seium levels Of 
different isofonns. 'l1,e aim of tltis population-based study was to investigate ti,e 
association betwecn the AIJOE genotypc, se11.un apoE level and atherosclerosis. 
84 
APOE and atiJerosderosis: the &tterdalll SIIIr!;' 
Methods 
Study population 
This study is part of d,e Rotterdam Study, a population-based, single-centre cohort 
study on chronic and disabling diseases in the elderly. All inhabitants of a suburb of 
Rotterdam, aged at least 55 years, including people living in homes for d,e elderly, 
were invited to participate, TIle design of thc shldy has been described previously. Hi 
From all subjects informed consent was obtained and the study was approved by the 
tnedical ethics committee of the Erasnms University ivledical School. In total 7983 
participants (responsc rate 78%) were examined, Here wc describe our observations 
on a rand01TI sarnple of the first 1000 subjects who visited the research centre. Thc 
analyses presented here are restricted to 934 persons of whom both d,e APOE 
genotype and setLUn apoE level were successfully determined. 
Clinical investigations 
To assess the presence of atherosclerosis in the common carotid arteries (CCAs), 
ultrasonography was performed with a 7.5 I'vll-lz linear-array transducer and a Duplex 
scalmer (A 1L Ultral'vlark IV). Both CCAs were evaluated for d,e presence of athero-
sclerotic plaques, defined as a focal widening relative to adjacent segments with pro-
trusion into the lunlen, as described previously,17 
In addition, d'e intima-media duckness of d,e distal part of bodl CCAs were 
measured and averaged, as described before. 17 TIle presence of plaques as well as an 
increased CCAs il1tima-l11edia wall thickness are considered to be indicators of 
generalised a thcrosclerosis.18 
Atherosclerosis of the arteries of the lower extreln.ities was assessed by the ratio 
of d,e ankle to brachial systolic blood pressure (ankle-arm index). A decreased ankle-
attn index is a measure for peripheral atherosclerosis.19 Arm blood pressure was 
Ineasllred in sitting position at the right upper atm with a randol11-zero sphygm0111a-
nometer, and the average of two measuretnents obtained at Olle occasion was used. 
Ankle systolic blood pressure was determined with the subject in supine position at 
both d,e tight and left poste110r tibial artery USUlg also a random-zero sphygmoma-
110l11etet and a Doppler ultrasound transducer. The analyses were based on the low-
est of d,e ankle-alm uldex on the left and d,e right side. 
Aortic adlerosclerosis was diagnosed by radiograpluc detection of calcific depos-
its itl the abdominal aorta.20 'I1lese calcifications are associated with cardiovascular 
disease, and correlate well with atherosclerotic plaques, as observed at autopsy.20,21 
Lateral abdoll1inal X-rays were made from a £i.xed distance with the subject seated. 
Calcifications were judged to be present \vhen linear densities were seen in an arca 
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parallel and anterior to the lumbar spine (Ll-TA). Tn the analyses, aorta calcifications 
were classified as absent or present. 
Information on health status, drug usc and snlOking behaviour was obtained with 
a computerised questionnaire. Height and weight were measured, and body mass 
index was calculated, 
Laboratory investigations 
APOE genotyping and the determination of the serum apoE level were perfonned 
on coded samples from non-fasting subjects, without knowledge of the other meas-
urements. Genotyping was performed using a polYl11erase chain reaction, as 
described elsewhere.22 Senun apoE levels were dctcnnincd by enzyme-linked itn-
munosorbent assay?} Senltn total and HDL cholesterol were determined with an 
automated enzymatic procedure.24 
Statistical analysis 
The association bcl:\vcen the APOE genotype and atherosclerosis was studied in the 
following multivariate models. The relative risks of plaques in the CCAs and aorta 
calcifications were estimated as odds ratios (OR) in a multiple logistic regression 
model, and presented wiu, a 95% confidence interval (95% CI). Differences in CCA 
intima-tlledia wall thickness and the ankle-arm index were studied in a multiple linear 
regression model. As dete1minants we studied firstly the APOE alleles, which were 
entered as dummy variables, using the most common APOE genotype (A1'OE3E3) 
as the reference. Persons with APOE2E2 or APOE2E3 were grouped, as well as 
those with APOE3E4 or APOE4E4; persons carrying both the A1'OE*2 and tl,e 
APOE*4 allele were excluded form these models. Secondly, we used models wid, dlC 
APOE alleles and serum apoE levels. Senun apoE leve1s were entered in the tllodcl 
as dununy variables, which assumes no a priori distribution. Catcgorics were made 
according to quintiles of the distribution of senun apoE level, and the lowcst qui.ntile 
was used as a reference. Thirdly, to explore whether the putative effects of A1'OE 
arc independent of total and HDL cholesterol, we constructed tllodels with thc 
A1'OE genotypes, total cholesterol and HDL cholesterol. Fourthly, we built models 
with the APOE genotypes and the following cardiovascular risk factors: systolic 
blood pressure, diastolic blood pressure, body tllaSs index, smoking, total and HDL 
cholesterol, in order to study effects of APOE irrespective of these variables. To 
study the effects of serum apoE level, wc used models with ql).intiles of serum aroE 
level as the dcterminant. Further, we built tllodels with serum aroE quintiles and 
total and J-IDL cholesterol, to investigate thc role of scrU111 aroE independent of 
total and J-JDL cholesterol. Finally, differences in total and HDL cholesterol were 
studied in a linear regression model with quintiles of senHll aroE level as the deter-
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tninant. To adjust for confounditlg, age and sex were itlcluded itl all the above mod-
els. 
The percentage of explained variance was estimated by the squared adjusted mul-
tiple correlation coefficient.25 The Pearson's chi-square statistic was used for cate-
gorical data, and the two sample t-test for continuous, nonnally distributed variables. 
In regression models widl total and HDL cholesterol or the above cardiovascular 
risk factors, dle indicator method for missing data was used.26 As no major differ-
ences between men and wonlen, or between age categories were observed itl dIe as-
sociations between the APOE genotype and atherosclerosis, or between serum apoE 
and atherosclerosis, fmdings are presented for the whole study-population. 
Results 
'n,e distriburion of the APOE polymorphism in our study population was in 
Hardy-Weinberg equilibrium (APOE2E2 0.7% (n=7), APOE2E3 14.7% (n=137), 
APOE2E4 2.0% (n=19), APOE3E3 55.7% (n=520), APOE3E4 24.9% (n=233) and 
APOE4E4 1.9% (n=18)). Descriptive statistics are presented in table 1. APOE*2 
carriers had, on average, a higher body mass index, lower total cholesterol levels, and 
higher levels of HDL cholesterol, as compared to carriers of APOE3E3 or APOE*4. 
Serum apoE level was highest in APOE*2 carriers, intermediate in subjects with 
APOE3E3 and lowest in carriers of the APOE*4 allele. For each APOE genotype 
group separately, unadjusted mean settun apoE levels were 1.72 J.lmol/L (SD 0.66) 
Table 1 - Characteristics of the study population according to APOE alleles' 
Characteristic 
APOE*2 + AP0E3E3 APOE*4 + 
n=144 n=520 n=251 
Age in years 69.1 (7.6) 68.9 (8.0) 69.1 (8.2) 
Men 33% (47) 41% (212) 45% (112) 
Systolic blood pressure in mmHg 135.5 (20.8) 136.0 (19.8) 134.5 (20.0) 
Diastolic blood pressure in mmHg 71.8(11.1) 70.5 (10.5) 71.0 (11.1) 
Body mass index in kgfm2 27.1 (3.5) 26.4 (3.8) 26.6 (4.0) 
Current smoking 23% (32) 23%(116) 23% (56) 
Total cholesterol in mmolJL 6.5 (1.2) 6.7 (1.2) 6.8 (1.2) 
HDL cholesterol in mmolJL 1.4 (0.4) 1.3 (0.4) 1.3 (0.3) 
Serum apoE level in~molJL 1.19 (0.50) 0.80 (0.33) 0.62 (0.25) 
* Values are unadjusted means (SO) or percentages (numbers), based on all available informa-
tion; APOE*2+ denotes the APOE2£2 or the APOE2E3 genotype; APOE*4+ denotes 
AP0E3E4 or APOE4E4. 
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for APOE2E2, 1.16 /lmol/L (SD 0.48) for APOE2E3, 1.08 funol/L (SD 0.45) for 
APOE2E4, 0.80 /lmol/L (SD 0.33) for AP0E3E3, 0.63 /lmol/L (SD 0.25) for 
APOE3E4 and 0.42 flmol/L (SD 0.12) for APOE4E4. 'n,eSe mean apoE concen-
trations did not change when adjustments were made for age or sex. '111C APOE 
genotype explained 24% of the variance in selUm apoE levels. 
As shown in table 2, we found a strong association between setutn apoE level and 
total cholesterol in the whole study-population and in strata of APOE3E3 and 
APOE*4 carriers. By contrast, ainong APOE*2 carriers, senun apoE level ,vas only 
weakly reb ted to senlffi total cholesterol. 
Table 3 shows d,at carriers of d,e APOE*2 allele had a lower prevalence of 
plaques in dle CCAs. TIllS inverse association held when adjusttnents were made for 
SClum apoE level. In addition, APOE*2 carriers had a lower prevalence of aorta cal-
cifications, which reached statistical significance when adjustments were tnude for 
senl1n apoE level. OveraU, APOE*4 was not associated with an increased prevalence 
of CCAs plaques or aorta calcifications. However, d,e APOE4E4 genotype was non-
significandy related to aorta calcifications (OR =1.6; 95% CI 0.6 to 4.8). Adjusting for 
total and HDL cholesterol yielded similar results as the models with adjustments for 
age and sex only. 
The median CCA intima-media wall thickness in the APOE3E3 group was 0.78 
mm (10th centile 0.62, 90d, centile 0.97 mm). As shown in table 4, APOE*2 carriers 
had a dunner CCA intima-media compared to this reference group. The CCA in-
tima-media was similar for persons widl d,e APOE3E3 genotype and for APOE*4 
carriers. The median ankle-arm index in d,e APOE3E3 group was 1.12 (10th centile 
Table 2 - Differences in serum total cholesterol level according to quintiles of serum 
apoE level* 
<0.53 0.53-0.68 0.68·0.85 0.85·1.09 ~1.09 
T alaI Cholesterol in mmol/L 
All o {reference} 0.30 0.37 0.85 0.91 
(0.07 to 0.52) (0.15 10 0.60) (0.63 to 1.08) (0.69 to 1.14) 
APOE*2 + o (reference) 0.17 ·0.18 ·0.01 0.71 
(·0.87 to 1.21) (-1.07 to 0.72) (·0.84 to 0.82) (-0.02 to 1.44) 
APOE3E3 o (reference) 0.28 0.45 1.09 1.36 
(-0.01 to 0.57) (0.16 to 0.74) (0.81 to 1.37) (1.0410 1.68) 
APOE*4 + a (reference) 0.46 0.65 1.43 1. 11 
(0.12 to 0.80) (0.29 to 1.01) (0.96 to 1.90) (0.49 10 1.72) 
.. Values are djfferences with 95% confidence interval; APOE*2+ denotes the APOE2E2 or the 
APOE2E3 genotype; APOE*4+ means APOE3E4 or APOE4E4; serum apoE levels are in 
~ulloi/lo 
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Table 3 - Odds ratios for common carotid artery plaques and aorta calcifications 
associated with APOE alleles' 
APOE'2 + APOE3E3 APOE*4 + 
CCA plaques' 
Events (observations) n=14 (n=142) n=93 (n=510) n=34 (n=245) 
Modell' 0.5 (0.3 to 0.9) 1 (reference) 0.7 (0.4 to 1.1) 
Model 2' 0.5 (0.3 to 0.9) 1 (reference) 0.7 (0.5 to 1.2) 
Model 31 0.5 (0.3 to 0.9) 1 (reference) 0.7 (0.4 to 1.1) 
Aorta Calcifications 
Events (observations) n=59 (n=128) n=186 (n=474) n=94 (n=226) 
Modell' 0.7 (0.5 to 1.1) 1 (reference) 0.9 (0.6 to 1.2) 
Model 2' 0.5 (0.3 to 0.8) 1 (reference) 1.0 (0.7 to 1.4) 
Model 31 0.8 (0.5 to 1.2) 1 (reference) 0.8 (0.6 to 1.2) 
* Values are odds ratios with 95% confidence interval; APOE*2+ denotes the APOE2E2 or the 
APOE2E3 genotype; APOE'4+ means APOE3E4 or APOE4E4; 
f CCA denotes common carotid arteries; 
* Modell: adjusted for age and sex; 
Model 2: adjusted for age, sex and serum apoE level; 
Model 3: adjusted for age, sex, serum total cholesterol and HDL cholesterol. 
Table 4 - Differences in common carotid artery intima-media thickness and ankle-arm 
index according to APOE alleles* 
APOE*2 + APOE3E3 APOP4+ 
CCA intima-media (rnm}t 
Observations n=142 n=513 n=247 
Modell' ·0.04 (·0.06 to ·0.01) o (reference) ·0.02 (·0.03 to 0.00) 
Model 2' ·0.03 (·0.06 to ·0.01) o (reference) ·0.01 (·0.03 to 0.01) 
Model 3' ·0.03 (·0.06 to -.001) o (reference) ·0.02 (·0.04 to 0.00) 
Ankle-arm index' 
Observations n=138 n=496 n=243 
Modell' 0.03 (·0.01 to 0.07) o (reference) 0.00 (·0.03 to 0.03) 
Model 2' 0.06 (0.02 to 0.10) o (reference) ·0.02 (0.05 to 0.01) 
Model 3' 0.02 (·0.01 to 0.06) o (reference) 0.00 (·0.03 to 0.03) 
• Values are mean differences with 95% confidence interval; APOE'"'2+ denotes APOE2E2 or 
APOE2E3; APOE*4+ means AP0E3E4 or APOE4E4; 
t CCA denotes common carotid arteries; 
Modell: adjusted for age and sex; 
Model 2: adjusted for age, sex and serum apoE level; 
Model 3: adjusted for age, sex, serum total cholesterol and HOl cholesterol; 
, The ankle-arm index is inversely associated with atherosclerosis.1 9 
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0.84, 90th centile 1.31). APOE*2 carriers had, on average, a higher index than the 
APOE3E3 group. The association between APOE*2 and the ankle-artn index be-
cmne stronger and reached statistical significance when adjustments were made for 
SClum apoE level, suggesting an independent effect of the APOE*2 allele. Persons 
with the APOE4E4 genotype had a slighdy lower ankle-arm index dlan homozy-
gotes for APOE*3 (difference: -0.01; 95% CI -0.10 to 0.08). However, caniers of 
APOE*4 had overall a similar ankle-arm index as d,e APOE*3 homozygotes, and a 
slightly lower ankle-arm index when adjustments were for setWl1 apoE level, but tlus 
was not statistically significant. When total and HDL cholesterol were added to the 
models on CCA intima-media and the allklc-al111 index, the associations slightly 
weakened as compared to the Inodels with adjustments for age and sex only. 
Table 5 shows tllat the prevalence of CCA plaques was not rcbted to 8e11.1111 apoE 
levels. By contrast, the prevalence of aorta calcifications was found to incrcase \vith 
increasing apoE level, and dus was observed both unadjusted (test for trend: 
1'=0.05), and adjusted for dlC APOE genotypes (test for trend: 1'=0.005). When we 
adjusted for serum total and HDL cholesterol, the association between senun apoE 
and aorta calcifications dimitushed (test for trend: 1'=0.50). 
The tnedian CCA intima-media wall thickness in the lowest quintile of the senal1 
apoE distribution was 0.75 mm (lOdl centile 0.60, 90th centile 0.96 mm). As shown 
in table 6, SCiutli apoE level was not associated with the CCA intima-tncdia wall 
thickness. The median ankle-artn index in the lowest quintile of thc sellun apoE dis-
tribution was 1.15 (10dl centile 0.89, 90d, centile 1.32 mm). Increasing serum apoE 
levels were found to be relatcd to decreasing ankle-attn indexes, both unadjusted 
(test for trend: 1'=0.03), "nd adjusted for d,e APOE genotypes (test for trend: 
1'=0.001). When adjustments were made for total and HDL cholesterol, the associa-
tion behveen senHn apoE and the ankle-ann index diminished (test for trend: 
1'=0.39). 
Discussion 
In tllls population-based study, we found overall no assocIation between the 
APOE*4 allele and various it,dicators of atherosclerosis, although d,e 1\POE4E4 
genotypc was weakly associated with atllerosclerosis in the abdolIllnal aorta and pe-
ripheral arteries. By contrast, wc found a consistent trend for an inverse relationship 
between APOE*2 and various indicators of atllerosclerosis, including p]ac}ues in the 
CCAs, aorta calcifications, the CCA intima-tnedia wall thickness and the ankle to arm 
systolic blood pressure it,dex. Adjusting for senun apoE levels strengdlened the "s-
sociation behveen APOE*2 and aorta calcifications and the ankle-arm index, whereas 
adjusting for total and HDL cholesterol only slighdy changed the estimates. SenUll 
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Table 5 - Odds ratios for common carotid artery plaques and aorta calcifications according to quintiles of serum apoE level* 
<0.53 0.53-0.68 0.68-0.85 
CCA plaquest 
Events (observations) n=26 (n=206) n=28 (n=178) n=33 (n=175) 
Modell' 1 (reference) 1.4 (0.7 to 2.4) 1.7 (1.0 to 3.0) 
Model2! 1 (reference) 1.3 (0.7 to 2.4) 1.7 (1.0 to 3.1) 
Model3 fl 1 (reference) 1.3 (0.7 to 2.4) 1.7 (0.9 to 3.0) 
Aorta Calcifications 
Events (observations) n=104 (n=193) n=95 (n=163) n=99 (n=166) 
Modell' 1 (reference) 1.2 (0.8 to 1.8) 1.2 (0.8 to 1.9) 
Model2! 1 (reference) 1.2 (0.8 to 1.9) 1.3 (0.8 to 2.0) 
Model 31 1 (reference) 1.1 (0.7 to 1.7) 1.1 (0.7 to 1.7) 
* Values are odds ratios with 95% confidence interval; serum apoE levels are in J..UT1oVI; 
t 
, CCA denotes common carotid arteries; 
Modell: adjusted for age and sex; 
Model 2: adjusted for age, sex and APOE genotypes; 
Model 3: adjusted for age, sex, total and HDL cholesterol. 
0.85-1.09 
n=30 (n=180) 
1.6 (0.9 to 2.8) 
1.6 (0.8 to 2.9) 
1.5 (0.8 to 2.8) 
n=88 (n=159) 
1.1 (0.7 to 1.6) 
1.2 (0.7 to 1.9) 
0.8 (0.5 to 1.3) 
;'1.09 
n=26 (n=176) 
1.4 (0.7 to 2.5) 
1.7 (0.9 to 3.2) 
1.3 (0.7 to 2.5) 
n=111 (n=165) 
1.7 (1.1 to 2.7) 
2.4 (1.4 to 4.0) 
1.4 (0.8 to 2.2) 
Table 6 - Differences in common carotid artery intima~medja and ankle-arm index according to quintiles of serum apoE level* 
<0.53 0.53-0.68 0.68-0.85 
CCA intima-media (mm;t 
Observations n=208 n=181 n=175 
Modell' o (reference) 0.02 (-0.01 to 0.04) 0.02 (0.00 to 0.05) 
Model 2' o (reference) 0.01 (-0.01 to 0.04) 0.02 (-0.01 to 0.05) 
Model 31 o (reference) 0.01 (-0.01 to 0.03) 0.02 (-0.01 to 0.04) 
Ankle-arm index' 
Observations n=203 n=175 n=173 
Model l' o (reference) -0.01 (-0.05 to 0.03) 0.01 (-0.03 to 0.05) 
Model 2' o (Teference) -0.01 (-0.05 to 0.03) 0.01 (-0.03 to 0.05) 
Model 31 o (reference) 0.00 (-0.04 to 0.04) 0.02 (-0.02 to 0.06) 
.. Values are differences with 95% confidence interval; serum apoE levels are in )..U11oljl; 
CCA denotes common carotid arteries; 
; Model 1: adjusted for age and sex; 
Model 2: adjusted for age, sex and APOE genotypes; 
Model 3: adjusted for age, sex, total and HOL cholesterol; 
'I The ankl~arm index is inversely associated with atherosderosis.19 
0.85-1.09 ,,1.09 
n=180 n=l77 
0.01 (-0.02 to 0.04) 0.00 (-0.03 to 0.03) 
0.01 (-0.02 to 0.04) 0.01 (-0.02 to 0.03) 
0.00 (-0.03 to 0.03) -0.01 (-0.04 to 0.01) 
n=174 n=171 
-0.03 (-0.07 to 0.01) -0.04 (-0.08 to 0.00) 
·0.04 (-0.09 to 0.00) -0.07 (-0.12 to -0.03) 
-0.01 (-0.05 to 0.03) -0.02 (-0.06 to 0.02) 
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apoE levels were not re11ted to atherosclerosis in the CCAs, but increasing senun 
apoE levels were associated with lower ankle~al1n indexes and the presence of aorta 
calcifications. TIlesc two associations ditninished when adjustments were tnade for 
total and HDL cholesterol. APOE*2 carriers had higher levels of serum apoE, but in 
these persons, apoE was only weakly associated with total cholesterol. 
TIle limitations of the present study should not be ignored. As tlus is a cross-sec-
tional SUIVCY, we can not exclude that selective sluvival tnay have occurred. How-
ever, when ,ve restricted the study~population to persons in whom tnortality may be 
less important (ie. non-diabetic persons younger than 65, witllout CHD or stroke, 
who have never smoked), similar findings were obtained (data not shown). A follow-
up study, in which APOE genotl1,ing is performed on material collected relatively 
early in life, could characterise participants who died before assessment of athero-
sclerosis. As far as we know, such a study has not been done. 
An advantage of this study is the population-based approach with a high response 
rate. We estimated the presence of atherosclerosis using established, validated tech-
luques. IB•19,21 However, some measurement error may have occurred. Since all labo-
ratory analyses were perfonned without knowledge of tlle other measurelnents, such 
lnisc1assification is n10st likely non-differential and will therefore t110st likely result in 
an underestimation of the tnle effect. 
Previous studies on tlle APOE genotype and atherosclerosis are litnited, and re-
sults have been inconcluslve,9-13 In an autopsy study in young males who died of ex-
ternal causes, the extent of atllerosclerosis was greatest in APOE*4 carriers, and least 
in carriers of APOE*2.9 By contrast, a report frotn the Atherosclerosis Risk In 
Communities (ARlC) study among subjects free from symptomatic cardiovascular 
disease showed opposite results; ie., carriers of APOE*2 were had a borderlitle sta-
tistically significant increased risk of carotid atherosclerosis relative to the APOE3E3 
genotype, while no association with APOE*4 was observed,I2 In a study mnong pa-
tients referred for coronary angiography, APOE*4 carriers had an increased thick-
ness of the internal carotid artel)' intima-media, while APOE*2 carriers had a de-
creased intima-tnedia wall thickness. 10 The latter findings were confirmed in a recent 
shldy mnong asytnptomatic individuals for CHD,Il By contrast, in non~diabetic 
Japanese who were asymptomatic for CHD, no association between the APOE 
polytnotphisn1 and carotid or femoral arterial wall tluckness was found.13 This is tlle 
first population-based iuvestigation on il,e APOE genotype and atherosclerosis of 
the aorta and the arteries of the lower extremities, and the first study on sertun apoE 
levels and non-invasively measured atllerosclerosis. 
The observation that APOE*2 carriers have in serum lugher levels of apoE and 
HDL cholesterol and lower levels of total cholesterol, and il,at APOE*4 has oppo-
site effects, is in line wiill earlier reports.2-4 Compared to il,e APOE3E3 genotype, 
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catabolism of chylomicron and VLDL relnl1ants occurs at a lower rate in APOE*2 
carriers, while a similar though opposite l11cchanism occurs in APOE*4 carriers.4 
Therefore, in APOE*2 carriers, the rate of conversion ofVLDL remnants to LDL is 
lower, resulting in an up-regulation of hepatic LOL receptors.' 'nus leads to lugher 
levels of cholesterol-containing remnant particles, and lower levels of cholesterol-rich 
LDL particles. Since remnant particles arc present in 11or111al subjects in small quan-
tities, the net APOE*2 alteration is a decrease in total cholesterolleve1.4 As apoE is 
found primarily in chylomicron and VLDL relnnants, a delayed catabolism will result 
in hjghcr apoE levels. TIus is in line \vith our obsctvation that APOE*2 carriers had 
lugher apoE levels and lower levels of total cholesterol than d,e other APOE groups. 
Furthertnore, in contrast to the other APOE groups, serum apoE levels were in 
APOE*2 carriers only weakly related to total cholesterol. 
In the present study, APOE*4 was overall not associated with the atherosclerosis 
indicators, although the APOE4E4 genotype was weakly related to atherosclerosis in 
the abdominal aorta and peripheral arteries. By contrast, APOE*2 was consistently, 
inversely related to atherosclerosis. Adjustment for senun apoE level strengdlCl1cd 
d,ese findings, whereas adjusting for total and HOL cholesterol, or cardiovascuL" 
risk factors only slighdy changed d,e inverse association. As d,e effects of d,e APOE 
polytnotphistll on atllcrosclerosls seel11 therefore not to result ftorn its effects on 
scrtun npaE or cholesterol levels, the APOE genotype lnay be involved in athero-
sclerosis through alternative pad1\vays. As the APOE alleles fully determine d,e apoE 
protein isoforms, the APOE*2 effects tnay result from structural differences in apoE 
isoforms. A therosderosis is associated with increased oxidative stress, as the oxida-
tive rnodification of LDL seems to be a crucial step in its development.27 The various 
apoE isoforms have been found to exert different antioxidant cffccts.28 Purthet111orc, 
as apoE seems to have several other properties with relevance to vessel wall homeo-
stasis, including d,e modulation of platelets aggregability and d,e proliferation and 
l1ugration of smood, muscle cells and lymphocytes,S.2' it is possible d,at d,ese prop-
erties may differ across the apoE isoforms. 
Although selutll apoE levels were found to be related to the ankle-artn index, and 
aorta calcifications, no association was observed between Senlt11 apoE levels and 
CCA atherosclerosis. Tlus nught suggest differences in d,e aetiology of 
atherosclerosis across sites. However, it is possible that these differences are due to 
chance. If selutll apoE levels are tnlly increased in atherosclerosis, this could be 
cause or consequence. The observation that increases in cholesterol level and 
oxidiscd LOL may stimulate apoE secretion by macrophages,S~O mal' suggest that 
apoE secretion increases after the devcloptnent of atherosclerosis. However, it 
should be noted that the large majority of apoE, as detected in serum, is produced by 
the liver.29 Any compensatory apoE secretion by macrophages will probably not 
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result in a substantial difference in selum apoE level. Senun apoE level seems 
therefore not to increase substantially as a consequence of atherosclerosis. On the 
other hand, tnost apoE is a constituent of VLDL and chylomicron renlllants, 
particles with atherogenic properties, while relatively small amounts of apoE are 
found in a subclass of HDL cholesterol.4~9 This is in line with our observation that 
apoE levels were positively related to total cholesterol levels. When we adjusted for 
total and HDL cholesterol, the association between serwn apoE level and 
atherosclerosis diminished, in agreement with previous observations. 14 These 
findings support the hypothesis that apoE level is positively related to 
atherosclerosis, because apoE is a component of adlerogenic lipoproteins. TIllS is 
also consistent wid} our finding that the inverse relation between APOE*2 and 
adlerosclerosis strengthened when adjustments were tnade for senun apoE level. 
In conclusion, we found dlat dIe APOE*4 allele was not strongly related to vari-
ous indicators of adlerosclerosis. By contrast, a consistent trend for an inverse rela-
tionship between APOE*2 and adlerosclerosis was observed, which was independ-
ent of serum apoE, total and HDL cholesterol level, and may dlerefore result from 
differences in d,e apoE isoforms. 
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ApOLIPOPROTEIN E, 
ATHEROSCLEROSIS AND 
DEMENTIA 

Abstract 
6.1 
Apolipoprotein E, 
atherosclerosis and 
cognitive decline 
The APOE*4 allele of Ihe a}x!lipopIVleill E gtlle (APOE) alld alheIVsdeIVsis aIV !isk/aclolJfor 
coglliliw dedli". /l7e illvesligaled Ivhelher Ih, efjects of Ihe APOE gello(ype alld alheIVsc/emsis 011 
,~gllilli" decline OJ" illdeptlldtlll. A }X!PII/alioll.based fo/!OW-11jJ sll/{fy Ivas p'1ill7",d 011 838 S/IbjedS 
who lvet" 1I01l-de//lellled 01 baseline. The klilli j'vIelllal Slale Exa//lillalioll (i\1MSE) SM" 01 fol-
10w-11jJ lVas sllldied as a /tlllctioll of APOE alld alheIVsc/elVsis, assessed f:y jiw illdicalon based 011 
lIoll-ilJIJasiJJe IIlfaSIIJPIlleJI!S filld dillic(l/ eJldpotiJls. IHild, IIOII-SigNificallt d]CdS 011 the .NliHSE SCOlf. 
I",IV folllld for alhetosc/'IVsis illlh, abm"" ,!/APOE*4 alld forAl'OE*4 illlhe abse"" of alh,-
IVsderosis. 14POE*4 mIners lvilh two or/llore illdkalors oj alhclVsdelVsis positive, had a sigllifi-
call1fy lower AIMSE seoIV 01 jO/!OIV-11jJ (//Ieall difjeIVllce -0.7 }x!illls; 95 pemlll collfidellce illleJ7Jal -
1.1 10 -0.2) IVlaliue 10 1I0IlAPOE*4 canim wilh 110 evidtllce of alheIVsc/eIVsis. O/ll'/illdillgs Sl(g-
gesllhal Ih, I'OlIseqll""'s of APOE alld alhelVsc/eIVsis OJ" 1101 illdeptlldtlll, alld Ihal paltiCl/lar/y 
APOE*4 mnim wilh athetosc/elUsis mr 01 illCirased lisk ofeogllitiue dec/ille. 
Introduction 
Cognitive decline in elderly persons is an important predictor of dctnentia and, frmn 
a public health point of view, of growing significance in our aging society. Several 
genetic and cnviromnental factors inay lead to age-related cognitive deterioration and 
eventually dementia,] An important genetic risk factor for cognitive decline and de-
mentia is the APOE*4 allele of the apolipoprotein E gene (APOE).'·' It is contro-
versial whether APOE*2, another APOE allele, decreases the risk of dementia and 
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cognitive decline.s-9 In Caucasians, APOE*4 has a frequency of approximately 15 
percent, APOE*2 a frequency of 8 percent, and the most conunon APOE allele, 
]\POE*3 has a frequency of 77 percent. 10 
Apart from its role in cognitive function, apolipoprotein E is known to playa 
central role in lipid metabolism. 10 APOE*4 carriers have higher total and LDL cho-
lesterol levels, and have an increased .risk of atherosclerosis, compared to persons 
without this allele,l0-12 although not in all studies. 13 
Atherosclerosis is also a risk factor for dementia l4 and cognitive decline. IS TIlere-
fore, one may hypothesize that atherosclerosis is an intertnediate factor in the asso~ 
dation between APOE*4 and cognitive decline. Up to date, few studies investigated 
the relation between APOE, atherosclerosis and cognitive function. In a case~control 
shldy of prevalent patients ,vith dementia, we found evidence that APOE*4 potenti~ 
ates the effects of atherosclerosis. 14 However, tlus study may have been subject to 
bias, since differences in stuvival have been obsetved for demented patients related 
to il,e APOE genotype.,,16 
Here we present a follow~up study on cognitive decline in 838 subjects who 'vere 
non~delnented at baseline. The aim of dus population-based investigation was to 
exatnine whether the effects of dle APOE genotype and atherosclerosis on cogtutive 
decline are independent. 
Methods 
Study population 
'Ilus study is part of il,e Rotterdam Study, a population-based follow-up study of 
dete11lunants of chronic diseases in il,e elderly. All inhabitants of a suburb of Rotter-
dam, aged 55 years or over, including those living in h01nes for the elderly, were in-
vited to participate. The design of il,e study has been described previously.17 From all 
subjects informed consent was obtained and the study was approved by the medical 
cilucs conullittee of ille Erasmus University Medical School. In total 7983 partici-
pants (response rate 78 percent) were examined from 1990 to 1993 (baseline). At 
follow-up in 1993 and 1994, 6315 persons (79.1 percent) were re-exatllined; 768 
subjects (9.6 percent) had died, 106 (1.3 percent) were inaccessible and 794 (9.9 per-
cent) refused to participate. The mean period of follow-up was 2.9 years (SD 0.4). 
At ille time of ille present analyses, a random sample of 1585 subjects was invited 
to participate in an ongoing Shldy on atherosclerosis of tile carotid arteries. 'flle 
analyses presented here are restricted to persons for whom data on cognitive func-
tion were available both at baseline and at follow-up (n=1I97). In individuals of 
whom blood was available, APOE typing was performed (n=899). Subjects who 
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were delnented at baseline (n=10), and those who were suspected of dementia at 
baseline (i.e. tvlini Mental State Examination (MlvISE) score of 25 points or less, 
n=51) were excluded. Tills resulted in a study population of 838 subjects. 
Measurements 
Cagm'five function The Dutch version of the IvIlvISE18 was used to assess global 
cognitive performance. The IvlJVISE is a test dlat covers several cognitive functions, 
and yields a maximwn best score of 30 points. The MMSE was admitllstered by spe-
cially trained research assistants. Dementia at baseline was diagnosed by a duee phase 
approach, as described in detail elsewhere,14 A panel of physicians and neuropsy-
chologists assessed whedler a dementia syndrotne was present according to criteria 
of the American Psychiatric Association (DSM-UI-R).19 
Apolipoproteil1 E We used coded blood samples for APOE genotyping. 11,is was 
performed without knowledge of the other measurements, using the pruners and 
amplification conditions as desctibed by Wenhatll and colleagues,20 The polytnerase 
chain reaction product was digested widl dlC restriction enzytne HhaI and fragtnents 
were separated by electrophoresis 011 a 5% agarose gel. APOE alleles were visualized 
by etllldium bromide staining.9 
Afherosclel'osis At baseline, we examined dle presence of atherosclerosis by clinical 
vascular disease O-llstory of stroke or previous tnyocardial infarction) and non-inva-
sive tneasurements (atherosclerosis of the arteries of the lower extremities and of the 
carotid arteries). A history of stroke and a Ills tot)' of myocardial infarction were as-
sessed by direct questioning and considered positive when dle diagnosis had been 
made by a treating physician, To estimate dle presence of adlerosclerosis in dle ca-
rotid arteries, ultrasonography of both carotid arteries was perfo.rmed with a 7,5 
MHz linear-array transducer and a duplex scanner (ATL UltraMark IV, Advanced 
Technology Laboratories, Betllel, \'I/A). BOtll carotid bifurcations were evaluated for 
the presence of atherosclerotic plaques, defined as a focal widening relative to adja-
cent segments with protrusion into dle lumen, as described previously.21 In addition, 
the intima-media tlllckness of ti,e distal part of botll common carotid arteries (CCA) 
were tneasured and averaged, as described before,22 The presence of plaques as well 
as an increased CCA intima-tl1cdia tlllckness arc reliable indicators of generalized 
atherosclerosis,23,24 Atherosclerosis of the arteries of the lower cxtrernities was as-
sessed by the ratio of ti,e ankle to brachial systolic blood pressure (ankle-arm index). 
A decreased ankle-arm index has been shown to be a reliable indicator of generalized 
adlel'osclerosis.25-27 To calculate dlC ankle-ann index) blood pressure was measured in 
the sitting position at dle right upper ann widl a random-zero sphygmomanotneter, 
and the average of two tl1CaSUrelnents obtained at onc occasion was used, Ankle 
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systolic blood pressure was determined widl the subject in supine position at both 
the right and left posterior tibial arteries using also a randoll1-zero sphygmomano-
meter and a Doppler ultrasound transducer. The analyses were based on the average 
of the ankle~arm index on the left and the right side, 
Possible confounders Infonnation on a family history of dClnentia, and lifetime 
formal schooling was obtained using a computerized questionnaire. The fatnity his-
tory of dementia was considered positive if one or morc first dCg1:ce relatives suf-
fered from dementia. Attained level of education was assessed according to the in-
ternational standard classification of education (Unesco, Paris, 1976).28 For the pres-
ent analyses participants were grouped into five categories. 
Classification 
Firstly, subjects were grouped according to the six possible 1\PO£ genotypes 
(1\POE2E2, 1\POE2E3, 1\POE2E4, 1\POE3E3, 1\POE3E4 and 1\PO£4£4), Par~ 
tidpants were also classified into APOE*2 carriers (subjects with 1\PO£2£2 or 
1\PO£2£3), homozygotes for APOE*3, and APOE*4 carriers (individuals with the 
1\POE3E4 or tl,e APOE4E4 genotype), whereby persons with tl,e APOE2E4 
genotype were excluded, Persons with the most common genotype (APOE3£3) 
were the reference group. 
Secondly, subjects were grouped according to the presence or absence of the 
above five indicators of atherosclerosis: a history of stroke, a previous tnyocardial 
infarction) the ankle-arm index) the CCA intima-media thickness and the presence of 
one or more plaques in both carotid bifurcations. Continuous variables were split at 
the median. Specifically) the indicator ankle-arm index was positive for those with an 
index beneath the tnedian) while the indicator CCA intima-tnerua thickness was 
positive in those with a wall duckness above the median. 
A probletn in dle analysis on the separate indicators is that these are not always 
positive simultaneously. For instance) persons without a Ius tory of stroke may have a 
history of tnyocardial infarction. To optimize the contrast, we constructed a tnore 
rigorous adlerosclerosis score to identify those with evidence of adlerosclerosis at 
tnultiple sites (i.e. two or more indicators) mentioned above) positive). These persons 
were assigned an atherosclerosis score of two. The atherosclerosis score was one in 
those with only one indicator positive. Persons with no indicators positive had an 
atherosclerosis score of zero) and were used as the reference group. 
Thirdly, tl,e combined effects of the APOE genotype and atherosclerosis were 
studied according to a strategy described by Ottman," We classified subjects into 4 
groups: (1) non~APOE*4 carriers witll no evidence of atherosclerosis (reference 
group), (2) APOE*4 can';ers witll no evidence of atllerosclerosis, (3) non~APOE*4 
carriers with evidence of atherosclerosis, and (4) APOE*4 carriers with evidence of 
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atherosclerosis. These analyses were perfonncd for each of thc five indicators of 
atherosclerosis separately, as well as for the atherosclerosis score. Since the athero-
sclerosis score had three values, tlus resultcd in SL'X subgroups. The cffccts of botll 
APOE*2 and atherosclerosis were studied similarly. 
Statistical analysis 
The chi-square statistic was used to cotnpare categorical data, and tlle two satnple t 
test to study normally distributed, continuous variables. :rvllvISE scores were studied 
in a tnultiplc linear regression 1110del, with the shldy groups entered as dLUll1uy vari-
ables, using tlle above classification. Differences in Ivr:rvISE scores are presented with 
a 95 percent confidence intetval (CI). All analyses on d,e I'v[MSE score were adjusted 
for age, gender and level of education. All reported p values are based on two sidcd 
tests using a significance level of 5%. 
Table 1 - Baseline characteristics of the study population* 
Characteristic APOE'2 + 
APOE3E3 APOE*4 + 
n~136 n~459 n~224 
Age at baseline (years) 67.8 (6.8) 68.1 (7.4) 67.9 (7.3) 
Men 30.9% (42) 41.2% (189) 45.5% (102) 
Family history of dementia 21.5% (29) 21.5% (98) 32.3% (72) 
Educational level: primary 13.3% (18) 21.3% (97) 19.2% (43) 
education only 
History of stroke 1.5% (2) 4.2% (19) 3.6% (8) 
History of myocardial infarction 3.0% (4) 8.3% (37) 7.3% (16) 
CCA intima·media (mlllp 0.75 (0.12) 0.78 (0.15) 0.78 (0.15) 
Plaque in carotid bifurcations 43.2% (51) 54.7% (208) 49.7% (89) 
Ankle-arm index 1.12 (0.19) 1.10 (0.21) 1.10 (0.19) 
Atherosclerosis score zero t 27.3% (36) 20.7% (93) 22.0% (48) 
Atherosclerosis score onet 34.1% (45) 28.7% (129) 29.8% (65) 
Atherosclerosis score twol 38.6% (51 ) 50.7% (228) 48.2% (105) 
* Values are unadjusted means (SD) or percentages (numbers), based on all available informa-
tion; APOE*2+ denotes the APOE2E2 or the APOE2E3 genotype; APOE*4+ denotes 
APOE3E4 or APOE4E4. 
CCA indicates common carotid arteries. 
Atherosclerosis score is zero when none of the indicators of atherosclerosis are positive, one 
when only aile indicator is positive, and two when two or more indicators are positive. 
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Results 
Descriptive statistics 
The distribution of the APOE genotype in our slndy population was: APOE2E2: 1.3 
percent (n=l1), APOE2E3: 14.9 percent (n=125), APOE2E4: 2.3 percent (n=19), 
APOE3E3: 54.8 percent (n=459), APOE3E4: 24.S percent (n=20S) and APOE4E4: 
1.9 percent (n=16). The APOE genotype distribution was in Hardy-Weinberg equi-
librium (X2=5.1; degrees of freedom=3: P>O.2). Descriptive statistics of the study 
population are presented in lable I. Significantly more persons with APOE*4 had a 
positive family history of dementia in first degree relatives, compared to subjects 
without this allele. There were significantly more Incn among APOE*4 carriers than 
among APOE*2 carders. APOE*2 carriers had less often primary education only, as 
compared to the APOE3E3 group. In persons Witl1 APOE*2, we found a signifi-
cantly tlunner CCA intima-media wall tluckness, less often plaques in the carotid 
bifurcations and a larger proportion of subjects with an atherosclerosis score of zero) 
as compared to tl,e APOE3E3 group. The inverse association between APOE*2 and 
indicators of atl1erosclerosis could also be observed in a multivariate model with ad-
justments for age and gender (data not shown) . 
Apolipoprotein E and MMSE 
The median tvUvfSE score at follow-up in the APOE3E3 group was 28 (10tl1 centile 
25, 90tl, centile 29). As shown in lable 2, APOE*4 carriers performed significantly 
worse compared to tlus reference group. APOE*2 carriers had a similar MMSE 
score as the APOE3E3 group. 11,e MMSE score at follow-up was comparable for 
subjects with APOE3E4 relative to tllOse with APOE4E4, and also for persons with 
APOE2E2 as compared to tllOse with APOE2E3. However, the statistical power for 
tl,ese comparisons was limited, since there were only 16 homozygotes for APOE*4 
and 11 for APOE*2. 
Table 2 - Difference in MMSE score at follow-up according to the APOE genotype' 
APOE'2+ 
-0.1 (-0.5 to 0.2) 
n=136 
AP0E3E3 
reference 
11=459 
APOE'4+ 
·0.4 (-0.7 to -0.1) 
11=224 
* Values are means (95% confidence interval) adjusted for age, gender and education level; 
APOE*2+ denotes the APOE2E2 or the APOE2E3 genotype; APOE*4+ denotes APOE3E4 or 
APOE4E4. 
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Atherosclerosis and MMSE 
As shown in fable 3, subjects with evidence of atherosclcrosis as estimated by a his-
tory of stroke, the CCA intima-media thickness, the presence of plaques in the ca-
rotid bifurcations and the ankle-arm index, pcrfonned worse on d,C lvllVlSE at fol-
low-up, compared to those for whom that indicator was negative, although this did 
only reach statistical significance in analyses on the CCA intima-tnedia duckncss. 
Table 4 shows dlat the 1vITvfSE score at follow-up is lowest in dl0se \vith two or 
more indicators positive, intcnncdiate in persons with one indicator positive, and 
highest in those with no indicator positive. The median IvITvISE score at follow-up in 
persons wid,no indicator positive was 28 (lOd1 ccntile 26, 90d, centilc 29). 
Table 3 - Difference in MMSE score at follow-up according to the presence or absence 
of various indicators of atherosclerosis at baseline· 
indicator indicator ~ indicator + 
History of stroke reference -0.2 (-0.8 to 0.4) 
n"804 n~29 
History of myocardial reference 0.1 (-0.4 to 0.5) 
infarction n"758 n~59 
CCA intima-media t reference -0.3 (·0.6 to 0.0) 
(Median: 0.75 mm) n~412 n"414 
Plaque in carotid reference 0.0 (·0.3 to 0.3) 
bifurcations n~339 n"355 
Ankle-arm index reference -0.2 (-0.4 to 0.1 ) 
(Median: 1.13) n~403 1l~402 
* Values are means (95% confidence interval), adjusted for age, gender and education level. 
t CCA indicates common carotid arteries. 
Table 4 - Difference in MMSE score at follow-up according to the atherosclerosis score· 
Atherosclerosis score zero 
reference 
1l~184 
Atherosclerosis score one 
-0.1 (·0.4 to 0.3) 
1l~242 
Atherosclerosis score two 
-0.3 (-0.6 to 0.1) 
1l~393 
-t Atherosclerosis score is zero in those with 110 indicator of atherosclerosis positive, one in per-
sons with one indicator positive, and two in those with two or more indicators positive; 
values are means (95% confidence interval) adjusted for age, gender and education level. 
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Apolipoprotein E, atherosclerosis and MMSE 
The combined effects of ApOE*4 and atherosclerosis on the MMSE score at fol-
low-up, are show11 in table 5. Among APOE*4 carriers, those with evidence of athe-
rosclerosis (column 5) performed worse compared to those without (column 3). In 
the absence of APOE*4, none of the indicators of atherosclerosis were associated 
with a statistically significantly lower NllvlSE score at follow-up (compare collUnn 4 
versus cohunn 2). 
The vanous indicators were studied simultaneously using the adlcrosclerosis 
score. In tIus analysis, nOll-APOE*4 carriers with an atherosclerosis score of zero 
were ti,e reference group (median Ml\·ISE at follow-up 28, 10th centile 26, 90tl, cen-
tile 29). As shown in table 6, APOE*4 carriers perfonned worse conlpared to persons 
without tIus allele, in all strata of the atherosclerosis score. The performance on the 
"tvllvISE at follow-up decreased with increasing atherosclerosis scores, for those \vith 
and without AI'OE*4. With this classification we could study the effects of ApOE*4 
and atherosclerosis separately. In the absence of evidence of atherosclerosis (score 
Table 5 - Difference in MMSE score at follow-up according to the presence or absence 
of APOE*4 and various indicators of atherosclerosis at baseline· 
atherosclerosis APOE'4 - APOE'4 + APOE'4 - APOE'4 + 
indicator atherosclerosis atherosclerosis atherosclerosis atherosclerosis 
indicator - indicator - indicator + indicator + 
History of stroke reference -0.4 -0.3 -0.6 
(·0.6 to ·0.1) (-1.1 to 0.5) (-1.8 to 0.6) 
n~571 n~233 n~21 n=8 
History of myocardial reference ·0.3 0.2 ·0.7 
infarction (-0.6 to 0.0) (-0.3 to 0.8) (-1.6 to -0.1) 
n~538 n~220 n~42 n~17 
CCA intima· media' reference -0.1 0.0 -0.6 
(Median: 0.75 mm) (·0.5 to 0.3) (-0.3 to 0.3) (-1.0 to ·0.3) 
n~29B n~114 n~292 n~122 
Plaque in carotid reference -0.2 ·0.1 ·0.6 
bifurcations (-0.6 to 0.2) (·0.4 to 0.2) (-1.0 to -0.2) 
n~240 n~99 n~259 n~96 
Ankle-arm index reference ·0.3 ·0.1 ·0.4 
(Median: 1.13) (-0.7 to 0.1) (-0.3 to 0.2) (-O.B to ·0.1) 
n~2B2 n~121 n~2B6 n~116 
.. Values are mean differences (95% confidence interval), adjusted for age, gender and educa-
tion level. 
I CCA indicates common carotid arteries. 
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zero), the lnean difference in lvU"ISE score bctween pcrsons with and without 
APOE*4 was -0.2 (95 percent CI -0.7 to OA). In the absence of APOE*4, those \\~th 
an atherosclerosis score of two differed on average -0.2 MlvISE POUlts (95 percent CI 
-0.5 to 0.2) from those with a score of zero. However, dIc 1vllvISE score for 
APOE*4 carriers widl an adlerosclerosis score of two was on average -0.7 I\tTh,ISE 
points (95 percent CI -1.1 to -0.2) lower compared to nOll-APOE*4 carriers with a 
score of zero. This difference was larger than the sum of the separate effects (-0.2 
and -0.2), and could not be explained by an asymmetric distribution of homozygotes 
for i\POE*4. muong AIJOE*4 caniers widl atl adlcrosclerosis score of zero, 8 
pcrcent were h0111ozygote. In APOE*4 carriers with a scorc of one,S percent were 
hOlll0zygote, and among APOE*4 carfiers with an atherosclerosis score of two) 8 
percellt were homozygote (X2=0.7; degrees of freedom=2: 1'=0.7). 
'TI'ere was 110 evide11ce d,at d,e APOE*2 allele modified d,e effects of adleroscle-
rosis widl regard to the IVll'vISE score at follow-up (data not shown). 
Possible confounders and modifiers 
\Xlllen, in addition to age and gendef) adjustments were lllade for a positive family 
history of dementia, dIe findings were very similar for all analyses described above. 
FUlally, in all analyses effect modificatiOll by gender was studied. No major differ-
ences were observed between lnen and women. 
Discussion 
'\lie investigated the association of APOE, atherosclerosis and cogtutive decline in a 
population-based follow-up study of 838 subjects. Bodl APOE*4 carriers and per-
Table 6 - Difference in MMSE score at follow·up according to the presence or absence 
of APOE*4 and the atherosclerosis score· 
Atherosclerosis score Atherosclerosis score Atherosclerosis score 
zero one two 
APOE'4- reference 0(-0.4 to 0.4) -0.2 (-0.5 to 0.2) 
n~129 n~173 n~280 
APOE*4+ -0.2 (·0.7 to 0.4) -0.3 (-0.9 to 0.2) ·0.7 (·1.1 to -0.2) 
n~55 n~69 n~113 
* Atherosclerosis score is zero in those with no indicator of atherosclerosis positive, one in per-
SOilS with one indicator positive, and two in those with two or more indicators positive; 
values are means (95% confidence interval) adjusted for age, gender and education level. 
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sons with evidence of atherosclerosis had a lower 1VllYISE score at follow-up. \\1hcn 
studied simultaneously, we found mild, non-significant effects for atherosclerosis in 
the absence of APOE*4 and for APOE*4 in the absence of adlerosclerosis. Persons 
with both APOE*4 and evidence of atherosclerosis at several sites performed sig-
nificantly worse on the "NllvISE as compared to those widl neither risk factors. Fur-
thermore, the effects of both atherosclerosis and APOE*4 were found to be 
stronger than expected [fOlU the surn of the separate effects. 
In tlus study, cognitive function was assessed by the MlvISE. Although originally 
developed as a screening tool for dctnentia, this test has been shown to be suitable 
also for studies on cognition in non-demented cOl1Ullunity residents.3D The differ-
ences in ~l1vISE score that we observed were relatively small and may not be relevant 
for an individual, but can be important on a population level.3l To esti!nate the pres-
ence of atherosclerosis, we used indicators which have been well validated. 23-27 Nev-
ertheless, some Inisclassification may have occurred. Since all examinations were per-
formed without knowledge of the other measurements, any rnisclassification is Inost 
likely nondifferential and will therefore result in an lUlderestimatiotl of the tme effect. 
An advantage of our study is d,e prospective design. Since APOE rna)' be related to 
the survival of patients with dementia,9,t(, wc includcd only subjects who werc not 
demented at baseline. In dUs study d,e follow-up period was relatively short, on aver-
age 2.9 years. Hence, loss to follow-up due to mortality, wluch may be related to d,e 
APOE genotype,l()'12 was limited. 
Similar to our findings, od,ers found that APOE*4 rna)' be a risk factor for cog-
nitive decline.'·6 Diverse findings have emerged on the effects of APOE*2.5•6 We 
found no difference between APOE*2 and APOE3E3 widl regard to cognitive dete-
rioration. Furthermore, our findings suggest that atherosclerosis is not lnore preva-
lent in carriers of d,e APOE*4 allele, relative to persons with other APOE geno-
types, as has been suggested before. IO- I2 In addition, we found that atherosclerosis 
may be less conunan in carriers of the APOE*2 allele. However, analyses on the 
association betwccn the APOE genotype and atherosclerosis were based on cross-
sectional data, and should be confirmed in follow-up studies. 
One may hypothesize dlat adlerosclerosis is an intermediate factor in the associa-
tion between APOE and cogtutive decline. That is, APOE may be a determinant of 
adlerosclcrosis,I0-12 and atherosclerosis on its hun may he a determinant of impaired 
cognitive function. IS We found no evidence for an increased prevalence of athero-
sclerosis in APOE*4 carriers compared to persons widl od,er APOE genotypes. 
Besides, in d,e absence of APOE*4, cognitive performance was only mildly de-
creased in those widl adlcrosclerosis co!npared to dlOse widl0Ut. Furthennore, we 
found an inverse association between APOE*2 and adlcrosclerosis, but not a better 
cogtutive performance of APOE*2 carriers. These findings make it unlikel), d,at 
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atherosclerosis is an intermediate factor in the association between APOE and cog-
nitive decline. 
Earlier, we reported that APOE*4 potentiates the relation between atherosclero-
sis .in a series of prevalent patients with dementia. 14 In tltis prospective study ,ve ad-
dressed the question whether the effects of APOE*4 and atherosclerosis on cogtti-
tive decline are independent. \Ve found small, non-significant effects on the lvllvISE 
score for atherosclerosis in the absence of APOE*4 and for APOE*4 in the absence 
of atherosclerosis. 'I1l.e observation that the consequences of both APOE*4 and 
atherosclerosis were worse than the stun of the effects of these two factors separate-
ly, suggests a synergistic effect of the APOE*4 allele and atllerosclerosis. 
The presence of atllerosclerosis in the brain itself is difficult to investigate during 
life. However, the indicators we used are strongly associated witll cerebral wltite 
matter lesions, as has been shown in a study using lvlagtletic Resonance Imaging of 
tile brain.22 These white matter lesions arc associated with cerebral arteriosclerosis, 
hypoperfusion, and ischaetnia.32,33 Our study may indicate that the cognitive conse-
quences of tll.ese cerebral lesions tnay be more pronounced in carriers of the 
APOE*4 allele, compared to persons without APOE*4. In line with our findings, 
tll.ere is evidence from studies in rats that apolipoprotein E plays a role in the re-
sponse to cerebral ischaemia.34 Furtllcnnore, APOE*4 carriers may have a less favor-
able outcome after intracerebral haemorrhage, as compared to subjects without 
APOE*4,35 ivloreover, APOE may playa role in reinnctvation after neuronalloss.36,37 
In conclusion, tltis follow~up study suggests that in particular APOE*4 carriers 
with atherosclerosis arc at increased risk of cognitive decline. We found mild, non-
significant effects on cogttitive perfol1nance for atherosclerosis in the absence of 
APOE*4 and for APOE*4 in the absence of atherosclerosis. Our findings are not 
c01npatiblc \vitll tile view that atherosclerosis is an interlnediate factor in tile associa-
tion between APOE*4 and cogttitive decline. An important cwtical and public health 
issue will he whether the development of demenda of APOE*4 carriers may he pre-
vented by intervention on vascular risk factors. 
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Abstract 
6.2 
The role of apolipoprotein E 
and atherosclerosis in dementia 
1/;, APOE*4 allele of the apolipoplVleill E gelle (APOE) may illmase th, risk of bolh demelliia 
alld alhelVse/elVsis, IVh",as th, APOE*2 allele seems to have opposite efjeets. AtheIVse/eIVsis lVas 
sllggested to be a /7skjildol'jol' demClltia, pattltulady IiI APOE*4 cam'/Y. JF"e illvestigated the 
coJJJbilled efjeds of the APOE gellotype alld atheIVse/elVsis ill delJlelltia lVith melll olls,l. III a 
pOplllatioll-based s,ttillg, 244 deJJJet/tia cas,s lVith ",,"I OllS,t IV", (ollpat,d to 100211oll-delJJet/ltd 
tYJJ1!Jv/s,' a/herosde/Vsis was assessed /Ising Jloll-illtlflSiJ!tJ I/leasIllPIJJCIJ!S. If/'e fllllld thaI the assodafioll \ 
b,lIv,," the APOE get/otypes alld demelllia, did IIot esselltially altel' IVhet/ ao/lIStmellts IVm made 
jol' athelVsc/elVsis 01' oth,1' oasatlal'jadolJ. Athe/vsc/elVsis seel/Js Ihenifim IIot 10 be all illtmJlCdiate 
jadol' ill the assodatioll of APOE 'Pith del/JClltia. III addilioll, lVe obs,rv,d a SYllergistir efjeet of 
APOE*4 alld athelVsc/Clvsis 011 the risk oj deJJJ,"tia. Ollrjlll"li'!,s IVIIMb"te to th, glVlVli'!, ""~ 
det/" that APOE is illllol",d ill the IPSPOIIS' 10 m,bral daJJJage. 
Introduction 
It is now well known that the apolipoprotcin E gene (APOE) plays a role in the de-
velopment of dementia. \Xllille the APOE*4 allele increases the risk, the APOE*2 
allele may exert a protective effect. i ,2 Atherosclerosis is another common risk factor 
for dementia,} in which the APOE genotype seems to be involved as wcll.4,s The 
APOE*4 allele was found to increase the risk of atherosclerosis, although not in all 
studies.'·5 APOE*2 on the other hand appeared to he inversely associated with athe-
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rosclerosis.4,s 'n,erefore, it can be hypodlesised d,at d,e effects of the APOE poly-
tllotphism on dementia (partly) result from its effects on atherosclerosis. A synergis-
tic interaction has been observed for APOE*4 and atherosclerosis on the prevalence 
of delnentia.3 However, tlus cross-sectional study may have been subject to selective 
tuortality, as the APOE genotype was obsc1ved to be related to survival in AO.6 
TIle aim of this study is to investigate whether APOE is related to dClnentia, in-
dependent of its association with atherosclerosis. In addition, we wanted to further 
investigate the c0111bined effects of atherosclerosis and APOE*4 in dementia. These 
issues were explored in a population-based setting on dClnentia patients with recent 
onset. 
Methods 
Study population 
TIus investigation forms part of d,e Rotterdam Stndy, a population-based prospec-
tive follow-up stndy among elderly aged at least 55 years.' Approval was given by d,e 
local lvledical Ethics Comnuttec, and all subjects gave infortned consent. Participants 
were recruited from 10275 eligible residents of a suburb of Rotterdam, including 
institutionalised persons. A total of 7983 participants (response rate 78%) were ex-
amined at baseline. Of these, 7528 persons (94%) were cognitively tested, and 474 
appeared to be demented.' At follow-up, after an average of 2.1 years (SD 0.9 years), 
6315 persons (79%) were re-examined; 768 subjects (10%) had died, 106 (1%) were 
inaccessible and 794 (10%) refused to participate. Follow-up of all subjects who were 
not examined in person was completed by evaluating medical files. Of the 7054 par-
ticipants who were non-demented at baseline, 162 subjects were found to be de-
mented at follow-up.? 
The analyses presented here are restricted to dementia cases with onset within 3 
years before examinations for this study, in order to litnit any selective sUlvival, asso-
ciated with APOE Of atherosclerosis.3.6 The controls were a random sanlple of par-
ticipants in the Rotterdam Study, who were screen-negative for dementia at follow-
up. As persons with tnissing data on atherosclerosis or the APOE genotype wcre 
excluded, dus resulted in a study population of 244 dementia cases (157 prevalent 
and 87 incident patients) and 1002 non-demented controls. 
Dementia diagnosis 
For the assessment of delnentia, the same protocol at baseline and at follow-up was 
used.s,? Briefly, all subjects were screened on cognitive functioning. Screen positives 
underwent further neuropsychological testing, and an informant was interviewed on 
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daily functioning of the participant. Persons who were suspected of delnentia, were 
exarnined by a neurologist, underwent neuropsychological testing, and, if possible, 
had a Magnetic Resonance Imaging (~llU) brain scan made.'·' Of subjects who could 
not be re-examined in person, infortnation was obtained from general practitioners 
and the regional institute for outpatient mental health care (RlAGG), which covers 
the entire study population. In the Netherlands, the lUAGG is consulted for social 
and psychiatric problelns and is responsible for dementia-care-facility indications. 
Examinations by the RIAGG include (infonnant) interviews, neurological and neu-
ropsychological testing, blood biochemistry and syphilis serology. 
The diagnosis of dementia was made by a panel of study physicians, a neurologist 
and a neuropsychologist, which reviewed aU eXisting information and used Diagnos-
tic and Statisticalll-lanual of mental disorders (DSM-III-R) criteria. to A diagnosis of 
AD and vascular detnentia (VaD) was based on criteria of dIe National Institute of 
Neurological and Cotnrnunicative Disorders and Stroke and Alzheimer's Disease and 
Rebted Disorders Association (NINCDS-ADRDA),II and of the National Institute 
of Neurological Disorders and Stroke and Association Intemationale pour la Re-
cherche et l'Enseignement en Neurosciences (NINDS-AIREN).'2 Cerebrovascular 
disease was recognised by a history of stroke, evident transient ischaetnic attack, or 
evidence of vascular damage on brain scans. 
Measurements 
At study entry, people were interviewed about attained level of education and health 
status, using a computerised questionnaire. Height and weight were nleasured, and 
body mass index was calculated. 
At baseline, the presence of atherosclerosis in the cotntnon carotid arteries 
(CCAs) was assessed ultrasonographically with a 7.5 MHz linear-array transducer and 
a Duplex scanner (KIT, Ultra Mark I\~. Both CCAs were evaluated for the presence 
of adlerosclerotic plaques, defined as a focal widening relative to adjacent segtnents 
with protnlsion into the lumen, as described previously.13 In addition, the inti-
ma-media duckness of d,e distal part of bodl CCAs were measured and averaged, as 
described before. 13 The presence of plaques as well as an increased cas intima-me-
dia wall thickness are indicators of generalised adlerosclerosis.14 At baseline, athero-
sclerosis of the arteries of the lower extremities was assessed by the ratio of the ankle 
to brachial systolic blood pressure (ankle-arm index). A decreased ankle-arm index is 
a tneasure for peripheral atherosclerosis. IS Artu blood pressure was measured in sit-
ting position at the right upper ann with a random-zero sphygnloman01neter, and 
the average of two measurements obtained at one occasion was used. Ankle systolic 
blood pressure was determined widl d,e subject in supine position at bodl the right 
and left posterior tibial artery using also a randotu-zero sphygmomanometer and a 
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Doppler ultrasound transducer. The analyses were based on d,e lowest of d,e an-
kle-arm index on d,e left and ilie right side. 
APOE genotyping was performed on coded DNA samples widlOut knowledge 
of the diagnosis, as described elsewhere. 1 The results were read by three persons in-
dependendy. In case of discrepancies, APOE genotyping was repeated. Senun total 
and high density lipoprotein (HDL) cholesterol were determined wiili an automated 
enzymatic procedure,16 
Statistical analysis 
11,e relative risk of dementia or its subtypes was studied as an odds ratio (OR) in a 
multiple logistic regression model, and presented with a 95% confidence interval 
(95% CI). To overcome confounding, in all analyses adjustruents were made for age, 
sex and education level. Education was dichotomised as primary school or less) and 
more than primary school. To study atherosclerosis, a composite measure was used, 
as defined before.' Briefly, a point was added to this score if d,e following character-
istics were present: plaques in at least one of the CCAs, an average CCA int1tna-tne-
dia wall thickness in ilie highest quartile of d,e distribution in d,e Rotterdam Study, 
Of an ankle-arm index less than 0.9.3 TIllS atherosclerosis score was analysed in four 
categories, corresponding to score values of 0-3, with a zero score as the reference. 
To study whedler ilie APOE polymolphism is associated widl dementia, inde-
pendent of ailierosclerosis, we put bodl d,e APOE genotypes and ilie adlerosclerosis 
score in the model. This model was extended widl ilie following vascular factors: 
systolic blood pressure, diastolic blood pressure, body mass index, total and HDL 
cholesterol, in order to study effects of APOE irrespective of possible intermediate 
vascular factors. 
To investigate d,e combined effect of APOE and ailierosclerosis, d,e study 
population was dichotouused according to the atherosclerosis score, to yield tnaxi-
mum statistical power, and classified into 4 groups: (1) APOE3E3 carriers widl an 
adlerosclerosis of 0 or 1 (reference group); (2) Carriers of APOE*4 widl an adlero-
sclerosis score of 0 or 1; (3) APOE*3 homozygotes with an atherosclerosis score of 
2 or 3; and (4) APOE*4 carriers widl an ailierosclerosis of 2 or 3. Possible interac-
tion was studied according to d,e principles as descl1bed by Roiliman,l1,18 Briefly, 
interaction of factors A and B was considered to be a departure from additivity, and 
judged to be present if: 
(OR"s, - OR".) - (ORA<' - 1) > O. 
11,e combined effects of APOE2E2 or APOE2E3 and adlerosclerosis were studied 
similarly. As no major differences were observed between men and women, our ob-
servations are presented for all. 
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Results 
The dist11bution of the APOE genotype was in all subgroups in Hardy-Weinberg 
equilibrium. Some characteristics of the study population are presented in tab/, 1. 
Dementia patients wcre older, included a higher proportion of women and were 
lower educatcd than the controls. Besides, demented cases had, on average, a higher 
systolic blood pressure, a lower body lnass index, a lower Seiwn cholesterol level, 
and a higher atherosclerosis score. 
Table 2 shows the association between the APOE genotypes and dementia, as 
well as its main subtypes, AD and VaD (model 1). As expected, carriers of the 
APOE*4 allele were at increased risk of dementia. The APOE2E3 genotype was 
inversely related to dementia, AD and VaD, although not statistically significant. TI,e 
addition of the atherosclerosis score to the model, did not essentially alter d,ese ob-
selvations (model 2). Furdler adjustlnent for od,er vascular factors, i.e. systolic blood 
pressure, diastolic blood pressure, body mass index, total and HDL cholesterol, did 
not change risk estimates eid,er (not shown). 
Tab/e 3 shows the combined effects of APOE*2 and atherosclerosis on dementia, 
AD and VaD. We did not obselve a clear interaction between APOE*2 and athe-
rosclerosis. Among persons with an atherosclerosis scorc of 2 or 3, the odds ratio for 
AD in APOE*2 was lower dlan in persons widl APOE3E3 (1.2 versus 2.0). How-
ever, dlc estimate in APOE*2 carriers is radler imprecise, as dle confidencc intclval 
is wide. 
Table 1 - Baseline characteristics of the study population * 
Age (SD) 
Women 
Primary education only 
Systolic blood pressure in mmHg 
Diastolic blood pressure in mmHg 
Body mass index in kg/m2 
Total cholesterol in mmmol/L 
HDL cholesterol in mmmollL 
Atherosclerosis score 0 
Atherosclerosis score 1 
Atherosclerosis score 2 
Atherosclerosis score 3 
All dementia 
n=244 
82.4 (7.5) 
67% (164) 
58% (129) 
142.3 (24.1) 
70.8 (14.2) 
25.6 (3.9) 
6.26 (1.16) 
1.34 (0.38) 
30% (74) 
24% (58) 
29% (71) 
17%(41) 
Controls 
n=1002 
68.7 (7.9) 
60% (604) 
23% (225) 
136.3 (20.7) 
71.1 (10.5) 
26.6 (4.0) 
6.69 (1.22) 
1.34 (0.38) 
67% (670) 
21%(215) 
9% (87) 
3% (30) 
• Values are unadjusted means (SO) or percentages (numbers), based on all available 
information. 
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Table 2 - Odds ratios for dementia associated with apolipoprotein E genotypes: adjustment for atherosclerosis· 
Dementia Alzheimer's disease 
Apolipoprotein E Modell' Model 2' Modell' 
APOE2E2 1.7 (0.3 to 10.1) 2.1 (0.3 to 13.4) 1.0 (0.1 to 11.9) 
AP0E2E3 0.6 (0.4 to 1.2) 0.7 (0.4 to 1.4) 0.6 (0.3 to 1.1) 
APOE2E4 3.6 (1.1 to 1.2) 3.9 (1.2·12.6) 1.5 (0.3 to 6.4) 
APOE3E3 1 (reference) 1 (reference) 1 (reference) 
AP0E3E4 1.6 (1.0 to 2.5) 1.7 (1.1 to 2.7) 1.5 (0.9 to 2.5) 
APOE4E4 15.0 (5.9 to 8.6) 15.2 (5.9 to 39.4) 17.2 (6.2 to 8.0) 
.. Values are odds ratios (95% confidence intervals), and number of patients/controls; 
Model 1: adjusted for age, sex and education level; 
Model 2' 
1.2 (0.1 to 14.4) 
0.6 (0.3 to 1.3) 
1.6 (0.4 to 7.0) 
1 (reference) 
1.5 (0.9 to 2.6) 
17.1 (6.1 to 48.4) 
Vascular dementia 
Modell' Model 2' 
0.5 (0.1 to 1.9) 0.6 (0.2 to 2.5) 
7.2 (1.5 to 3.5) 16.9 (3.4 to 83.2) 
1 (reference) 1 (reference) 
1.8 (0.8 to 3.9) 2.2 (1.0 to 5.1) 
Model 2 includes in addition the atherosclerosis score, systolic blood pressure, diastolic blood pressure, body mass index, total and HOL cholesterol. 
Table 3 - Odds ratios for dementia and Alzheimer's disease associated with both atherosclerosis and APOE*2* 
Dementia Alzheimer's disease Vascular dementia 
Atherosclerosis AP0E3E3 APOE*2+ APOE3E3 APOE*2+ AP0E3E3 APOE*2+ 
Score 0 or 1 1 {reference 0.7 (0.4 to 1.2) 1 (reference) 0.8 (0.4 to 1.5) 1 {reference 
61/490 18/148 47/490 15/148 3/490 0/148 
Score 2 or 3 2.1 (1.3 to 3.2) 2.1 (0.8 to 5.5) 2.0 (1.3 to 3.3) 1.2 (0.3 to 4.1) 4.1 (1.3 to 13.4) 5.7 (0.7 to 49.5) 
60/76 11/13 44/76 5/13 4/76 1/13 
* Values are odds ratios (95% confidence intervals) adjusted for age, sex and education level, and number of patients/controls. 
Table 4 - Odds ratios for dementia and Alzheimer's disease associated with both atherosclerosis and APOE*4* 
Dementia Alzheimer's disease Vascular dementia 
Atherosclerosis APOE3E3 APOE*4+ APOE3E3 APOE*4+ APOE3E3 APOE*4+ 
Score 0 or 1 1 {reference 2.1 (1.4t03.1) 1 (reference) 2.2 (1.5 to 3.4) 1 (reference 2.3 (1.1 to 5.3) 
61/490 53/247 51/490 46/247 51/490 0/148 
Score 2 or 3 2.6 (1.7 to 4.0) 7.3 (3.9 to 13.4) 2.5 (1.6 to 4.0) 6.8 (3.6 to 12.9) 5.9 (2.8 to 12.4) 12.4 (4.9 to 31.1) 
60/76 41/28 50/76 31/28 50/76 31/28 
* Values are odds ratios (95% confidence intervals) adjusted for age, sex and education level, and number of patients/controls. 
Chapter 6.2 
As shown in lable 4, the effects of both APOE*4 and atherosclerosis on dementia 
were stronger than the separate effects. APOE*4 with an atherosclerosis score of 0 
or 1, was related to an increased risk of all dementia, AD and VaD. The same held 
tme for APOE3E3 with an atherosclerosis score of 2 or 3. However, the highest 
odds ratio for all three outcomes was obsclved in APOE*4 carriers widl a score of 2 
or 3. This odds ratio could not be explained by an asymmetric distribution of homo-
zygotes for APOE*4 across the strata of the atherosclerosis score. For dementia, the 
interaction effect was \1.3 - 2.1) - (2.6 - 1) = 3.6 (95% CI -1.3 to 8.5). Similarly, the 
interaction effect for AD was 3.1 (95% CI -1.9 to 8.1), and for VaD 5.2 (95% CI -8.5 
to 18.9). Restriction of the cases to incident patients only, did not essentially change 
our observations. 
Discussion 
We found that the association between the APOE genotypes and dementia, did not 
essentially alter when adjustments were made for atherosclerosis Of other vascular 
factors. In addition, the combined effects of atherosclerosis and APOE*4 were 
stronger than the sum of the separate effects, although tltis did not reach statistical 
significance. 
A drawback of tltis study is the lack of autopsy confirmation of ti,e diagnoses of 
dementia subtypes. However, with clittical examination alone, approximately 90% of 
AD cases are diagnosed correcdy.19 Another issue is the assessment of atherosclero-
sis, wltich may have been subject to lltisclassification. It should be noted that all ex-
aminations were performed without knowledge of the otl,er measurements. There-
fore, any measurement error that occurred is random, and most likely resulted in an 
underestimation of the true relationsltip. All ti,e indicators of atherosclerosis are reli-
able estimates of generalised atherscierosis. 14•1S During life, it is difficult to assess the 
presence of atherosclerosis itl the brain. However, the methods that were used in this 
study are strongly associated with cerebral white matter lesions, as observed with 
MRI.W These lesions are believed to reflect arteriosclerosis, hypoperfusion, and 
hchaentia.2I A further advantage of our study is that it is population-based witll ltigh 
response rate and complete follow-up. Survival bias was litrtited by including subjects 
who deceased during follow-up, and because the study population was restricted to 
patients with recent detnentia onset. 
Our estimates of the odds ratio for dementia associated with the APOE geno-
types are in line wirll previous reports.2 We confirmed the elevated risk of AD for 
persons with the APOE2E4 genotype;2 the ltigh odds ratio for VaD is illaccurate, as 
the confidence interval is wide. The APOE2E3 genotype was found to be inversely 
related to all dementia, AD and VaD, although tltis did not reach statistical signifi-
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cance. The putative protective effect on atherosclerosis by the APOE*2 aUele,4,S did 
not explain this inverse association bctween APOE2E3 and dementia, as adjusting 
for atherosclerosis or other vascular factors did not make a difference. Adjustments 
for vascular factors did not alter the APOE*4 related odds ratios for dementia either. 
Thesc obsclvations show that atherosclerosis seems not to be intertnediate in the 
association between the APOE genotypes and dementia. 
\Ve did not observe an obvious interaction between APOE*2 and atherosclerosis 
in detnentia. By contrast, we could extend the previously reported interaction be-
tween APOE*4 and atherosclerosis in dementia,3 to a larger group of demented pa-
tients with recent onset. A synergistic effect on cognitivc decline has also been re-
ported between APOE*4 and atherosclerosis,22 and between APOE*4 and cerebro-
vascular clisease.23 Furdlel1nore, there may be a synergistic effect of white matter le-
sions and APOE*4 in d,e development of dementia." These findings are in line with 
post-mortem studies, which showed d,at APOE*4 is related to neuropadlological 
characteristics of AD,25 and d,at d,e AD neuropadlOlogy is especially related to clirti-
cal dementia in the presence of cerebral infarcts.26 
Therefore, the cognitive consequences of cerebrovascular damage seem to be 
tllore severe in carriers of the APOE*4 allele dIan in persons widI0ut this allele. This 
hypodlesis is supported by a growing body of literature d,at APOE is involved in the 
response to cerebral injuryP-29 'I11e effects of APOE may be through various 
tnechanisms, which are not necessatily exclusive. These include the reinnervation 
after neuronal injury, protection against oxidative insults and the modulation of in-
£lanunation.28 Interestingly, transgenic tuice canying hutnan APOE*4 were shown to 
have larger infarct volumes after cerebral ischaetnia than mice widl hmnan 
APOE*3.2B \VidI dIe exception of iiI Ililro experiments on apoE in oxidative stress,30 
"\ve are not aware of other reports that could explain thc inverse association of 
APOE*2 widl dementia. 
In conclusion, out shldy suggests that athcrosclcrosis is not an intenncdiate fac-
tor in the association between thc APOE genotype and delnentia. The putative syn-
ergistic effect of APOE*4 and atherosclerosis on the .risk of detnentia, contributes to 
the W:owing evidence that APOE plays a role in the response to cerebral damage. 
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Abstract 
6.3 
Smoking, apolipoprotein E 
and the risk of dementia 
Background P'PoiollS stlldies sllggested II pmleclioe effeci of smokillg 011 A/sjJeimer's disease. 
These stlldies Jvere lllostlJ' (mc-coJltrol studies based 011 prellfllent cflSes. ProspeclitJc sl/ldies 011 the 
I7sk ~ldellJell/itl associated lvi//; smoking arc scan-e alJd illcolldmin. 
Methods We pnjiJl7JJed II pop"/alioll-basedjol/ow-Itp Silldy of6870 elderly who Ivm illilial/)' 
jire of demelliia. Smokillg hislory was oblailled al base/ille alld sllbjeds WetV classified tIS """1' 
slI/okers, former slI/okers, and tll/Ttlll1 slI/okers. COlllplete flStel1aiIJJJjeJI/ of rases lll/l/; iwideJl! 
deJlJeJ/lia 1vas purslled. UsliJg lie/Ie,. smokers as the '-qereJlte, rdafliJc risks IVere mlm/a/ed lvill; 
Cox pmpol!iolla/ ha'{flnls I?gmsioll, IIdjllsliltgjor age, sex, edllmlioll, alld ahvho/ illiake. IVe 
examined modi{imlioll by {tge, sex alld {tpo/ipopmletil E (APOE) gellotype. 
Findings Dllliltg all a",rage jol/O/ll-Itp of 2.1 ),etllJ, 146 illddelll mses of demetClia w"" de-
leded, I!lWhOIll 105 had A/sjJeilll,r's diseast. Smokm had a IIIOIP Ihall Iwojold illClPtlSed lisk 
o/delllflliia (ldal;", lisk (RR) 2.2; 95% CI 1.3 10 3.6), alld A/:dleimer~ disease (RR=2.3; 
95% CI 1.3 10 4.1). SI/Joktitg app""pd a sllVltg tisk fador of A/sjJeil/Jer~ diwI.fe ill Ihoff 
wilholll Ihe APOE*4 al/ele (RR=4.6; 95% CI 1.510 14.2), ,vhmas 110 ,!Jed was ob"'"I,,1 ill 
sllo/eds with Ihe APOE*4 a/lele (RR=0.6; 95% CI 0.1 104.8). 
Interpretation This pmspedillf sllld)' did 1101 tVltjiml IPSII/ls jiVIII p"violls silldies, which 
sllggesled II ge",ra/ pmledillt e!Jed 0/ SIllOklitg 011 demelliia IIlId A/sjJeill;er~ disease. Smokillg 
was IIssorialed wilh II dOllbltitg 0/ the lisk of demelllill alld A/:d;eilller~ disells •. Ca"i,," of'lh. 
Al'OE*4 allele had 110 imwlsed lisk, sltggesliltg illieradioll bellveell slllokillg alld th. APOE 
gellotype ill Ihe aeli%gy q/ A/sjJeilll.r~ disease. 
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Introduction 
DClnentia is a frequent disorder with itnmense impact on quality of life. Its preva-
lence increases exponentially with age to at least 30% in people aged 85 years and 
ovcr,l Alzheimer's disease and vascular dementia are the inaja! subtypes of dementia, 
and account for about 90% of patients.' Smoking has both been related to vascular 
dementia and Alzheimer's disease. As an important risk factor for cardiovascular 
diseases,2,3 smoking is supposed to increase the risk of vascub.r dementia,4 In con-
trast, an inverse association has been ObSC1"Vcd between smoking and Alzheitner's 
disease,s In a study on early onset Alzheimer's disease this possible protective effect 
of smoking was found to be limited to carders of the apolipoprotein E4 allele 
(APOE*4).6 Although there are several possible explanations for a protective effect 
of smoking on Alzheimer's diseasc,5,6 it is also conceivable that findings in previous 
studies were the result of biasJ Also, Stl10king strongly increases mortality and sll1ok-
ers who survive till later age may be a luore selected group than contelnp0faneous 
non-smokers.8 
We performed a prospective population-based study of the association of ciga-
rette smoking with dementia and Alzheimer's disease> while considering the effects 
of age, sex and the APOE genotype. 
Methods 
Study population 
TI,e Rotterdam Study is a community-based prospective cohort study among per-
sons aged 55 years and over,' for which approval was given by the local Meclical 
Ethics Committee. All 10275 residents of a suburb of Rotterdam over the age of 55 
years were eligible and of those 7983 (78%) participated and gave informed consent 
and permission to obtain meclical information from treating physicians. Baseline ex-
ami.nations took place from 1990 to 1993 and comprised a home interview and 
tuedical examinations at the study centre or> for institutionalised persons> at their 
institution. At baseline, 7528 persons (94%) were evaluated for dementia,' of whom 
474 were cliagnosed with dementia and excluded from the present study. Of those 
without dementia an additional 184 were excluded because of missing data on 
smoking history. The remaining 6870 subjects were followed-up for an average of 
2.1 years (range 1.5-3.4), until the second round of examinations. During tills folIo\\'-
up period 429 participants (6.2%) clied. Another 962 subjects (14.0%) were not re-
examined because of refusal or severe illness. Follow-up of all subjects who were not 
examined in person was completed by evaluating their medical files. 
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Dementia diagnosis and measurements 
For the assessment of detnentia the satne protocol was used at baseline and at fol-
low-up. as described in more detail clsewhere. 1,10 Briefly. all subjects were screened 
with a brief test of cognition (tvlini Mental State Examination" and d,e GeL1atric 
hrIental State schedule, organic leve112). Screen positives underwent further cognitive 
testing, and an informant was ulterviewed on daily functioning of the participant. 
Persons who were suspected of detnentia, were examined by a behavioural neurolo-
gist, undenvent neuropsychological testing, and if possible had a brain scan Inade by 
magnetk resonance imaging. 1•10 Of subjects who could not be re-examined in per-
son, infonnation was obtained £rOln general practitioners and the regional institute 
for outpatient mental health care (RIAGG), which covers d,e entire study popula-
tion. In d,e Nedlerlands, the RIAGG is responsible for dementia-care-facility indica-
tions. Examinations by the lUAGG include (infonnant) interviews, neurologic and 
neuropsychologic testing, blood biochemistry and syphilis serology. We avoided mis-
diagnosing tel1ninal decline for deinentia by not diagnosing deinentia in subjects with 
unexplained mental deterioration within half a year before death. 
The diagnosis of dementia was based on Diagnostic and Statistical I'vlanual of 
mental disorders (DSM-III-R) criteria," and made by a panel of study physicians, a 
neurologist and a neuropsychologist. which reviewed all existing information. A di-
agnosis of Alzheimer's disease and vascular dementia was based on criteria of the 
National Institute of Neurological and Conununicati\~e Disorders and Stroke and 
Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA),14 and 
of d,e National It.lstitute of Neurological Disorders and Stroke and Association In-
ternationale pour la Recherche et l'Enseignement en Neurosciences (NINDS~ 
AlREN).lS Alzheimer patients were furd,er classified into those with and widlout 
cerebrovascular disease. 14 For other deinentias, DShrl~III~R criteria were used.13 
Cerebrovascular disease was recognised by history of stroke or transient ischaemic 
attack, or by evidence for cerebrovascular lesions on brain scans. 
At baseline, participants were asked about d,eir present and fOlmer smoking llab-
its. People who smoked cigarettes were asked for dle age at first smoking, for the 
duration of interval periods without slnokulg. and for average daily nlunber of ciga~ 
rcttcs stnoked. Fonner sl110kcrs were asked about starting agc) interval periods widl-
out slllokil1g, age at quitting, and average daily m.unber of cigarettes smoked. Subjects 
were also asked about attained level of education and) as part of a detailed food fre-
quency qucstionnaire, about their average daily alcohol consumption. 16 
APOE gena typing was performed on coded DNA samples without knowledge 
of d,e diagnosis for subjects who developed dementia (DNA available for 122 sub-
jects) and a random sample of 1428 non-demented participants. The polymerase 
chain reaction product was digested with dlC restriction enzynle fThaI, and fragments 
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were separated by electrophoresis. 17 The results of the APOE typing were read by 
three persons independently. In case of discrepancies, APOE genotyping was re-
peated. 
Data analysis 
Cigarette smoking at baseline was categorised into never, former and current stuok-
ing. The nwnber of pack-year exposure was calculated by the average daily number 
of cigarettes divided by 20 and multiplied with tl,e mnnber of years smoked. In all 
analyses never smokers were used as reference category. The relative risk of dementia 
by smoking was calculated with Cox proportional hazards regression, and presented 
with a 95% confidence interval (95% CI). Age at onset of dementia was taken to be 
the tnidpoint between baseline age and age at diagnosis. For non re-exanlincd cases 
without known age at diagnosis, onset age was defined as the midpoint behveen 
baseline age and age at the end of tl,e follow-up period. For non re-examined sur-
viving subjects tl,e follow-up ended at December 31, 1994.10 Since age is a major 
determinant of dementia and age-distributions differed by smoking status, age was 
adjusted for by including linear and squared baseline age in tl,e models. Sex, educa-
tion and alcohol conswnption were judged to possibly confound the association and 
tllerefore added to all models. Because in our data only primary education was asso-
ciated with incident dementia, education was dichotomised into pl1mary school or 
less, and more tl,an primary school. Daily alcohol intake, expressed in grams of pure 
alcohol per day, was added as continuous variable. 
We also investigated whether tl,e smoking related risk of dementia was modified 
by tlle APOE genotype. 'Il,e APOE genotype was available for 122 of those who 
developed dementia and a random sample of 1428 non-demented participants. Data 
were analysed as a nested case-control study using logistic regression analysis. Cor-
rections for age, sex, education and alcohol intake werc made similarly to the above 
models. Lengtll of follow-up was considered to possibly affect the association be-
cause the probability of developing dementL1 increases with duration of follow-up, 
whereas stlloking may increase mortality. ll1crefore, we added dtuation of follow-up 
as a continuous variable to the logistic regression models. 
Results 
Table 1 summarises characteristics of the study population. More tlml half of all 
women had never smoked) whereas tnore than half of the men had stopped stlloking 
cigarettes. Slnokers wcre on average younger than never smokcrs. Those who never 
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Table 1 - Baseline characteristics of the study population by gender and status of cigarette smoking. 
Total (n=6870) Men (n=2776) Women (n=4094) 
Never Former Current Never Former Current Never Former Current 
smokers smokers smokers smokers smokers smokers smokers smokers smokers 
Proportion 39.1% 40.1% 20.7% 16.4% 58.6% 25.0% 54.6% 27.6% 17.8% 
Age (years) 71.9 (9.9) 68.3 (8.0) 66.4 (7.6) 69.8 (9.8) 68.2 (7.7) 67.1 (7.9) 72.3 (9.9) 68.5 (8.5) 65.7 (7.3) 
(SD) 
Primary education 29.9% 19.4% 22.4% 15.0% 15.5% 18.5% 32.9% 25.0% 26.1% 
only 
Alcohol intake 5.6 (9.8) 12.2 (15.3) 15.1 (19.8) 12.3 (15.2) 15.8 (17.2) 21.0 (23.6) 4.2 (7.6) 7.1 (10.2) 9.9 (13.7) 
(gram/day) 
Table 2 - Relative risk of dementia by baseline cigarette smoking, for the entire study population, women, and men* 
Total study population Men Women 
Never Former Current Never Former Current Never Former Current 
smokers smokers smokers smokers smokers smokers smokers smokers smokers 
Adjusted for age 1.3 2.2 3.7 5.9 1.1 2.0 
(and sex) (reference) (0.9 to 2.0) (1.4 to 3.6) (reference) (1.1 to 12.7) (1.7 to 21.3) (reference) (0.7 to 1.8) (1.0 to 3.7) 
Adjusted for age, 1.4 2.2 3.9 5.8 1.1 2.0 
alcohol intake, (reference) (0.9 to 2.0) (1.3 to 3.6) (reference) (1.1 to 13.5) (1.6 to 20.9) (reference) (0.7 to 1.8) (1.0 to 3.7) 
education 
(and sex) 
* Relative risks with 95% confidence intervals. 
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smoked lllore often had primary education only. Average daily alcohol intake was 
higher among stnokers than non-smokers. 
TI,e mean follow-up period was 2.1 years (range 1.5-3.4), and included 14761 
person-years of observation. We detected 146 incident cases of den1entia, of whom 
105 (72%) had Alzheimer's disease and 19 (13%) vascular dementia. The incidence 
rates of dementia per 1000 personyears for the agegroups 55-64 years, 65-74 years, 
75-84 years, and 85 years and over were 0.9, 2.7, 20.1, and 52.0. For men these fig-
ures were 1.1, 2.5, 18.6,28.0 and for women 0.8, 2.7, 20.9, and 58.8, respectively. 
Table 2 sho\~s that smokers were at increased risk of dementia. Smoking increased 
the risk of delnentia for bod1 men and WOluen. In men, the relative small nwnber of 
cases in the reference category resulted in high relative risks, but these were rather 
unstable. Sllloking both increased the risk of Alzheimer's disease and vascular 
dctllcntia (table 3). The relative risk of denlcntia for current smokers at baseline was 
higher in persons who died or were not rc-exatnined than in participants who were 
re-examined in person: 2.7 (95% CI 1.2 to 6.0) versus 2.0 (95% CI 1.0 to 3.7). TI,e 
mean age at onset of dementia for never stllokers was 85.5 years. Both fanner and 
current smokers were on average younger at dementia onset dIan never smokers 
(respectively 4.1 years, 95% CI 1.7 to 6.6; and 8.6 years, 95% CI 5.2 to 12.1). 
TI,e total amount of pack-years smoked was available for 1368 (96%) of current 
smokers and for 2527 (92%) of former smokers. For current smokers at baseline, the 
relative risk of dementia was 2.5 (95% CI 1.1 to 5.5) for those who smoked less illan 
20 pack-years and 3.0 (95% CI 1.6 to 5.4) for illOse who smoked 20 pack-years or 
more. For former smokers illCse figures were 1.5 (95% CI 1.0 to 2.5) and 2.1 (95% 
CI 1.2 to 3.7), respectively. 
The APOE*4 allele modified il,e association between smoking and dementia 
(Iable 4). In subjects wiillOut the APOE*4 allele, smoking increased il,e risk of de-
mentia substantially (RR=3.2; 95% CI 1.2 to 8.5). However, among carriers of 
Table 3 - Relative risk of dementia subtypes by baseline cigarette smoking,O+ 
Never Former CUrrent 
smokers smokers smokers 
All Alzheimer's disease (n= 105) 1 (reference) 1.3 (0.8 to 2.1) 2.3 (1.3 to 4.1) 
Alzheimer's disease without CVD (n=88) 1 (reference) 1.4 (0.8 to 2.3) 2.1 (1.1 to 4.0) 
Alzheimer's disease with CVD (n=17) 1 (reference) 1.2 (0.4 to 4.2) 3.9 (1.0 to 15.2) 
Vascular dementia (n=19) 1 (reference) 1.4 (0.5 to 4.4) 2.2 (0.6 to 8.4) 
Other dementia (n=22) 1 (reference) 1.5 (0.5 to 4.2) 2.1 (0.6 to 6.8) 
'* Relative risks with 95% confidence intervals, adjusted for age, sex, alcohol intake, and 
education. 
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APOE*4, there appeared to be no association between smoking and detnentia 
(RR=1.4; 95% CI 0.3 to 5.6). TIus effect modification was more marked in Alz-
heuner patients with an increased relative risk of 4.6 (95% CI 1.5 to 14.2) for subjects 
without APOE*4 and a non-significantly decreased relative risk of 0.6 (95% CI 0.1 to 
4.8) in tllOse with APOE*4. 
Discussion 
In this large prospective population-based study, people who smoked cigarettes were 
at increased risk of dementia and Alzheimer's disease. An elevated relative risk was 
particularly present for smokers without the APOE*4 allele. 
The present investigation has several advantages over previous studies on stllok-
ing and dementia,5 Selection bias was avoided because the study was prospective and 
population-based witll a IUgh response rate and complete follow-up. As slllokulg 
habits were assessed before onset of delnentia, major recall bias was avoided. It is 
conceivable though, in particular because of our relatively short follow-up period, 
that some persons who developed clitUcal dementia during the follow-up period had 
already slight impaitment of memory or judgement at baseline. Tlus may have re-
suIted in some misclassification of exposure status among cases. If tillS has occurred, 
we consider it lncre likely that it concerned underreporting rather than overreporting 
of smokitlg habits. Consequently, if any recall bias occurred, tlus most likely resulted 
in an underestimation of the true effect. SUlvival bias was avoided by including sub-
jects who died during follow-up. However, case fmding metllOds differed for sub-
jects that could be re-exatnined in person and those who could not, and as a result 
we may have missed some very early cases in the latter group. Relative risks by 
Table 4 - Relative risk of dementia and Alzheimer's disease by baseline cigarette 
smoking and apolipoprotein E4. * 
All dementia 
APOE'4 absent (n~73) 
APOE'4 present (n~49) 
Alzheimer's disease 
APOE'4 absent (n~57) 
APOE'4 present (n~33) 
Never 
smokers 
1 (reference) 
1 (reference) 
1 (reference) 
1 (reference) 
Former 
smokers 
1.9 (0.8 to 4.6) 
1.0 (0.3 to 3.3) 
2.4 (0.9 to 6.5) 
0.9 (0.2 to 3.6) 
Current 
smokers 
3.2 (1.2 to 8.5) 
1.4 (0.3 to 5.6) 
4.6 (1.5 to 14.2) 
0.6 (0.1 to 4.8) 
* Relative risks estimated as odds ratios with 95% confidence intervals, adjusted for age, sex, 
alcohol intake, and education. 
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smoking were slightly higher in those who died, refused, or were too ill to be re-ex-
amined, than in the re-examined group (2.7 versus 2.0). Because we possibly slightly 
underdiagnosed dementia in the non-re-examined g1:0up, the actual difference may 
even be larger. The higher relative risk of dementia in subjects who died or could not 
be re-examined illustrates that survival bias may indeed have diluted the association 
of smoking and delnentia in previous, cross-sectional studies. 
Educational level and alcohol intake are well-known correL'lies of smoking habits, 
and both have been invoked in relation to demetltia as well.t,tS ·When we adjusted for 
these variables in the analyses, the smoking associated risk of dementia remained 
virtually unchanged. 
The follow-up 1n tlus study was relatively short. The main disadvantage of tlus is 
the linuted munber of incident delnentia cases, which restricted the power in some 
of our subanalyses. On the other hand, it facilitated botll the complete follow-up of 
the cohort and tl,e use of identical screening alld cliagnostic procedures at baseline 
and follow-up. 
A limitation of the present sllldy is the lack of autopsy confirmation of our Alz-
heimer's disease diagnoses. Another problem is tllat Alzheimer's disease pathology 
and cerebrovascular disease are often concurrefltly present and it may be difficult, 
botll clinically alld pathologically, to estimate their contribution to tl,e development 
of dementia. tS Although our clitucal work-up was extensive and we adhered to C0111-
tnonly accepted and reliable criteria, we can not rule out dlat we nusclassified tlle 
dementia subtype in some cases. 
Slnoking increased the risk of dementia for bodl sexes. 'TIle relative risks seemed 
higher for men than for ,vmnen. However, the l1tunber of never smoking men (the 
reference group) was small, and among dle1n only a few became demented. 'Ilus led 
to greater vatiability in relative risk estimates in tnen and the gender differences may 
be due to chance. Possible effect moclification between gender and smoking should 
be looked at more closely in further studies. 
"IVfost previous studies on stnoking and dementia used prevalent cases and a case-
control design.5 As reviewed by Lee, 4 out of 17 studies reported a significant inverse 
relation between s1110king and Alzheimer's disease.s Some earlier results may differ 
from the present findings due to cliffcl1ng metllOds.7 Of particular concern is the 
definition of Alzheuner's disease in tlle earlier studies. Patients witll coexisting vas-
cular disease may have been classified as {mixed' dementia. By excluding these frotn 
tlle Alzheinlcr category, these studies 1nay have selectively cleated cigarette smokers 
from the cases, as s1nokers are lnore prone to vascular diseases.2,3 However, we 
found tllat sl110kers had also an itlcreased risk of Alzheimer's disease witllout cere-
brovascular disease. The few studies wluch estimated tlle relation with vascular de-
Inentia found, as we did, a positive association with smoking. 19,20 A few studies have 
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used incident cases to assess the risk of Alzheimer's disease by smoking, with varying 
results.21-24 However, none of these looked at a possible effect-tnodification by 
APOE genotype. 
Smoking is a .risk factor for vascular disease, including atherosclerosis and throm-
bosis,2,3 Reduction of cerebral perfusion is an acute effect of cigarette smoking, and 
tlus may be harmful in elderly with a compromised cerebral cttculation.25 In the 
pathogenesis of Alzheimer's disease, by far the most conunon dementing illness, 
vascular involvement is probably more important than previously thought.26,27 
Van Duijn et al previously reported that the inverse association between stnoking 
and Alzheimer's disease was limited to carriers of the APOE*4 allele.' In line with 
that observation we found that the increased risk of dementia and Alzheimer's dis-
ease associated with smoking was restricted to persons without tlus allele. Before 
considering possible explanations for tltis apparent effect modification by APOE*4, 
one should consider tllat elderly smoking APOE*4 carriers may be a selected group. 
The APOE*4 allele not only increases the risk of Alzheimer's disease but also of car-
diovascular disease.29 111erefore, mortality filay be disproportionately increased 
among smoking APOE*4 carriers.7 If atherosclerosis is indeed the intermediate fac-
tor in the association between smoking and dClnentia, various explanations could be 
hypotllesised for a modifying effect of APOE*4. Firstly, ti,e presence of ti,e 
APOE*4 allele might alter ti,e association between smoking and atherosclerosis. 
However, in thc Rotterdam Study the strength of the relation between smoking and 
various indicators of atherosclerosis was similar for subjects with or without an 
APOE*4 allele. Secondly, ti,e APOE*4 allele may inltibit the association between 
vascular damage and dementia. Tlus is however in sharp contrast to the synergistic 
effect tI,at we observed between APOE*4 and atherosclerosis on the risk of demen-
tia.27 Thirdly, smoking may exert different and opposite effects on ti,e risk of Alz-
heimer's disease, being generally harmful duough for example a vascular Inecharusm, 
but also pardy beneficial in selected individuals, especially in dlose who cany an 
APOE*4 allele. This hypotllesis may be supported by ti,e observation tI,at in Alz-
heimer patients carriers of APOE*4 have fewer tucotinic receptor binding sites and 
decreased activity of choline acetyl transferase, as compared to non-carders of this 
allele." Smoking could have some effects on the cholinergic system, which might 
counterbalance the selective impairtnent that was found to be associated with 
APOE*4, including increasing ti,e density of nicotine receptors or facilitating ti,e 
release of acetylcholine.',22 
In conclusion, we found that for dlC majority of the population, namely dlOSC not 
carrying the APOE*4 allele, smoking increased ti,e risk of dementia and Alzheimer's 
disease. For subjects with ti,e APOE*4 allele however, smoking was not associated 
with an increascd risk of dementia. 
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The impact of the apolipoprotein E genotype 
on myocardial infarction, 
stroke, dementia and mortality 
Abstract 
The ill/Pild of Ihe iljJolipopmle/il E (APOE) gellotyp' Iii /laSt"'ilr diseases, demelliia alld IIJOItality 
was aJSessed ill 5290 elderly pill1ieipilllis ill a poplllalioll-based Silldy who w,," jollOlved fiJI; 011 av-
emge, 4.0 ),ean SlIbjetls lVilh Ih, APOE4E4 gellotype had a higher lisk of III)'ocardial illjimlioll 
Ihall pmolls wilh APOE3E3, iii pilltiarlar befim 65 ),ea" of age. The illeidence of slmke lVas 1101 
slmllg/y ,vialed 10 Ihe APOE polyll/OIphislJJ. Allhollgh canim of Ihe APOE*4 allele IV,," al 
illCIPased lisk of demenlia, Ihe tWlltiblllioll of APOE*4 10 Ihe illcidmce of dell/elliia 011 a pop"la-
lioll le/lel was modesl. This rifleds Ihe ,.Ialively low ji?quellD' of Ihis allele. MOitality was 0""'(111 1101 
,vial,d 10 APOE, bill illClPased ill pmolls wilh eilher Ih, APOE2E4 or Ihe APOE4E4 gello-
Dpe who w"" )'Ollll!/" Ihall 65 ),eIIlJ. Ollr Silldy JIIggesls Ihallhe APOE gmoDpe does 1101 play {III 
impOitall1 mle ill IIJoltality or Ihe lisk of vasarlar diseases Iii Ihe elderly. 
Introduction 
TIle rapid deve10ptnents in genetics have led to the discovery of non-traditional .risk 
factors for disease. One genetic variation (polymolphism) with possibly large public 
health implications is d,e apolipoprotein E genotype (APOE). The APOE gene has 
three conUllon alleles, APOE*2, APOE*3 and APOE*4. As compared to APOE*3, 
the most cotntnon allele, APOE*2 is associated with lower senun levels of athero-
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genic lipoproteins, while APOE*4 has opposite effects.' Yet, studies on APOE and 
vascular diseases have been contradictory, particularly in older populations.2-6 
The APOE genotype was found to be involved in Alzheimer's disease/'s and 
other, less conunon types of dementia.9 Almost all studies on APOE and dementia 
are based on prevalent, clinic-based patient-series, which arc subject to selection bias. 
Reliable estimates of the risk of dementia, associated with the APOE genotypes, are 
currently not available. 
The APOE polymorphism has been suggested to be a determinant of longevity, 
but the few repotts on this issue are all based on case~control studies on the oldest 
old. I ,IO,n It is tlms unclear how APOE allele frequencies change with ageing, and 
follow-up studies on the association of APOE with mortality are lacking. 
TI,e impact of the APOE genotype on major causes of morbidity and mortality 
has never been studied simultaneously. The aim of tlus population-based single~ccn­
tre follow-up study was to investigate d,e role of d,e APOE genotype in myocardial 
infarction, stroke, delllentia and tllortality. 
Methods 
Study population 
The Rotterdam Study is a population-based prospective cohort study among persons 
aged 55 years or over,I2 for which approval was given by the EraStllus University 
Medical School Edrics Conuruttee. Participants were recmited from 10275 eligible 
residents of a suburb of Rotterdam, including institutionalised persons. A total of 
7983 participants (response rate 78%) were examined at baseline. During follow-up, 
information on vital status was complete for all participants. At d,e time of d,e pres-
ent study, follow~up on the occurrence of myocardial infarction or stroke was com~ 
plete for 7053 subjects (88% of the cohort). At d,e second wave, after an average of 
2.1 years (SD 0.9 years), 6315 persons (79%) were re-examined; 768 subjects (10%) 
had died, 106 (1%) were inaccessible and 794 (10%) refused to participate. As per-
sons widl a yet undetermined APOE genotype were excluded (n=2693, 34% of d,e 
cohort), our study population comprised 5290 individuals. 
Baseline measurements 
At baseline, people were intenrlewed about their health status, drug usc, and attained 
level of education. Cogtutive function was assessed using tile tnini~mental state ex-
antination (lv!.MSE) and the geriatric mental state schedule (GMS).13.14 An electrocar-
diogram (ECG) was made, and digitally stored it, 4854 participants of the present 
study (92%). These ECGs were analysed by d,e Modular ECG Analysis System 
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(lVlEANS), which has been evaluated extensively." tvIissing ECGs were mainly due 
to temporary technical problems. Blood was collected for laboratory analyses. 
Follow-up procedures 
The follow-up period for the present study ended in April 1996 (mean duration 4.0 
years (SD 1.2». The occurrence of myocardial infarction or stroke was recorded in 
4805 participants of the present study (91%). TI,ese events were reported by general 
practitioners with a computerised surger), (85% of d,e participants). All reported in-
formation was verified by study physicians who inspected all available information. 
In addition, the complete medical records of all participants in non-computerised 
practices (adler 15%) were regularly checked by research physicians. 
All even!s were classified independently by two study physicians. In case of dis-
agreetnent, a consensus was reached in a separate session. All events were verified by 
an expert in the field of vascular or neurologic diseases. If d,e expert disagreed widl 
the research physician, the expert's opinion was considered final. 
Myocardial infarction 
A myocardial infarction before baseline was diagnosed on the basis of ECG findings 
and self-report. Besides, of subjects with self-reported nlyocardial infarction Witllout 
ECG evidence, and of persons widl no self-report of myocardial infarction but with 
ECG evidence, additional information was collected from tlle general practitioner or 
cardiologist." Definite myocardial infarction was defined according to d,e general 
practitioner, cardiologist or ECG (n=631 participants in d,e present study). Possible 
tllyocardial infarction was based on self-report without verification by general practi-
tioner, cardiologist or ECG (n:::::::32). As the first occurrence of a tnyocardial infarc-
tion was utilised, we exclu~ed frotn the longitudinal analyses subjects with tnyocardial 
infarction before baseline (n=663), as well as tllose with tnissing data on a previous 
myocardial infarction (n=345). Myocardial infarction during follow-up was diagnosed 
in 87 of d,e remaining 3840 participants widl complete follow-up, using the defini-
tions of d,e 10d, revision of d,e International Classification of Diseases (ICD-l0),11 
Stroke 
A stroke before baseline was determined on tlle basis of the question 'did you ever 
suffer fr0111 a stroke, diagnosed by a physician?' Signs and symptoms had to last 
tnore tllan 24 hours. Of the persons with an affirmative answer, tlle general practi-
tioner was asked for supplementary infolmation. To optimise prevalence data, medi-
cal records of subjects living in homes for the elderly, who were cognitively impaired, 
were systetnatically reviewed. 18 In total, 221 participants in the present study were 
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identified with a stroke before baseline, who were excluded from the longitudinal 
analyses. Persons with missing data on a stroke before baseline (n=207), were in-
cluded in the group of 'no previous stroke" as these groups appeared not to differ in 
risk of stroke during follow-up. As there was no complete follow-up in another 471 
participants, this resulted in a cohort of 4598 subjects at dsk of stroke, of whom 154 
cases were detected. Stroke diagnosis was based on all available info1macion,19 using 
ICD-l0 criteria. 17 
Dementia 
Besides the above described rcports during follow-up, dementia cases were identified 
in the Rotterdam Study cxatninations. The saine protocol was used by dIe salne in-
vestigators at dIe first and second w3ve. 18,20 Briefly, all subjects were screened with 
the lvUVISE and the GlvlS. Those suspected of dementia, were examined by a neu-
rologist, underwent neuropsychological testing, and if possible, neuro-imaging. Be-
sides, an informant was intctviewed on daily functioning. Of subjects who could not 
be re-examined in person, infounation was obtained fr01n the regional institute for 
outpatient mental health care (lUAGG).18.20 TI,e diagnosis of dementia was made by 
a panel of study physicians, a neurologist and a neuropsychologist, which reviewed all 
information and used Diagnostic and Statistical Manual of mental disorders (DSM-
III-R) criteria." In the present study, 348 participants were demented at baseline, and 
excluded from the longihldinal analyses, together with subjects whose dementia 
status at baseline was uncertain (n=16). This resulted in a cohort of 4926 participants 
in the present study at risk for detnentia, of whom 134 patients were diagnosed as 
demented during follow-up. 
Mortality 
Information on the vital status of all 5290 participants was obtained at regular inter-
vals from dle municipal healdl authorities. Our studies on mortality are based on 
21188 person-years of follow-up, in which 913 persons died. 
Laboratory analysis 
APOE genotyping was performed on coded samples widlOut knowledge of d,e 
other tneasuretnents or diagnoses. Genotyping was performed using a polymerase 
chain reaction, as described in detail elsewhere.'> Results were read by thtee persons 
independently. In case of any discrepancies, APOE genotyping was repeated. Senun 
total and high density lipoprotein (HDL) cholesterol were determined with an auto-
mated enzytuatic procedure.22 
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Statistical analysis 
Differences in baseline characteristics by the APOE genotypes were explored with 
the chi-square test for categorical data, and an analysis of variance (ANOVA) was 
used for continuous, normally distributed variables. Cox' proportional hazards mod-
els were used to assess the rebtive risks (RR) of myocardial infarction, stroke, de-
mentia and death, which is presented with a 95% confidence interval (95% CI). TI,e 
APOE genotypes were entered in the tnodel as dununy variables, using the 
APOE3E3 group as the reference group. To adjust for confounding, age and sex 
were added to models on tnyocardial in£1fction, stroke and dementb. In addition, 
education level was added to models on dementia. For genotypes significantly related 
to a certain outcome, we used the population attributable risk to estimate the excess 
rate in population tI,at is attributable to tI,at specific APOE genotype. The popula-
tion attributable risk was computed as the product of the difference in incidence rate 
witll the APOE3E3 group, and ti,e proportion of subjects with ti,e particular APOE 
genotype. To estimate the slll-vival CU1-ves for the various APOE genotypes, we used 
K,plan-Meier analysis. 
Results 
The distribution of ti,e APOE polymOlphism in our study population was in 
Hardy-Weinberg equilibrium (X'=0.5; df=3; 1'>0.2). Descriptive statistics are pre-
sented in tabl, 1. As compared to fie APOE3E3 group, persons witll APOE2E3 had 
on average lower total cholesterol levels and higher levels of HDL cholesterol. By 
contrast, subjects with ti,e APOE3E4 or APOE4E4 genotype had, a higher mean 
total cholesterol level than persons with APOE3E3, and a lower level of HDL cho-
lesterol in serum. TI,e APOE genotype was not related to a hist01'Y of myocardial 
infarction or stroke at baseline. Detnentia was more prevalent at baseline atuong 
APOE*4 carriers compared to persons without this allele. 
Table 2 shows absolute and relative risks of myocardial infarction associated with 
ti,e APOE polymOlphism. Persolls with ti,e APOE4E4 gellotype were at increased 
risk of myocardial illfarctioll (RR 2.1; 95% CI 0.8 to 6.0), in particular men and indi-
viduals younger than 65 years, although numbers in subgroups were small. Overall, 
APOE3E4 carriers had a similar risk of myocardial infarction compared to persons 
with ti,e APOE3E3 genotype. The APOE2E3 group had a slightly lower risk of 
myocardial infarction (RR 0.7; 95% CI 0.3 to 1.5), but tlus did not reach statistical 
significance. Sirnilar findings were obtaincd when adjustments wcre made for both 
total and HDL cholesterol. Por instance, dIe adjusted relative risk associated widl 
APOE4E4 was 2.1 (95% Cl 0.7 to 5.8). Also when we analysed tl,e risk of fatal myo-
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Table 1- Baseline characteristics of the study population* 
APOE2E2 AP0E2E3 APOE2E4 APOE3E3 APOE3E4 APOE4E4 
n=41 n=698 n=143 n=3046 n=1229 n=133 
Age 71.3 (9.3) 69.6 (9.2) 69.1 (8.9) 69.9 (9.1) 69.8 (9.0) 68.3 (8.1) 
Women 61% (25) 61% (428) 57% (81) 55% (1688) 55%(681) 54% (72) 
Primary education on!y 31% (12) 26% (177) 21% (28) 25% (722) 26% (303) 21% (27) 
Cholesterol level (mmol/L) 6.59 (1.68) 6.32 (1.31) 6.47 (1.17) 6.59 (1.19) 6.75 (1.22) 6.81 (1.05) 
HDL-cholesterol level (mmol/L) 1.30 (0.33) 1.40 (0.38) 1.35 (0.38) 1.33 (0.36) 1.31 (0.37) 1.29 (0.36) 
Previous myocardia! infarction 15% (6) 12%(81) 13% (18) 13% (393) 13% (151) 11% (14) 
Previous stroke 3% (1) 3% (23) 8% (11) 4% (130) 4% (51) 4%(5) 
Preva!ent dementia 7%(3) 6%(40) 7% (10) 6% (177) 8%(98) 15% (20) 
* Values are unadjusted means (SO) or percentages (numbers), based on all available information. 
Table 2 - Risk of myocardial infarction associated with apolipoprotein E genotype* 
APOE2E2 APOE2E3 APOE2E4 APOE3E3 APOE3E4 APOE4E4 
Overall 
Events/person-years 0/146 7/2176 3/452 51/9229 22/3659 4/395 
RR (95% CI) 0.7 (0.3 to 1.5) 1.3 (0.4 to 4.1) 1 (reference) 1.0 (0.6 to 1.7) 2.1 (0.8 to 6.0) 
Men 
Events/person-years 0/64 4/720 2/197 29/3832 12/1540 3/175 
RR (95% CI) 0.8 (0.3 to 2.2) 1.4 (0.3 to 5.9) 1 (reference) 0.8 (0.4 to 1.7) 2.4 (0.7 to 8.0) 
Women 
Events/person-years 0/82 3/1456 1/256 22/5397 10/2119 1/220 
RR (95% CI) 0.6 (0.2 to 2.1) 1.2 (0.2 to 9.0) 1 (reference) 1.2 (0.6 to 2.7) 1.5 (0.2 to 11.2) 
Age tertile 1 « 65 yrs) 
Events/person-years 0/46 0/777 1/165 11/3470 5/1299 3/196 
RR (95% CI) 2.2 (0.3 to 18.4) 1 (reference) 1.0 (0.3 to 3.0) 4.0 (1.1 to 14.3) 
Age tertile 2 (65-73 yrs) 
Events/person-years 0/39 6/743 0/153 16/2919 9/1175 0/100 
RR (95%CI) 1.7 (0.7 to 4.4) 1 (reference) 1.3 (0.6 to 3.2) 
Age tertile 3 (> 73 yrs) 
Events/person-years 0/61 1/656 2/135 24/2840 8/1185 1/100 
RR (95% CI) 0.2 (0.0 to 1.6) 2.1 (0.5 to 9.0) 1 (reference) 0.7 (0.3 to 1.8) 1.4 (0.2 to 1 0.7) 
* Relative risk (RR) with 95% confidence interval (CI), adjusted for age and sex. 
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cardial infarction (n=23; excluding n=64 non~fatal myocardial infarctions), we ob-
tained rather similar findings. When subjects with missing baseline data 011 a previous 
myocardial infarction were included (n=345), our fuldingS did not change either. 
As shown in lable 3, the APOE genotype was overall not strongly related to the 
development of stroke during follow-up. Although persons with the APOE4E4 
genotype had a l.4-fold increased l1sk, this did not reach statistical significance (95% 
CI 0.5 to 3.9). Also subjects with APOE2E3 had a non-significantly increased risk of 
stroke (RR 1.3; 95% CI 0.9 to 2.1), but tius was not consistently increased over tl,e 
age strata. The APOE3E4 genotype was associated witll a 40% lower risk of stroke 
in men, and with a 30% increased risk in women, but again, not statistically signifi-
cantly. We detected an increased risk of stroke in APOE2E2 carriers younger tllan 65 
years, but numbers were s1nall. No consistent differences were observed across age 
strata. Furthermore, similar findings were obtained when restrictions were made to 
fatal stroke or ischaentic stroke. 
Table 4 shows tl,e absolute and relative risks of dementia for tl,e various APOE 
genotypes. Persons with tile APOE4E4 genotype had a more than five-fold higher 
risk of dementia than homozygotes for APOE*3, while heterozygotes for APOE*4 
were at an almost two-fold increased risk. The APOE2E3 genotype was associated 
Witil a decreased risk of dementia, but not statistically significant (0.7; 95% CI 0.4 to 
1.3). The relative risk of dementia associated Witll tl,e APOE genotype was not con-
sistently different across strata of sex. Among men, homozygotes for APOE*4 had 
an almost three-fold increased risk to become demented; women with the 
APOE4E4 genotype had an six-fold increased the risk of dementia. By contrast, one 
APOE*4 allele was associated with a higher relative risk of dementia among men as 
compared women. No major differences were observed between age strata. Al-
though tl,e relative risk of dementia was ltighest in the APOE4E4 group, the popu-
lation attributable risk was found to be higher in persons with tl,e APOE3E4 geno-
type (1.35 per 1000 person-years), than in homozygotes for APOE*4 (0.50 per 1000 
person-years). Thus, each year, an estimated 185 per 100000 individuals aged 55 or 
over, may become demented as a consequence of carrying tile APOE3E4 or 
APOE4E4 genotype instead of APOE3E3. 
Table 5 shows that overall, mortality was similar between ti,e APOE genotypes 
Oogrank=0.69; df=5; P=0.98). However, in tl,e youngest age tertile, mortality was 
ahnost two-fold increased in persons witll tl,e APOE2E4 or APOE4E4 genotype 
relative to homozygotes for APOE*3. 
To furtl,er explore tile role of APOE in longevity, ti,e Jiglll< shows tile APOE 
allele frequencies in 5-years age strata of tile study population. The APOE*4 aUele 
frequency decreased from 0.166 in 55 year-olds to 0.118 in subjects aged 90 or over. 
The change in APOE*4 frequency was estimated to be -0.005 (95% CI -0.009 to 
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Table 3 - Risk of stroke associated with apolipoprotein E genotype* 
APOE2E2 AP0E2E3 APOE2E4 AP0E3E3 APOE3E4 APOE4E4 
Overall 
Events/person-years 1/168 26/2569 2/513 87/11279 34/4569 4/467 
RR (95% 0) 0.7 (0.1 to 5.0) 1.3 (0.9 to 2.1) 0.6 (0.1 to 2.4) 1 (reference) 1.0 (0.7 to 1.5) 1.4 (0.5 to 3.9) 
Men 
Events/person-years 1/72 9/938 2/206 36/4862 9/2027 2/205 
RR (95% 0) 1.3 (0.2 to 9.7) 1.2 (0.6 to 2.5) 1.2 (0.3 to 5.1) 1 (reference) 0.6 (0.3 to 1.2) 1.5 (0.4 to 6.4) 
Women 
Events/person-years 0/96 17/1631 0/307 51/6417 25/2542 2/262 
RR (95% 0) 1.5 (0.8 to 2.5) 1 (reference) 1.3 (0.8 to 2.1) 1.3 (0.3 to 5.3) 
Age tertile 1 « 65 yrs) 
Events/person-years 1/49 3/887 0/183 7/3912 2/1472 0/194 
RR (95% 0) 12.9 (1.6 to 108) 2.0 (0.5 to 7.7) 1 (reference) 0.8 (0.2 to 3.7) 
Age tertile 2 (65-73 yrs) 
Events/person-years 0/46 2/839 2/173 20/3501 7/1490 2/128 
RR (95% 0) 0.4(0.1 to 1.9) 2.1 (0.5 to 8.8) 1 (reference) 0.8 (004 to 2.0) 2.7 (0.6 to 11.7) 
Age tertile 3 (> 73 yrs) 
Events/person-years 0/72 21/843 0/157 60/3866 25/1606 2/145 
RR (95% 0) 1.6 (1.0 to 2.7) 1 (reference) 1.1 (0.7 to 1.7) 1.1 (0.3 to 4.6) 
* Relative risk (RR) with 95% confidence interval (0), adjusted for age and sex. 
Table 4 - Risk of dementia associated with apolipoprotein E genotype* 
APOE2E2 APOE2E3 APOE2E4 AP0E3E3 APOE3E4 APOE4E4 
Overall 
Events/person-years 1/91 10/1458 4/277 70/6180 42/2450 7/224 
RR (95% CI) 1.0 (0.1 to 6.9) 0.7 (0.4 to 1.3) 1.7 (0.6 to 4.8) 1 (reference) 1.9 (1.3 to 2.8) 5.4 (2.4 to 11.8) 
Men 
Events/person-years 0/36 0/545 2/117 17/2696 14/1098 1/96 
RR (95% CI) 3.0 (0.7 to 12.9) 1 (reference) 2.3 (1.1 to 4.8) 2.9 (0.4 to 22.2) 
Women 
Events/person-years 1/56 10/913 2/160 53/3484 28/1352 6/128 
RR (95% CI) 1.6 (0.2 to 11.7) 1.0 (0.5 to 1.9) 1.4 (0.3 to 5.7) 1 (reference) 1.8 (1.1 to 2.8) 6.3 (2.7 to 14.8) 
Age tertile 1 and 2 (55·73 yrs)t 
Events/person-years 0/54 0/1030 1/204 9/4177 7/1693 2/179 
RR (95% CI) 2.2 (0.3 to 17.3) 1 (reference) 1.9 (0.7 to 5.0) 5.1 (1.1 to 23.8) 
Age tertile 3 (> 73 yrs) 
Events/person-years 1/38 10/428 3/73 61/2003 35/2760 5/45 
RR (95% el) 1.0 (0.1 to 7.5) 0.8 (0.4 to 1.6) 1.6 (0.5 to 5.1) 1 (reference) 1.9 (1.2 to 2.9) 5.2 (2.1 to 13.0) 
* Relative risk (RR) with 95% confidence interval (el), adjusted for age, sex, and education; 
t The coefficients did not converge when in first tertile because of limited number of dementia patients (n=5). 
rable 5 - Mortality as a function of the apolipoprotein E genotype' 
APOE2E2 APOE2E3 APOE2E4 AP0E3E3 APOE3E4 APOE4E4 
Overall 
Events/person~years 8/173 117/2819 27/566 522/12154 219/4964 20/512 
RR (95% el) 0.9 (0.3 to 2.4) 0.9 (0.7 to 1.2) 1.0 (0.6 to 1.7) 1 (reference) 1.1 (0.9 to 1.4) 0.9 (0.5 to 1.6) 
Men 
Events/personwyears 4/66 50/1046 14/242 237/5209 89/2190 10/223 
RR (95% el) 1.0 (0.4 to 2.8) 1.0 (0.8 to 1.4) 1.3 (0.7 to 2.2) 1 (reference) 0.9 (0.7 to 1.1) 1.1 (0.6 to 2.0) 
Women 
Events/person~years 4/107 67/1773 13/323 285/6945 130/2774 10/290 
RR (95% 0) 0.9 (0.3 to 2.4) 0.9 (0.7 to 1.2) 1.0 (0.6 to 1.7) 1 (reference) 1.1 (0.9 to 1.4) 0.9 (0.5 to 1.6) 
Age tertile 1 « 65 yrs) 
Eventsjpersonwyears 0/50 12/1006 4/208 43/4266 16/1670 4/230 
RR (95% 0) 1.2 (0.6 to 2.3) 2.0 (0.7 to 5.7) 1 (reference) 1.0 (0.5 to 1.7) 1.8 (0.6 to 5.0) 
Age tertile 2 (65·73 yrs) 
Events/personwyears 1/51 24/939 6/187 91/3762 38/1587 3/135 
RR (95% 0) 0.8 (0.1 to 5.9) 1.0 (0.7 to 1.6) 1.3 (0.6 to 3.1) 1 (reference) 1.0 (0.7 to 1.4) 1.0 (0.3 to 3.2) 
Age tertile 3 (> 73 yrs) 
Events/personwyears 7/72 81/874 17/170 388/4126 165/1706 13/147 
RR (95% 0) 0.9 (0.4 to 1.9) 1.0 (0.8 to 1.3) 1.0 (0.6 to 1.7) 1 (reference) 1.0 (0.8 to 1.2) 1.0 (0.5 to 1.7) 
* Relative risk (RR) with 95% confidence interval (0). 
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~O.OOl) for every five years. 'l1,e decrease in the frequency of APOE*4 was to ti,e 
benefit of the APOE*3 frequency (increase 0.013; 95% CI 0.003 to 0.022 per five 
years), as also ti,e frequency of ti,e APOE*2 allele slightly decreased with age (~0.007; 
95% CI ~0.015 to 0.000 per five years). 
Discussion 
Using data from a large prospective population~based study, we found that APOE*4 
homozygotes had an increased risk of myocardial infarction, but that the incidence of 
stroke was not strongly related to the APOE polymoiphism. AltllOugh APOE*4 
carriers had an increased .risk of dementia, the contribution of APOE*4 to the inci-
dence of dementia was tnodest, reflecting the relatively low frequency of tllls allele. 
11,e APOE genotype appeared not to be a strong determinant of mortality up until 
95 years of age. 
In ti,e inteipretation of these findings, a major concern is tI,at we could not de~ 
teimine ti,e APOE genotype of the whole Rotterdam Study cohort. The group of 
subjects in whom APOE was measured, were on average younger (69.8 versus 72.2 
years), included more males (44 versus 29%), and less persons who died during fol~ 
low~up (17 versus 26%), tI'an tI,ose with an undete111uned l\POE genotype. How~ 
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ever, the proportions of patients with a previous tnyocardial i.11farction, stroke or 
dementia were similar, and also the level of total and HDL cholesterol did not differ 
between those with and without a dctennitled APOE genotype, Based on dle above 
characteristics, persons with an unknown genotype do not specifically fit into one of 
the APOE genotype groups as observed in the present study. As the distribution of 
the APOE genotypes was in Hardy-Weinberg equilibrium, it seems further unlikely 
dlat selective APOE genotyping has occurred, Anodler issue is dlat there was com-
plete follow-up on myocardial infarction or stroke in 910/0 of the participants in tllls 
study. However, d,e distribution of the APOE genotypes in persons with alld wid,-
out complete follow-up on vascubr diseases was similar (X2=3.9; df=5; P=O.57). 
Therefore, dlere seems not to be selective loss to follow-up, The determinant of tills 
study, the APOE genotype, was accurately measured, without knowledge of the out-
comes,9 Based on tllese considerations, it seems unlikely that our study is subject to 
tnuch measurement error or bias, 
A possible limitation of d,e present study dlough, is that we could not explore d,e 
role of APOE in subtypes of myocardial infarction, stroke and dementia in detail. 
However, it should be noted that this study aimed to investigate d,e population im-
pact of d,e APOE polym01phism. With regard to the implications for public health, 
associations with rarer subtypes of disease tnay be less relevant. 
An advantage of dus study is d,e population-based approach with a lugh response 
rate, willch tninitnises the possibility of selection bias, There was cotnplete follow-up 
with regard to survival. The occurrence of stroke and tnyocardial infarction during 
follow-up were ascertained using files of general practitioners, who cover the whole 
study population, As access to primary care is Illgh in the Netherlands, also less se-
vere events could be detected, 
There is some controversy in dle literature widl regard to dle association of dle 
APOE genotype to myocardial it,farction.2·' Aldlough some studies reported an it,-
creased APOE*4 frequency in patients with coronary heart disease, it should be 
noted that the APOE*4 related summary odds ratio for corona,), heart disease it, a 
meta-analysis of cross-sectional studies did not exceed 1.3,2 The two prospective 
population-based studies up utltil now are inconsistcnt.3,4 One suggested that 
APOE*4 increases d,e risk of death from coronary heart disease,' while in d,e other 
survey, no association could be detected,4 The llwnbcr of patients in tilC present 
study exceeds the previous ones five tunes, We found that hOlllozygotes for 
APOE*4 were at increased risk, in particular dlose younger than 65 years, 11us 
could imply that tlus genetic predisposition to myocardial infarction wanes with age-
ing. On the other hand, we cannot exclude that we lnisscd S01ne cases of 'silent' 
myocardial infarction, which becomes lnore and more frequent with aging,16 Possible 
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underestimation of the nwnber of myocardial infarctions during follow-up could 
further explain the relative low number of incident cases in our study (n=87). 
The literature on APOE and stroke is rather inconsistent as well.4-6 In cross-sec-
tional shldies, both an increased APOE*2 frequcncy,24 as well as an increased 
APOE*4 frequency have been reported." Of the three population-based cohort 
studies on APOE and stroke, two reported no assodatiol1,4.6 while a third suggested 
a decreased risk for APOE*2 carriers younger than 80 years.s It has been postulated 
that some of the inconsistencies in the literature on APOE and stroke may be ex-
plained by a modifying effect of age.s In our large study, with a wide age range, we 
did not find consistent evidence for this, although we cannot exclude that APOE 
may be associated with stroke before the age of 55 years. In our investigation, the 
APOE genotype was not strongly related to the development of stroke durulg fol-
low-up. 
This is the first study that quantified the absolute risk of dementia associated with 
the APOE polymorphism. Besides, we assessed its contribution to the incidence of 
dementia on a population level. Although carriers of the APOE*4 allele are obvi-
ously at ulcreased risk of dementia, we found dlat the corresponding population at-
tributable risk was modest, which results from the relative rarity of the allele. AI-
dlOugh d,e APOE2E3 genotype was found to be inversely related, dus effect was 
modest and did not reach statistical significance. Besides, any relative protective ef-
fect of APOE*2 on a population level would be meaningless, given the low APOE*2 
allele frequency. 
Previous studies on the APOE genotype and longevity suggested dlat APOE*2 
increases, and d,at APOE*4 reduces life expectancy.I,IO,1I In dlCse studies, d,e oldest 
elderly were compared to younger individuals. In the present study, we found till d,e 
age of 90, 'a weak decrease in the frequency of both APOE*2 and APOE*4. AJ-
dlOugh overall, APOE was found to be uurelated to survival, in the youngest age 
category, d,e APOE2E4 and APOE4E4 genotypes were associated widl ulcreased 
tnortality. TIlcse observations arc consistent with our observations on AI)OE and 
myocardial infarction and stroke, both .major causes of death. 
An ultimate goal for genetic studies is to provide information d,at ,vill unprove 
our ability to identi/}' individuals at ulcreased risk of disease. AldlOugh the APOE 
genotype is involved in the development of dementia, the population contribution of 
the risk allele, APOE*4, seems to be modest. Our study suggests dlat d,e APOE 
polymorplusm does not play an unportant role Ul mortality or the risk of vascular 
diseases in the elderly. 
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General discussion 
In this general discussion, a brief ovelview will be given of the major findings to-
gether with observations from other studies. These findings will be discussed widl 
special attentiol1 to the underlying tnechanism. Fillally, reconuncndations for future 
research will be given. 'D,e methodological aspects of d,e studies in tills tI,esis are 
described in the discussion sections of the previous chapters, and will be briefly 
considered here togedler witll our findings. As ti,e p11mary topic of dlls tI,esis is de-
Inentia, this chapter will focus on dIe association between apolipoprotein E and de-
Inentia. 
Background 
It has been suggested tlrat apolipoprotein E (APOE=gel1e; apoE=protein) is in-
volved in atherosclerosis and dernentiu,l,2 two conditions which severely disturb the 
quality of life of munerous elderly individuals. Atherosclerosis is an important cause 
of mortality,' while dementia is d,e major threat to the wellbeing of older people.· As 
dIe frequency of both atherosclerosis and dClnentia increases with advancing age, the 
two conditions are huge problems as the geriatric population is increasing at a con-
siderable pacc.5,6 Atherosclerosis as \vell as dClnentia are heterogeneous disorders, 
\vith an incompletely understood aetiology. 
Crucial in the developtnent of atherosclerosis is the level of cholesterol in se-
n11n.3,7 The APOE genotype is a deterrninant of senun cholesterol level, and has 
three common alleles, APOE*2, APOE*3 and APOE*4 wllleh fully determine the 
respective apoE2, apoE3 and apoE4 isofonns,1 Compared to hotnozygotes for 
APOE*3, the most con11n011 genotype, APOE*2 is associated widl lower levels of 
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total and low density lipoprotein (LDL) cholesterol and with higher levels of high 
density lipoprotein (HDL) cholesterol, while APOE*4 has opposite effects.' Yet, 
findings on APOE and atherosclerosis have been inconsistcnt,8,9 and it is not yet 
clear how APOE is related to lllortality and vascular diseases, such as stroke and 
coronary heart disease. lO,t! 
Besides its role in lipid metabolism, the APOE*4 allele is more prevalent in pa-
tients with Alzheimer's disease (AD) than in cognitively normal controls. AldlOugh 
tills association is well established, tile magnitude of the fisk was not clear at the start 
of dus study.I2·14 In addition, it remained to be established whether the APOE*2 
allele exerts a protective effect, whether the APOE genotype is also involved in other 
dementing diseases than AD, and, related to the latter topic, whether APOE testing 
could be used in the differential diagnosis of dementia. Furthermore, it was unclear 
whedler the level of apoE in semm conttibutes to the aetiology of AD, and whether 
APOE is related to AD progression and survival. Furdlermore, the putative syner-
gistic effects of APOE*4 and atherosclerosis deserved further investigation, as these 
are both common risk factors for dementia,l5 TIle aitn of this thesis was to cladfy the 
above issues. 
Findings and methodological considerations 
Apolipoprotein E in atherosclerosis and vascular disease 
Some inconsistencies have emerged £r01n studies on the APOE genotype and cid1er 
atherosclerosis or vascular diseases.s.H It should be noted however that few popula~ 
tion-based investigations have been performed on these topics. In the Rotterdam 
Study, APOE*4 was overall not related to adlerosclerosis, although d,e APOE4E4 
genotype was weakly associated widl atherosclerosis in d,e abdominal aorta and pe-
ripheral arteries. The APOE*2 allele appeared to be inversely related to atherosclero-
sis (tlmpter 5.2). Adjusting for senun apoE levels strengdlelled dlC inverse association 
of APOE*2 and adlerosclerosis, whereas adjusting for total and I-IDL cholesterol 
only slightly changed d,e estilllates. These observations suggest firstly dIat setUln 
apoE level is not an intermediate factor. Secondly, the main APOE*2 effects on 
atherosclerosis do not seetn to result £r01n its influence on lipid levels. 
The association of APOE wid1 1nyocardial infarction and stroke was studied in a 
follow-up setting. Persons widl d,e AP0E4E4 genotype had an increased risk of 
myocardial infarction, while subjects with APOE2E3 were at a slighdy lower lisk 
(thllpter 7). Adjusting for total and HDL cholesterol did not change these findings, 
suggesting that the level of these lipids is not inter1nediate. The incidence of stroke 
was not strongly related to d,e i\POE P01Y1U01phislU. Aldlough persons widl d,e 
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APOE2E3 or APOE4E4 genotype had a slightly higher risk than homozygotes for 
APOE*3, this did not reach statistical significance. ivlortality was overall not re1'lted 
to APOE, but increased in persons with either ti,e APOE2E4 or ti,e APOE4E4 
genotype who were younger dlan 65 years. 
Apolipoprotein E and dementia 
Differe11tial diagnosis As discussed in dlapter 3, APOE typing for differential di-
agnostic putposes of dementia seems not to be valuable. However, both approaches 
used to explore this issue, i.e. a consideration based on the available literaturc (chapter 
3.1), and an evaluation using data from a population-based study (chapter 3.7), have 
dleir limitations. The first Inedlod is subject to publication bias. It is questionable 
whedlcr conclusions based on dlC second approach will apply to patients who have 
been referred to a clinic. Clinical patients differ in several characteristics, itlcluding 
the APOE*4 fre'luency, from cases derived from a population-based study." The 
best way of evaluating the value of APOE testing in the differential diagnosis of de-
tnentia, is a study on patients who are referred because of a possible dementia s)'n-
ciroule, using autopsy confirtned diagnoses as a golden standard. An investigation 
like this has recently been published, and showed tI,at APOE genotyping is indeed 
not info1'1native when used as a single diagnostic test, but may improve specificity 
when used in conjunction with clinical characteristics. I? 
Risk of aU deme11tia a11d Alzheimer's disease Estimates of ti,e relative risk of 
AD associated with the APOE genotypes differ widely across studies. 18 The strong-
est effects of tile APOE genotypes were reported in clinic and autopsy studies as 
compared to population-based studies (table 1).19 In ,hapter 2, differences between 
clinic and population-based studies are discussed in more detail. Table 1 compares 
findings frotn the Rotterdanl Study with a meta-analysis of cross-sectional studies 
among Caucasians. 19 :~vlost risk estimates frotn dle Rotterdam Study were quite COln-
parable with those derived from the meta-analysis. The exception is the APOE4E4 
related relative risk of incident AD, which waS much lower in tile Rotterdam Study. 
Interestingly, dle odler two population-based incidence studies till so far, reported 
also a weak association between APOE*4 and dementia,B,2o but confidence intervals 
were wide. AltllOugh the APOE4E4 related risk estimates of AD from population-
based incidence studies are conceptually superior, precision is curtently lacking. 
Contradicting f111dings have been reportcd on the association between dlC 
APOE*2 allele and AD.21-24 Long-term population-based follow-up studies will ulti-
tnatcly darify whetller) compared to dle tnost C01111non genotype APOE3E3, 
APOE*2 is protective or has similar effects. Taken into account the wide variety in 
obselved effects, it is not likely that possible protective effects of APOE*2 will be 
impressive. 
161 
Table 1 - Odds ratio for Alzheimer's disease according to apolipoprotein E genotype in meta-analysis and Rotterdam Study· 
APOE2E2 APOE2E3 APOE2E4 AP0E3E3 APOE3E4 APOE4E4 
Meta-anafysisl 9i' 
Clinic/autopsy studies 0,6 (0.2 to 2,0) 0,6 (0,5 to 0,8) 2,6 (1.6 to 4,0) 1 (reference) 3.2 (2,8 to 3,8) 14.9 (10,8 to 20,6) 
Population-based studies 0,9 (0.3 to 2,8) 0,6 (0,5 to 0,9) 1.2 (0,8 to 2.0) 1 (reference) 2.7 (2.2 to 3.2) 12.5 (8,8 to 1 7.7) 
Rotterdam Study 
Prevalent cases 0,6 (0.1 to 6.3) 0,6 (0.3 to 1.2) 1.4 (0.3 to 6,6) 1 (reference) 1.5 (0,9 to 2.5) 13.2 (5.2 to 34,0) 
Incident cases 0,5 (0,2 to 1.2) 1.1 (0.3 to 4.7) 1 (reference) 1.9 (1.2 to 3,0) 3,2 (1.0 to 10.3) 
* Odds ratios with 95% confidence intervals; 
t Based on cross-sectional studies among Caucasians (total sample size: n=5107 cases and n=6262 controls). 
Genera! dismssioJl 
Non-Alzheitner's disease dementias \Xllille there 1s only one study that did not 
report an increased risk for APOE*4 caniers on sporadic AD,25 much more contro-
versy exists in the literature on APOE and the non-AD dementias, including vascular 
detnentia, Lewy body disease, Parkinson's disease dementia, frontal lobe dementia 
and Creutzfeldt-Jakob disease l ' \Y/e found that APOE*4 was also related to demen-
tia with stroke, which included patients with either vascular dementia or AD with 
cerebrovascular disease (thapter 4.1). TIle lack of an observed association between the 
APOE*4 allele and dle non-1\D del11entias in some autopsy studies, tnay be due to 
selection bias. As APOE*4 appears to be related to various neuropadlological char-
acteristics of AD,26 diagnosing the non-AD detnentias only in the absence of any 
evidence for AD, implies dIat APOE*4 camel'S arc selectively excluded. 
Serum apoE JeveJ We found that serwn apoE levels were lower in AD compared 
to non-demented controls (d}apter 4.2). When we adjusted for the APOE genotype, 
the difference in serum apoE levels diminished. l1Ierefore, it is unlikely that Se11.l111 
apoE level is related to AD, independently of tl,e APOE genotype. 
Prognosis of Alzheimer's disease Previous studies on APOE and dIe course of 
AD are hased on patients who were included at different stages of disease. Tltis 
hampers the comparison of the rate of decline, and could explain the inconsistencies 
in the literature. W/c included patients at a similar stage, i.e. before dIe onset of 
symptoms, and found that the APOE*4 allele was not a strong determinant of sur-
vival in AD (chap!er 4.5). As change in cogttitive function and severity of dementia 
were similar for AD patients widl and without APOE*4, our ShIdy suggests that dIe 
progression of AD is not related to tl,e APOE*4 allele. 
Apolipoprotein E, atherosclerosis and dementia 
\X'hen shIdying dIe association of APOE, atherosclerosis and cogtuUve function, 
APOE*4 carriers with adlerosclerosis appeared to have the worst cognitive perform-
ance «hap!er 6.1). lvWd, non-sigttificant effects on cogttitive fUilCtioil were observed 
for atllerosclerosis in tl,e ahsence of APOE*4 and for APOE*4 in tl,e ahsence of 
atherosclerosis. 
In addition, the effects of both APOE*4 and atherosclerosis on dementia were 
found to be stronger than the s,un of tl,e effects of APOE*4 alone and atllerosclero-
sis alone (chapter 62). This again suggests a synergistic interaction.27 
As tl,e APOE genotype was shown to be associated with atllerosclerosis (d}ap!,r 
5.2), and atherosclerosis was found to be related to dementia, we studied whether 
atherosclerosis could be intertnediate in the association of APOE and detnentia 
(chtlp!er 6.2). The association hetween tl,e APOE genotypes and dementia did not 
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essentially change when adjustments were tl1ude for atherosclerosis or other vascular 
factors. This suggests that atherosclerosis is not an intCrtl1cdi.'lte factor, 
I'or the majority of the population, namely those not cartying the APOE*4 allele, 
smoking increased the risk of dementia and AD (cbapter 6.3). For subjects with the 
APOE*4 allele however, smoking was inversely associated with dC1nentia, although 
tlus did not reach statistical significance. 
Mechanisms 
The reader is referred to <,hapter 5.1 for a discussion of APOE in lipid metaholism 
and atherosclerosis. Tills section will fOCllS on the involvctuent of APOE in the aeti-
ology of the dC111cntias. First, a review will be given on the role of APOE in AD, the 
most frequent type of dementia. This is followed hy a discussion on the role of 
APOE in the response to damage to the brain, which is not necessarily the neurode-
generation as absenTed in AD. 
Apolipoprotein E and Alzheimer's disease 
Tlus section starts with a discussion on the possible role of cerehral apoE level in the 
patllOgenesis of AD. Afterwards) an overview is given of the role of the various 
apoE isof01ms in the metabolism of the various components of the AD pathology. 
ApoE level in the AD braitJ A small study reported d,at the APOE*4 allele was 
associated with lower levels of apoE in the hippocampus and cortex of AD patients) 
and d,e audlOrs proposed that d,e harmful effects of APOE*4 are due to reduced 
levels of available apoE4 protein.28 However, there is litde support for tlus hypodle-
sis. Several studies reported d,at apoE level in cerebrospinal fluid was unrelated to 
the APOE genotype.29~O By contrast, APOE*4 allele expression was found to be 
increased in d,e Alzheinler brain," aldlOugh it remains to be deternllned whedler dus 
is cause or consequence. Furthetmore, a recendy identified polymorplusm may be 
Inore conunon in AD) and was suggested to increase APOE gene expression.32 Al-
dlOUgh d,ese observations could not be confirmed in a population-based study on 
carly onset AD.33 
Tlus section will furdlCr discuss d,e role of the different apoE isoforrns in d,e 
AD padlOlogy. Important neuropadlOlogical characteristics of AD are extracellular 
neuritic plaques, intracellular neurofihrill~ry tangles and neuronal loss. 11,e different 
apoE isoforms may be involved in all features, through various pathways. 
Neuritic plaques The major component of d,e neuritic plaques is B-amyloid. It 
has been shown d,at in the AD brain, d,e nwnber of plaques and d,e burden of B-
amyloid is related to d,e APOE genotype.26~* APOE*4 carriers were found to have 
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an increased density of iI-amyloid,26)' wlule APOE*2 carriers had less ii-amyloid 
depositions.26 It has been suggested that the differences in the deposition of B-amy-
loid tnay result from isoform specific variation in the binding to B-atnyloid, but 
studies on this topic have not been consistent.3s-.n The apoE isoforn1s were further 
reported to have a specific effect on the formation, aggregability,38 or clearance,39 of 
ii-amyloid ill vitIV. Support for a role of apoE in the deposition of ii-amyloid came 
from a study on transgenic mice. Among mice that over-express human Alnyloid 
Precursor Protein (APP), those with a deficiency for apoE had a sharp reduction in 
B-runyloid deposition as cotnpared to mlce with native apoE.40 These mice studies 
suggest thus that apoE is somehow involved in the deposition of fi-atnyloid, but 
leave unanswered the specific consequences of the various APOE alleles. A weak-
ness in the hypodlesis d,at d,e APOE genotype is involved in AD because of its role 
in fi-atnyloid metabolism, is that it is still controversial whether fi-runyloid deposition 
is direcdy involved in AD, or whether it is just a seconda1), consequel1ce.41 All argu-
tnent in favour of tlus so called amyloid hypothesis is that several APP tnutations are 
known that invariably lead to fi-amyloid. deposition and to AD. IS However, in the 
vast majority of AD cases, without abnormalities in the API' gene, d,e link between 
the presence of fi-amyloid in dle brain and measures of dementia is tenuous, as sev-
eral snldies failed to find an association between d,e ii-amyloid burden and disease 
scverity.41,42 
Nellrofibrillary tangles The number of neurofibrillaty tangles correlates more 
closely widl d,e severity of AD d,an the number of se.ule plaques." The neurofibril-
b1T tangles that occur in the cytoplastn of neurons in the AD brain contain hyper-
phosphorylated tau protein. Tau normally stabilises d,e skeleton of d,e cell, and dus 
effect is dlOugh to be dependent on its phosph01ylation." The apoE protein was 
observed to be localised to neurofibrillary tangles. 11,e binding of apoE to tau ap-
pears to differ between d,e isoforms. The apoE4 isoform may bind less strongly than 
apoE3, wluch was speculated to result in the development of neurofibrillaty tangles.« 
In d,e absence of apoE3, tau binding sites are free and may pair widl that of od,er 
tau proteins, thus forming neurofibrillary tangles. It should be noted that relatively 
lugh concentrations of both tau and apoE were used in dlese ill tJlllV experiments.44 
However, support for d,e hypothesis that apoE is related to AD because of its role 
in tau metabolisn1 was obtained by an iiI lJizJ() ShIdy, which reported d1at tau was hy-
pelphosph01ylated in nuce deficient for apoE." Again, fmclings on nllce caflying d,e 
val"ious human APOE alleles remain to be reported. 
Neuronalloss The nUlnber of neurons decreases with increasing severity of AD.42 
The cholinergic neurotransmitter systetn may be specifically impaired in AD, and 
attenuation of choline acctyltransfcrasc (ehA 1) activity is a consistent neurochemical 
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marker. 11,e APOE genotype mal' have direct impact on cholinergic function, as 
knockout mice for apoE have shown synaptic damage and low ChAT activity." 
Whether neurotransmitter impairments in apnE deficient mice are limited to the 
cholinergic system remains to be reported. By contrast, studies on APOE and ChAT 
activity in the AD brain have been inC0l1sistent.47-49 The loss of neurons in the AD 
brain was found to be unrelated to the APOE genotype." 
Apolipoprotein E in the response to cerebral injury 
As described above, there arc several possibilities for the mvolvcJnent of the APOE 
genotype in d,e padlOgenesis of AD. Besides, APOE mal' be related to AD because 
of its role in the response to cerebral injUty,50 for instance due to atherosclerosis. The 
latter option is compatible with several studies in tius thesis. 
Firstly, a synergistic effect was observed between APOE*4 and atherosclerosis on 
d,e risk of dementia and cognitive impairment (t'haptm 6.1 alld 6.2). Secondly, d,e 
APOE polym01phism was found to be related to dementias of other aetiology than 
AD (rhaptm 3.2, 4.1 alld 4.2). Dementia is a vety heterogeneous condition which re-
sults from sufficient damage to d,e brain.· In persons widl an impaired capability to 
recover from cerebral injury (supposed to be carriers of the APOE*4 allele), cerebral 
datnage of whatever nature may lead to dementia) while others may have a higher 
chance to recover without loss of cognitive function. A schematic representation of 
dle above fmdings is shown il1jiglll'f 1. 
These observations are dms compatible with the view dlat dle consequence of 
atherosclerotic damage to the brain is more severe .in. presence of APOE*4. Besides) 
APOE*4 mal' interact with other types of damage including neurodegeneration, 
which would explain an association of APOE*4 widl dementia in the absence of 
adlerosclerosis. This section will furdler focus on dle hypothesis of an impaired re-
sponse to cerebral injuty in APOE*4 carriers. 
Other epidemiological studies A wide variety of studies have been perfonned on 
the outcome after cerebral damage as a function of d,e APOE genotype (table 2). 
Most studies suggest a synergistic effect between the APOE*4 allele and injmy, 
APOE*4 
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Figure 1 - Schematic representation 
of the interrelationship of APOE*4, 
atherosclerosis and dementia. 
lhe thickness of the arrows indicates 
the strength of the association, a dot-
ted line means no relationship. 
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which is compatible with an impaired recovery in APOE*4 carders. However, two 
population-based studies could not confirm the observation dlat APOE*4 carriers 
are prone to dcmcntia after head injuty.62,63 For the insulin resistance syndrome and 
smoking, only persons without the APOE*4 allele had an increased risk of AD.M,6S 
There are at least two explanations for these inconsistencies. Firstly, it may suggest 
anodler, stronger interaction witll tile APOE genotype in the opposite direction, as 
discussed in c/;apter 6.3 Witll regard to smoking. Secondly, these inconsistencies can 
be considered as argmnents against the hypothesis that APOE*4 is related to the 
dcmentias because of a poor response to cerebral injU1Y. 
Neurobiological studies Cerebral injuty was found to increase the production of 
apoE by astrocytes." A brief episode of global ischaemia increased APOE gene tran· 
scription,66 and led to an accwnulation of apoE close to the tuicrovessels, possibly 
due to alterations of the blood brain battier.67,68 Strong apoE immunoreactivity was 
also ohsclved in neurons exhibiting signs of ischaemic cell datnage.68 
ApoE deficient m.ice exhibited impaired ability to recover as compared to wild· 
type mice after focal ischaemia or closed head injuty.69.7o Treating apoE knockout 
Table 2 - Epidemiological studies on apolipoprotein E4 and outcome after brain injury 
First author Type of damage Outcome 
Synergistic effect 
Alberts51 intracerebral haemorrhage morlality, functional outcome 
Hofman l5 atherosclerosis dementia 
Siootcr52 atherosclerosis cognitive decline 
Kalmijn51 cerebrovascular disease cognitive decline 
Skoog54 white matter lesions dementia 
Mayeux55 head injury Alzheimer's disease 
Taesdale5& head injury mortality, functional outcome 
Jordan57 boxing chronic neurologic deficits 
Nicoll 58 fatal head injury deposilion of g-amyloid 
Sorbi5<J post-traumatic coma recovery of consciousness 
Tardiff" cardiac bypass surgery cognitive decline 
Itzhaki&! herpes simplex-l in brain Alzheimer's disease 
No synergistic effect 
Mehta62 head injury dementia 
Q'Mearao} head injury Alzheimer's disease 
Ott!,11 smoking dementia 
KULIsistd'S illSLJlin resistance syndrome Alzheimer's disease 
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mice with intraventricular injections of either apoE3 or apoE4, improved learning 
capacity and restored neuronal degeneration. 71 The latter study suggest that the ef-
fects of apoE4 are not harmful in itself, but less beneficial than the effects of apoE3. 
Transgenic mice expressing hutnan apoE4 have larger infarct volwnes following 
focal transient ischaemia compared to animals expressing luunan apoE3.12 ApoE 
seems thus to be involved in neuronal rcpill following injury. There arc various pos~ 
sibilities with regard to the underlying mechanism, which are not necessarily exclu-
stve. 
- Mechal/ism: 1. l/etimtlVphk eJjicls 
Injured neurons and glia need large amounts of cholesterol and od,er lipids for 
plasma membrane hiosyndlesis. The supply of dlCse hydrophobic molecules is made 
possible by apolipoproteins. ApoE has a special relevance for the central nervous 
system, as it is the predominant apolipoprotein in the brain, and od,er major plasma 
apolipoproteins such as apoAl and apoB are absent.73 Cells with excess lipids may 
release these compounds to apoE-lipid-complexes, which can be transported to cells 
requiring d,em for cell proliferation or repair. After injury, apoE expression by 
astrocytes increases, followed by an increase in LDL receptor activity in neurons 
which undergo dendritic proliferation and synaptogenesis.50 After binding, d,e apoE-
cholesterol-LDL receptor complex is believed to be internalised and degraded and 
d,e cholesterol is used for membrane and synapse formation.5o The binding of apoE 
to d,e LDL receptor appeared to be isoform-specific.74 Based on the poor recovery 
from brain injury as observed in APOE*4 carriers, it would be expected d,at binding 
of the apoE4 isoform to LDL receptors would be lowest. In contrast, binding of 
apoE2 containing lipoproteins appeared to be lowest in bodl rat astrocytes and 
neutolls,74 
In neuron culture experinlents, apoE together widl 6-VLDL could stimulate neurite 
extension and branching. TI,ese effects appeared to differ between d,e apoE 
isoforms. Addition of apoE3 led to extensive neurite outgrOWdl and elongation, 
wlme apoE4 was associated widl short, stunted neurite extensions.75 TI,e effects of 
the apoE2 isoform remain to be reported. 
Growth, adhesion and extension of neurites require interactions between the neuron 
and d,e extracellular substrate. ApoE binds to lamUun, a component of the 
extracellular matrix, and tius complex enhanced adhesion and branching of rat 
neurons, compared to lanunin alone.76 However, these effects were similar for apoE3 
and apoE4.76 Furthermore, there is evidence that apoE interacts with growth factors 
to support neuronal outgrowth and viability. The survival promoting effects of ciliary 
neurotropluc factor on luppocampal neurons was found to be potentiated by apoE, 
but apoE3 was as effective as dlC apoE4 isoform.77 
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- MechallislI1: 2. (/II/Io>;idall/ pmp"1ies 
Another wa)' by which apoE ma), be involved in the repair after cerebral damage is 
by protecting against oxidative stress. Oxidative insults are believed to be involved in 
various neurodegenerative ruseases.78 The cytotoxic effects of B-runyloid on neuronal 
cells could be blocked by physiological levels of apoE." The antioxidant activit), of 
apoE appeared to be isofonn specific, with apoE2 being most effective, apoE3 
moderately effective, and apoE4 least effective,19 111 VitlO studies further showed a role 
for apoE in oxidative stress. Mice deficient for apoE express higher titres of 
antibodies against oxidised lipids as compared to control nuce.80 In addition, these 
knockouts have increased levels of 3-nitrotyrosine in their brain, a marker of 
oxidative stress.SI 
~ j\,1ethallism,' 3. mle ill illflammatio1l 
A third possibility by which apoE may exert its beneficial effects is by modulating d,e 
glial response to inflatrunation. TIlere is growing evidence that inflanunatolJ' 
processes are involved in the pathogenesis of the dementias. Various features of 
inflanunation have been observed in the AD brain, including microglial activation, 
cytokine production, and completnent activation.82 Secondly, the use of non-steroidal 
anti-in£lamtnatory agents appeared to be inversely associated with AD.S3 
Furthel1nore, brain ischaemia, the principal cause of vascular dementia, is followed 
by an in£lrulllilatory response.84 
ApoE is known to have immunotnodulatory functions ill IIi/IV. l1lese include the 
suppression of lymphocyte proliferation and synthesis of inununoglobulins,73 as well 
as inhibition of TNF-a secretion.85 Moreover, apoE3, but not apoE4, could block 
the activation of microglia, the phagocytes of the brain, due to treatment with 
secrctcd APP.S6 An illllillO study furthcr suggested an itnmunomodulatory function of 
apoE, as mice deficient for apoE wcre found to have discrete abnonnalities of 
cellular and Inulloral itnnmne responses,12 Therefore, apoE seems to be involved in 
the regulation of the inflammatory rcsponse, which may play a role itl protecting 
neurons from secondary injUiY. 
Discllssion In conclusion) there are various possible mechanistTIs for a role of 
apoE itl the response to cerebral injury, which are schetnatically rcpresented in jigl/l'IJ 
2. Although thesc hypotheses are not necessarily exclusive, the hypothesis on neuro-
tropluc effects is best supported. However, weaknesses in the vic\v that apoE exerts 
its effects by transporting lipids to regenerating neurons, arc the receptor binding 
experiments. 111 IlitlV shldies 011 the antioxidant properties of dlC apoE isoforms arc 
pronusi.ng, but await experiments 011 nucc can-ying the various hUlnan APOE alleles. 
TIle role of apoE itl itlflanunation has not yct been studied itl detail for the various 
specific isofo.rms. \Vith the exception of the lillliflv expe.riments 011 apoE itl oxidative 
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stress,79 we are not aware of other reports that could explain the inverse association 
of APOE*2 widl dementia. 
Suggestions for future research 
Apolipoprotein E in atherosclerosis and vascular disease 
Given the varying results across studies, tnore research is needed to further explore 
whether the APOE genotype is related to atherosclerosis and vascular disease. Futw:e 
investigations should ideally have a follow-up design in order to cttcwnvent selective 
survival. Such studies, in which APOE genotyping is performed on material collected 
relatively early in life, could characterise participants who died before assessment of 
atherosclerosis. 
If d,e APOE is truly related to atherosclerosis and vascular disease, independent 
of lipid levels, furdler shldies should focus on oilier effects of d,e apoE isofolms 
d,an its role in lipid metabolism. These include possible anti-oxidative properties,".80 
the involvement of apoE in inflanunatory processes,72,73 and the role of apoE in ves-
sel wall homeostasis, such as d,e modulation of platelets aggregability and ilie prolif-
eration and migration of smoodl muscle cells and lymphocytes.73•87 
1. NEUROTROPHIC 
APOE 
astrocyte 
laminim_--
+c-apoE 
.+ \ ;-._._. 
lipid 
apoE -"- apoE-lipid~-~-
oxidative stress 
Ill. ANTI·INFLAMMATORY 
apo~~fo\ 
-1 ~D 
A. 
lymphocyte 
neuron 
II. ANTI OXIDATIVE 
Figure 2 - Possible mechanisms for the role of apoE in the response to cerebral injury. 
APOE = apolipoprotein E gene; apoE = apolipoprotein E protein; CNTF = ciliary neuro-
trophic factor; LDL·R = low density lipoprotein receptor. A minus sign (-) indicates inhibi-
tion; a plus sign (+) indicates stimulation. 
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Apolipoprotein E genotype and Alzheimer's disease 
TIle best way to further characterise the association of the APOE genotypes with 
AD is to use a population-based study, in order to avoid referral bias. Problems as-
sociated with selective survival can only be overcotne in a follow-up setting. How-
ever, in these surveys it has been difficult to implement neuropathologic confirma-
tion of the diagnosis. An estimated 10 percent of clinically diagnosed AD patients 
appear to have another dc.mcnting illness at autopsy.88 TIus may result in non-differ-
ential misclassificatiol1, reducing statistical power. Nevertheless the problctll of nllS-
classification in population-based studies is outweighed by the opportunity to study 
gene-environment interactions, using p.rospectively collected data on exposttte. More 
reliable risk estimates await longer foHow-up. Pooling of various population-based 
cohort studies will increase the number of person-years observation. Although this 
obviously increases efficiency, pooling assun1es that there are no important modifiers 
that differ between the pooled cohorts. Further, problems related to admixture could 
be encountered.89 This means dlat dle association under study may be confounded 
by differences in the frequency of both determinant and outcome between the 
pooled populations. 
Apolipoprotein E genotype and non-Alzheimer's disease dementias 
Studies on APOE and the non-AD dementias may be difficult as the distinction 
between different types of delnentia can be a tnaUer of intelpretation, and inclusion 
of AD patients tnay happen. In particular dle distinction between AD and vascular 
dementia may not be very clear.90 Therefore, it is important to study all dementia as 
well as AD and vascular dctnentia separately. Besides, the frequency of sonle de-
Inenting illnesses is relatively low, and a more efficient approach than a population-
based setting may be used. An alternative design, suitable for studies on Lewy body 
disease, frontal lobe dementia and Creutzfeldt-Jakob disease, is a case-referent study. 
The essence is dlat referent subjects are sampled from the SalliC study base fronl 
which the cases emerge, and that sampling is independent of exposure status.91 
However, a case-referent design may hamper the Shldy of characteristics before as-
signment as case or referent subject. 
Apolipoproteill E gene expression and protein level 
Invcstigations on cerebral apoE levels should be extended, as existing studies are 
limited, and included only few brains." To detect genetic variability in APOE expres-
sion, sequencing of the possible regnlat01Y elements of the APOE gene, should be 
followed by studies on transcription activity, and ill IIi/IV binding experiments to nu-
clear extracts. l\Jlutations which seem to be functionally relcvant, can bc further in-
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vestigated in association studies. TIle contribution of newly identified genes to thc 
occurrence of disease should be disclosed in prospective, population-based studies 
with, ideally, autopsy confirmation of the diagnoses. 
Apolipoprotein E genotype, atherosclerosis and dementia 
Epidemiological studies The obselved interaction between the APOE*4 allele 
and atherosclerosis on cognitive function (chapler 6.1) and dementia (chapler 6.2) 
should be confirmed in other population-based studies with long duration of follow-
up. A matter of concen} in these studies is the assessment of atherosclerosis. Thc 
presence of atherosclerosis in the brain is, during life, difficult to investigate directly. 
Related to cerebral arteriosclerosis, hypoperfusion, and ischaemia are cerebral white 
matter lesl0ns,92,93 which can be obsclved with magnetic resonance imaging (lvIRI). It 
should be further exatnined whether the cognitive consequences of these white Inat-
ter lesions are indeed more pronounced in carriers of the APOE*4 allele, cOlnpared 
to persons with other APOE genotypes, as has been observed recently. 54 Neuro-itn-
aging studies, ideally implemented in a population-based setting,"'.' will make an 
important contribution to this field. In addition, the same type of study mal' reveal 
whether datnaging of the white matter by atherosclerosis is more pronounced in car-
riers of the APOE*4 allele, which would further support the hypothesis of an itn-
paited recovery from cerebral itljUl'y itl APOE*4 carriers. Other it,dicators of athero-
sclerosis, vascular pathology or hypoperfusion may be used to unravel the exact na-
ture of dIe association between the APOE genotype, adlerosclerosis and dementia. 
These itrclude cerebral hypoperfusion, as estimated by single photon emission com-
puted tomography (SPEC!), blood pressure, haemostatic factors and lipid levels. 
Follow-up shldies are needed to dctcrmine whether the putative synergistic ef-
fects of APOE*4 and atherosclerosis can be extended to other functions than cogni-
tion. In particular, it remaitls to be disclosed whedler the functional outcome after 
stroke, usually a reflection of adlerosclerosis, is dependent upon the APOE geno-
type. The possible role of APOE in d,e response to injUl'y should furdler be ex-
plored itl relation to the outcome after other types of cerebral damage, including 
trawna, radiation, and enccphalitis. 
NellropatllOlogical studies In addition, d,e association between APOE, athero-
sclerosis and delnentia should be further explored itl neuropathological studies. 
Autopsies are usually perfotmed on selected patients. Restriction to cases who died 
of external causes may overcome possible selection bias, but numbers will probably 
be small. 
The observation d,at d,e AD padl010gy is more often related to clinical dementia 
in the presence of cerebral itlfarcts,90 is vetT interesting and should be confmned. 
Such an autopsy study mal' furdler reveal whedler d,e degree of atherosclerotic 
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changes of the cerebral arteries is associated with dementia and whether there is any 
modification by the APOE genotype. 
EyperiJnellts 011 genetically modified animals TIle introduction of thc various 
hutnan APOE genotypes into mice as wcll as the gcncration of APOE-knockout 
trUcc, has already proven to be useful in the shldy of the consequences of ischaemia 
and other types of cerebral injury. As this is a rapidly evolving area) it is to be ex-
pected that multiple genes will be incOlporated in order to resemble closely the dis-
ease process (figllre 3). In the future) transgenic animals may provide a substrate with 
which to test pharmaceutical compounds that may mimic apoE2 or apoE3 protec-
tion or protect against the relatively harmful effect of apoE4. 
Apolipoprotein E genotype, smoking and dementia 
Further population-based cohort studies are needed to reveal whether the conse-
quences of stuoking on the risk of dementia) ttuly differ between carriers and non-
carriers of the APOE*4 allele. It should be further investigated whether smoking 
might have neuroprotective properties in some individuals)9s-97 and whedlcr selective 
impairtnent of cholinergic neurotranSttUssion occurs in association with 
APOE*4.47,48 Positron emission tomography may be used for dlcse pUlposes when 
tnore specific radioligands have been generated. 
Apolipoprotein E in therapeutic trials on dementia 
In future trials of drugs generated to alter the development or progression of AD, 
d,e APOE genotypes should be considered in the evaluation of d,e observed effects, 
as APOE seems to be involved in tuany neurochemical processes. In rand01rUsed 
clinical trials, randomisation may be done after APOE genotyping in order to yield 
symmetrical distributions of d,e APOE genotypes across d,e different arms of the 
trial. Further) in the analysis of a randonused clinical trial) analyses in strata of the 
APOE genotypes, may reveal whedler any observed effect is modified by the APOE 
polym0'1,hism. 
Purthettnore) the observation that intraventricular infusion of apoE improved 
learning capacity and neuronal struchuc in apoE deficient lrUce)71 suggcsts dlat apoE 
nlay have therapeutic potential. FurdlCr studies arc necessary to develop agents widl 
similar effects as apoE, which can pass the blood-brain-barder. Given the devclop-
Incnts in genetic testing, eventually) neuroprotcctive treatment mar be adtninistercd 
to brain injured persons with a genetic predisposition for poor outcome. 
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SUMMARY 

9.1 
Summary 
'l1,is thesis descl1bes the role of the apolipoprotein E genotype (APOE; 
apoE=protei11) in atherosclerosis and dementia. These are two major disorders with 
increasing impact in our ageing society. TIle consequence of adlcrosclerosis, vascular 
disease, is the leading cause of tllortality and disability. Detnentia severely disturbs the 
quality of life, and is feared by l1wnerous older persons. 
High levels of total and LDL cholesterol and low levels of HDL cholesterol pre-
dispose to the development of atherosclerosis. The level of these lipids in serum is 
partly determined by the APOE polymorphism, Besides, tl,e APOE genotype was 
found to be involved in Alzheimer's disease, the lnost COlntnOll type of dementia. 
For the results presented in dus thesis, data were used frotn the Rotterdatl1 Study, 
a population-based cohort study aillong inhabitants of the suburb Ommoord in 
Rotterdam. In total, 7983 persons (response 78%) participated, who were aged 55 
years Of over at baseline. Atherosclerosis was non-invasively assessed by the presence 
of plaques in the conunon carotid arteries, calcifications of the abdominal aorta, the 
cornmon carotid artery intima-tnedia wall thickness, and the ankle to arm blood pres-
sure index. The 1111n1 mental state exanunation was used to assess cognitive function. 
DC111cntia was diagnosed using neuropsychological testing, neurological examination, 
and neuro-imaging. Events of interest, including death, myocardial infarction and 
stroke, were recorded after baseline examinations. After on average 2.1 follow-up 
years, 6315 (88%) of the 7215 subjects who were still alive participated in the second 
wave of the Rotterdam Stud),. 
Chapter 2 provides a review on the genetic epidemiology of Alzheimer's disease. 
Up until now, various autosomal dorninant mutations have been identified in three 
genes. 111ese encode for the a111yloid precursor protein (APP; chro1110S0111e 21)) pre-
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senilin 1 (pS-1; chromosome 14) and presenilin 2 (pS-2; chromosome 1). However, 
these mutations are all extremely rare. lYfore common is the APOE*4 allele. and its 
effects are probably modified by various genetic and environmental factors. Findings 
on other susceptibility genes have been difficult to reproduce. It is to be expected 
that other, yet unknown genes are involved in the aetiology of Alzheimer's disease. 
Our studies suggest that APOE testing is not infonnative in the differential diag-
nosis of dc.tllcntia. 'nus issue was first considered using the available literature on 
APOE and the non-Alzheimer's disease dementias (chapter 3.1). As APOE*4 
seems to be associated with dle most important alternative diagnosis for Alzheimer's 
disease, vascular dementia, and possibly also with odlcr detnenting diseases, it is not 
to be expected that APOE testing can detect Alzheimer cases in a population of de-
mentia patients. 
We inv~stigated this topic further among 249 mildly to moderately dementia pa-
tients who participated in the Rotterdam Study (chapter 3.2). APOE genotyping did 
not change diagnostic certainty ~ikeWlOod ratio was 0.75 based on the presence of 
one APOE*4 allele; likeWlOod ratio was 1.38 based on homozygosity testing), and 
seems therefore of little value in the differential diagnosis of dementia. 
Chapter 4.1 describes d,e association between d,e APOE genotype and demen-
tia with stroke, which included either vascular dementia or Alzheimer's disease with 
cerebrovascular disease. Tlus issue was studied using data frotn the Rotterdam Study 
and the Washington Heights Study, a population-based follow-up study performed 
in Northern l"Ianhattan, New York. As no major differences were obsclved between 
the two sites, we pooled the data from both studies. Relative to APOE3E3, persons 
with the APOE4E4 genotype had a nearly 7-fold increased risk of dementia with 
stroke (OR=6.9; 95% CI 1.6 to 29.4) while d,e OR associated widl the APOE3E4 
genotype was nearly 2-fold u1Creased (OR=1.8; 95% CI 1.2 to 2.7). 
In chapter 4.2 we evaluated the role of senun apoE level in Alzheimer's disease. 
Senlffi apoE level was lower in Alzheimer patients dIan in non-demented controls 
(0.75 Ilmol/l (SD 0.35), versus 0.83 Ilmol/l (SD 0.40)). TillS fuuling is Ul accordance 
with lower selUm apoE levels as observed ill carriers of the APOE*4 allele, who are 
over-represented among Alzheimer patients. After adjustments were made for the 
APOE geno!)1)e, the difference Ul serum apoE levels largely disappeared. This ob-
servation suggests that the level of apoE in serum does not contribute to the patho~ 
genesis of Alzheimer's disease, independent of the APOE genotype. 
We furdler studied whether the APOE geno!)'Pe is related to the course of Alz-
heuner's disease (chapter 4.3). For this purpose, 97 Alzheimer patients were Ul-
eluded at a sitnilar stage i.e. before the onset of symptoms, and followed for up to 5 
years. The change it} cognitive function and the severity of dementia were similar for 
Alzheimer patients with and widlOut d,e APOE*4 allele. 'n,e median survival after 
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the onset of symptoms did not differ between the hvo g1:oups either. However, 
mortality rate was higher in APOE*4 carriers after adjusting for age (1.5; 95% CI 0.8 
to 2.8), as carriers of the APOE*4 allele were younger at dementia onset. 
Cbapter 5.1 briefly sUll11narises the role of apoE in atherosclerosis. Besides its 
function in the tlletabolism of lipoproteins, apoE is involved in several processes in 
the arterial wall. ApoE may inhibit the aggregability of platelets and modulate lym-
phocyte function. In addition, apoE t11ay interact with the extracellular tnatri."{, 
thereby influencing the retention of lipoproteins. 
In cbapter 5.2 the association between the APOE genotype and atherosclerosis 
,vas evaluated, using data £rot11 the Rotterdatn Study. We found overall no relation-
ship between the APOE*4 allele and atherosclerosis, although the APOE4E4 geno-
type was weakly associated with atherosclerosis in the abdotninal aorta and peripheral 
arteries. By contrast, the APOE*2 allcle appeared to be inversely associated with 
atherosclerosis. Adjusting for senun apoE levels strengthened the association be-
tween APOE*2 and atherosclerosis, whereas adjusting for total and HDL cholesterol 
only slightly changed the estimates. These fUldings suggest that serum apoE level is 
not an intermediate factor. Secondly, the main APOE*2 effects on atherosclerosis 
seetn not to result from its influence on lipid levels. 
Purthertllore, the effects of both APOE and atherosclerosis were studied in rela-
tion to cognitive function (chapter 6.1), and dementia. Carriers of tl,e APOE*4 
allele perfortned worse on the mini tnental state examination than persons without 
this allele. Furthermore, cognitive function in persons with atherosclerosis was worse 
as compared to subjects without evidence of atherosclerosis. \XThen the study popula-
tion was further stratified, we found that APOE*4 carriers widl atherosclerosis had 
the ,vorst cognitive perfortnance. J'vIild, non-significant effects on cognitive function 
observed for atherosclerosis in the absence of APOE*4, and for APOE*4 in dle 
absence of atherosclerosis. Our findings suggest a synergistic effect of APOE*4 and 
atherosclerosis with regard to cognitive performance. 
In cbapter 6.2 we studied the combined effects of APOE and atherosclerosis on 
dementia. The consequences of both APOE*4 and atherosclerosis wcrc stronger 
than the stun of the effects of APOE*4 alone and atllerosclerosis alone. This again 
suggests a synergistic interaction. Besides, as dle APOE genotype was shown to be 
associated widl atherosclerosis, and atherosclerosis was found to be related to de-
tnentia, we studied whether atherosclerosis could be intermediate in the association 
of APOE and dementia. The association behvccn the APOE genotypes and demcn~ 
tia, did not esscntially alter when adjustments were made for atherosclerosis or other 
vascular factors. Tlus suggests that atherosclerosis is not an intermediate factor. 
Chapter 6.3 evaluates tllC association of APOE, smoking and dementia. Al-
though smoking is a ,vell ktlo,vn risk factor fOf atherosclerosis, dle combined effects 
185 
Cbapter 9.1 
of smoking and APOE*4 on the occurrence of delnentia, were opposite from the 
c0111bined effects of atherosclerosis and APOE*4. Among APOE*4 carriers, cunent 
smoking was associated with a lower risk of Alzheimer's disease (OR=0.6; 95% CI 
0.1 to 4.8), as cOlnpared to non~smokers. Among non-APOE*4 carriers, current 
smokers had a higher risk of Alzheimer's disease than never slnokers (OR=4.6; 95~/O 
CI 1.5 to 14.2). These observations suggest an interaction between APOE*4 and 
s1110king in the aetiology of Alzheimer's disease. In dus chapter it is discussed that 
smoking could affect the cholinergic system, counterbalancing the putative impati·-
ment associated with APOE*4. 
Chapter 7 describes the population impact of the APOE genotype with regard 
to vascular diseases, dementia and mortality. Persons with APOE4E4 younger than 
65 years were at increased risk of tnyocardial infarcuon. However, the incidence of 
stroke was not strongly related to the APOE polymorphism. Although carriers of the 
APOE*4 allele were at increased risk of dementia, the contribution of APOE*4 to 
the incidence of dementia on a population level, was l11odest, wluch reflects the rela-
tively low frequency of the APO£*4 allele. An estimated 185 per 100000 individuals 
aged 55 or over, become del11ented each year as a consequence of carrying 
1\POE3E4 or APO£4£4 instead of the APOE3E3 genotype. Mortality was overall 
not related to 1\PO£, but increased in persons wid, either the 1\POE2£4 or d,e 
APOE4E4 genotype who were younger than 65 years. 
Chapter 8 sut1unarises our findings together with observations from other 
studies and methodological considerations. The discussion of the rnechanism under-
lytilg our observations focllses on the involvement of APOE in dIe neuropadlOlogy 
of Alzheimer's disease. APOE may be related to Alzheimer's disease because of its 
role in the response to cerebral injury, for instance due to adlerosclerosis. As this 
hypodlesis is compatible with several studies in dus dlesis, it was discussed in t110re 
detail. There are various n1echanisms possible how apoE may playa role in the re-
sponse to cerebral injuty. ApoE is involved in dIe transport of components for 
plasll1a membranes to injured neurons, and may interact with the extracellular matl'L,(, 
or with growth factors. FurthetIDore) apoE could protect against oxidative stress, 
and may tnodulate the glial response to inflammation. Finally, reconunendations for 
future research arc given. 
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Samenvatting 
Dit proefschrift beschrijft de rol van het apolipoprote1ne E genotype (APOE; 
apoE=eiwit) in atherosclerose en dClncntie. Deze twee stoofl1issen speIcn in GilZe 
vergtijzende samenleving cen steeds belangrijker rol. De conscquentie van athero-
sclerose, hart- en vaatziektcn, is de belangrijkste oorzaak van morhiditeit en mOf-
taliteit. Denlcntie is een zeer ingtijpende aandoening voor de patient en zijn omge-
vin.& en wordt gcvreesd door vele Quderen, 
Hypercholesterolemie en lage spiegels HDL cholesterol verhogen het risico op 
atherosclerose. De concentratie van deze lipiden in senun wordt gedeeltelijk bepaald 
door het APOE polymorfisme. Daarnaast bleek het APOE genotype een ral te spe-
len bij de zickte van Alzheimer, de incest voorkomende vortn van dCtncl:tic. 
Voor de resultaten die gepresenteerd worden in dit proefscluift, werd gebruik 
gemaakt van gegevens van het Erasmus Rotterdam Gezondheid en Oudcrcn 
(ERGO) ollderzoek, cen bevolkingsonderzoek onder inwoners van de Rotterdamse 
wijk 01l11l1aard. In tataal deden 7983 personen hieraan1l1ee (res pons 78%), clie allen 
55 jaar of ouder waren bi; aanvang van het onderzoek. De aanwczigheid van 
atherosclerose werd niet-invasief getneten tniddels het voorkoluen van plat]ues in de 
arteriac carotides conUl1unes, ca1cificaties in de aorta abdotninalis, de intima-media 
wanddikte van de arte.riae carotides C0111111uncs, en de enkel-at111 index. De 'mini 
111ental state examination' werd gebruikt Oln het cognitief functioneren te beoor-
delen. De diagnose delnentie werd gebaseerd op neuropsychologisch onderzoek, 
neurologisch onderzoek cn beeldvormend onclerzoek. Sterfte, evenals het optreden 
van een Inyocatdinfarct of een cerebrovasculair accident werd geregistreerd na inclu-
sie. Na ge1l1iddeld 2.1 jaar werden 6315 (88%) yan aile nag in leven zijnde 7215 
deelnctners voor de tweede keer ondeelocht. 
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Hoofdstuk 2 geeft een overzlcht van de genetische epidemiologie van de ziektc 
van Alzheimer. Tot nu toe zijn et verscheidene autosomaal dorninante mutaties 
gevonden in drie genen. Deze coderen "lOOt het amylot'd precursor prote1ne (APP; 
chromosoom 21), preseniline 1 (PS-!; chromosoom 14) en preseniline 2 (pS-2; cluo-
fnOSOOtn "1). Echter, deze mutaties zijn aUe bllitengewoon zeldzaam. Veel frequenter 
is het APOE*4 aIlel, de effecten hiervan worden waarschijnlijk gemodificcerd door 
verschillende genetische en omgevingsfactoren. Bevindingen naar andere ~vetsbaar­
heidsgenen' konden echter nlet altijd gereproduceerd worden. Bet ligt in de Hjn der 
verwachting dat er meer genen een rol spelen in de etiologie van de ziekte van 
Alzheimer. 
APOE genotypering lijkt niet informatief te zijn in de differentiaal diagnosuek 
van dementie. In i100fdsIIlk 3.1 wordt dit onderwetp beschouwd gehruikmakend 
van de literatuur over APOE en de niet-Alzheimer dementieen. APOE*4 is waar-
schijnlijk ook geassocieerd met de meest frequente type detnentie na de ziekte van 
Alzheimer, vasculaire detnentie, en mogelijk eveneens met andere vormen van 
dementie. Het is daarom niet waarschijnlijk dat APOE genotypering gebruikt zal 
kunnen worden am Alzheit11er pacienten te onderscheiden' van tllensen met een 
andere vonn van dementie. 
De diagnostische waarde van APOE genotypering werd verder gecvalueerd onder 
249 mild tot matig ernstig demente patienten die deelnamen aan het ERGO 
onderzoek (hoofdslIlk 3.2). APOE genotypering verhoogde de diagnostische 
zekerheid niet (waarschijnlijkheidsverhouding was 0.75 gebaseerd 01' de aanwezig-
heid van een APOE*4 allel; waarschijnlijkheidsverhouding was 1.38 gebaseerd 01' 
testen voor twee APOE*4 allelen), en lijkt daarom van weinig waarde in de differen-
ciaal diagnostiek van dementie. 
Hoofdstllk 4.1 beschrijft de relatie tussen het APOE genotype en 'dementie met 
beroerte', een verzameltenn voor vasculaire demen tie en de ziekte van Alzheimer 
t11et cerebrovasculaire pathologic. Dit onderwerp werd ondcrzocht tnet gegevens van 
de ERGO studie en the Washington Heights Study, een cohort onderzoek onder de 
algemene bevolking van het noordelijk deel van Manhattan in New York. Aangezien 
er geen grote verschillen waren tussen de twee populaties, werden de gegevens 
gecombineerd. Vergeleken met het APOE3E3 genotype, hadden dragers van twee 
APOE*4 allelen een bijna 7-keer hoger risico 01' dementie met beroerte (OR=6.9; 
95% BI 1.6 tot 29.4) terwijl dragers van het 1\POE3E4 genotype een bijna twee keer 
verhoogd risico hadden (OR=1.8; 95% BI 1.2 tot 2.7). 
Hoofdstllk 4.2 behandelt de rol van serum apoE bij de ziekte van Alzheimer. 
De concentratie apoE in serum was lager bij Alzheimer patienten dan bij niet·· 
demente controles (0.75 J.lmol/I (SD 0.35), versus 0.83 J.lmol/I (SD 0.40)). Deze 
bevinding past bij de lagere se1unl apoE concentraties die gemeten worden bij 
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dragers van het APOE*4 allel, die over-vertegenwoordigd zi;n onder Alzheimer 
patienten. Na correctie voor het APOE genotype, verdween het verschil in selunl 
apaE spiegels grotcndecls. Dit wijst erop dat de conecntratie apaE in setwu geen 
determinant lijkt te zijn van de ziekte van Alzheimer, onafhankelijk van het APOE 
genotype. 
\'(/e onderzochten verder of het APOE genotype gerelateerd is aan het be!oop 
van de ziekte van Alzheimer (hoofdstuk 4.3). Hiervoor werden 97 Alzheimer 
patienten gci:ncludeerd op het tnoment dat zij nog geen symptomen vertoonden, en 
tot 5 jaar gevolgd. Dc verandering in het eognitief functioneren en de ernst van de 
dementie waren gelijk voor Alzheimer patienten met en zonder het APOE*4 allei. 
De mediane overleving na het begin van de symptomcn was eveneens gelijk voor de 
twee groepen. Eehter, de mortaliteit onder APOE*4 dragers was hoger na eorreetie 
voor leeftijd (1.5; 95% TIl 0.8 tot 2.8), aangezien patienten met het A1'OE*4 alie! 
jongcr waren bij aanvang van de dcmentie. 
Hoofdstuk 5.1 vat kort de rol samen van apoE bij atherosclerose. Naast de 
funetie in het metabolistne van lipoprotemen, is apoE betrokken bi; vcrsehillende 
proeessen in de arteriCle vaatwand. ApoE kan de aggregatie van tromboeyten 
renunen en de funetie van lytnfoeyten belnvloeden. Daarnaast kan apoE een inter-
aetie aangaan mct de cxtraecllulaire matrix, en daardoor dc ophoping van lipopro-
teinen beinvloeden. 
In hoofdstuk 5.2 wordt de associatie tussen het APOE genotype en adlero-
sclerose bestudccrd, gebnuktnakend van gegevens van de ERGO studie. \'\Iij vonden 
overall gccn relatie tussen het APOE*4 allcl en atherosclerose, hoewel er een zwak 
verband bestond tussen het A1'OE4E4 genotype en adlerosclerose in de aorta 
abdominalis en de perifere arteriCn. Het 1\POE*2 allel daarentegen bleek omgekeerd 
geassoeieerd te zijn tnet atherosclerose. Coneetie voor serum apoE spiegcls vcr-
stcrkte de inverse associacic hlsscn APOE*2 en atherosclerose, tenvijl eorrectie voor 
tataal en HDL cholesterol sleehts weillig invloed had. Deze bevindingen suggereren 
tcn ecrste dat de spiegel van apoE in serum geen intel1nedaire factor is. Ten t\veede) 
de belangrijkste effecten van APOE*2 op atherosclerose lijken niet het resu!taat te 
zijn van het APOE*2 effect op lipiden spiegels. 
Verder wcrden de effecten van zowel APOE als athcrosclerosc bcstudeerd in 
relatie tot het cognitief functioneren (hoofdstuk 6.1), en dementie. Dragers van het 
APOE*4 ailel presteerden slechtcr op de 'mini tllcntal statc examination' dan 
personcn zonder dit alld. Daarnaast was het eog11itief funetioncrcn van tncnscn tnct 
athcrosclerosc slcchter vcrgeleken 1net personen zonder aanwijzingen voor athero-
sclerose. \V'muleer we de onde1'7.:oekspopulatie verder stratificeerden, vonden we dat 
APOE*4 dragers tnet atherosclerose het sleehtst presteerden. Geringe, niet-signifi-
cante cffcctcn \vat betreft het eognitief futletioneren was gerelateerd aan athero-
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sclerose zander APOE*4, en voor APOE*4 zander atheroscIerose. Deze be-
vindillgen doen cen synergistisch effect van APOE*4 en atheroscIerose vermoeden 
ten aanzien van het cognitief functioneren. 
In boofdstllk 6.2 bestudeerden we de gecombineerdc cffecten van APOE en 
atherosclerose 1net be trekking tot dClnentic. Dc consequentie van zowcl APOE*4 als 
atherosclerosc was sterker dan de som van de afzonderlijke factoren. Dit suggereert 
wcderom cen synergistische interactie. Daarnaast bestudeerden we in hoevcrrc 
atherosclerose cen inte.rmediare factor zeu kunncn zijn in de associatic van APOE 
1net dementie, nangezien hct APOE genotype geassocieerd bleek te zijn 1net athe-
rosclerosc, en atheroscIerose gerelateerd was aan dementie. De associatie tussen het 
APOE genotype en dementie veranderde nauwelijks na statistische correctie voor 
atherosclerose of andere vasculaire factoren. Dit suggereert dat atherosclerose geen 
intennediare factor is. 
Hoofdstuk 6.3 bespreekt de relatie tussen APOE, roken en dementie. Hoewel 
roken een bekende tlsico factor is voor atherosclerose, verschillen de gecombineerde 
effecten van roken en APOE*4 ten aanzicn van het voorkomen van dementie, van 
de gecombineerdc effecten van atherosclerose en APOE*4. Onder dragers van het 
APOE*4 allel, hadden rakers een lager risico op de ziekte van Alzheimer (OR=0.6; 
95% BI 0.1 tot 4.8), dan mensen die nooit hadden gerookt. Onder niet-APOE*4 
dragers hadden rokers een hoger tlsico Dtn de ziekte van Alzheimer te krijgen dan 
mensen die nooit hadden gerookt (OR=4.6; 95% BI 1.5 tot 14.2). Deze bevindingen 
suggereren een interactie hlssen APOE*4 en roken in de etiologic van de ziekte van 
Alzheimer. Roken ZOU mvloed nit kunnen oefenen op het cholinerge systeetn, en 
daannec de nadeligc cffectcn van APOE*4 kunnen compenseren. 
Hoofdstuk 7 beschrijft de invloed van het APOE genotype op populatie niveau 
tnet betrekking tot hart- en vaatziekten, dementie en sterfte. Personen tnet het 
APOE4E4 genotype die jonger waren dan 65 jaar, hadden een verhoogd risico om 
een myocardinfarct te krijgen. Daarentegen was de incidentie van het cerehro-
vasculair accident niet duidelijk gerelateerd aan het APOE polymorfisme. Hoewel 
dragers van het APOE*4 aUel een verhoogd risico hadden op dementie, was de 
bijdrage van APOE*4 aan de incidentie van dementie op populatie niveau gering. Dit 
weerspiegelt de relatief lage frequentie van het APOE*4 aUe!. Naar schatting 185 per 
100000 mensen van 55 of ouder, worden jaarlijks dement omdat zij tenminste draget 
zijn van APOE3E4 of APOE4E4, in plaats van het APOE3E3 genotype. De mor-
taliteit was overall niet gerelateerd aan APOE, maar verhoogd onder personen tnet 
het APOE2E4 of het APOE4E4 genotype, jonger dan 65 jaar. 
Hoofdstuk 8 vat onze bevindingen samen tnet die van andere shldies en be-
steedt aandacht aan enkele methodologische aspecten. De bespreking van het mecha-
nisme dat ten grondslag ligt aan onze epidemiologische bevindingen concentteert 
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zich op de rol van APOE in de neuropathologie van de ziekte van Alzheuner. APOR 
zou een rol kunl1en spelen in de pathogenese vanwege zijn rol in het herstel na 
cerebrale schade, bijvootbeeld vanwege atheroscletose. Deze hypothese \vcrd 
gcdetailleerdet besproken aangezien deze compatibel is tnet verschillende studies van 
dit procfschrift. Er zijn verschillende tnechanismen mogelijk \Vat betreft de tol van 
apoE in het hetstel na cerebrale schade. ApoE is betrokken bij het transport van 
componenten voor plasma tnembranen naar beschacligdc neuronen, en Zou een 
ultcractie aangaan met de extracellulaire tnatrix, of tnet groeifactoren. Ook zou apoE 
kunnen beschermen tegen oxidaticvc stress, en zou de ul£lamtnatoll:e reactie van glia 
cellen kunncn tnoduleren. Ten slotte werden suggestics gedaan voor toekomstig 
ondcrzoek. 
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